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SUMMARY 
Asthma morbidity and mortality have been increasing in most industrialised countries over the 
last two decades despite anti-asthmatic medication sales at an all time high. Drug therapy 
remains the mainstay of treatment in asthma yet there have been concerns that modern drug 
therapy may be contributing to this increase in morbidity and mortality. The research presented 
in this thesis sought to examine several issues related to current asthma pharmacotherapy. 
In recent years, asthma management guidelines have emphasised the earlier introduction of 
inhaled corticosteroids and less reliance on Pzagonists. The prescribing of anti-asthmatic drugs 
within Tasmania was examined from April 1991 to April 1994 using computerised dispensing 
records from nearly one-third of all the community pharmacies within the State. Trends in 
prescribing were compared with national data and regional State differences were examined. It 
was found that drug utilisation, both nationally and within Tasmania, appeared to be changing 
in line with current management guidelines with increases in inhaled corticosteroid and 
sodium cromoglycate usage while (3 zagonists usage remained fairly stable. There was a marked 
decrease in the ratio of 13 zagonists:inhaled corticosteroids dispensed over the period of the study. 
Nebulised ipratropium bromide (an anti-cholinergic drug) is often combined with nebulised 
agonists in the treatment of asthma and chronic obstructive airways disease. To reduce the time 
that patients spend inhaling nebulised drug ipratropium bromide is often mixed with (3 - 
agonists immediately prior to administration but is sometimes bulk mixed and stored for 
several days before use. A reversed-phase ion-pair assay wing UV detection was developed to 
study the stability of these bulk mixed nebuliser solutions. The stability of an admixture of 
proprietary ipratropium bromide and salbutamol nebuliser solution (1:1, v/v) was then 
examined for 5 days under different storage conditions. It was found that admixtures of 
ipratropium bromide and salbutamol nebuliser retain greater than 90% of their initial 
concentrations if stored at or below 22° C for periods of up to 5 days. 
Finally, an assay using solid-phase extraction was developed to measure urinary levels of 
salbutamol in a relatively large group of asthmatic patients using inhaled therapy. Salbutamol 
levels in 'spot' urine samples were investigated as a potential indicator of over-we. Median 
levels of unchanged drug were 378 ng/ml (range 0-34.4 pg/m1) and 2.55 tig/m1 (range 0- 
49.8 pg/m1) in community and hospital patients respectively. Even when conceding the 
limitations of 'spot' urine sampling there were large inter-patient differences in levels corrected 
for dosage, probably due to differences in technique of administration and pharmacokinetic 
variability. There were also indications of possible low level saturation of metabolism which 
may have clinical implications. 
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CHAPTER 1 
General Introduction 
Over recent years, asthma morbidity and mortality has been increasing in most 
industrialised countries despite effective drugs for control of asthma symptoms 
(Musk et al, 1987; Jackson et al, 1988). Over the same period drug sales have also 
increased (Jenkins et al, 1988, Klaukka et al, 1991). There have been suggestions 
that modern drugs used in the treatment of asthma may actually be causing the 
increase in asthma morbidity and mortality (Barnes and Chung, 1992). Because 
drug use has been closely associated with rising asthma prevalence, the objective of 
this study was to examine several current issues in the pharmacotherapy of asthma 
and related conditions such as chronic obstructive airways disease and emphysema. 
Asthma is now regarded primarily as an inflammatory disease rather than simply 
bronchoconstriction (Barnes, 1989). This has led to changes in the management 
guidelines of asthma with greater emphasis on earlier introduction of inhaled 
corticosteroids (Anonymous, 1992; Tse and Bridges-Webb, 1993). In addition, 
there have been concerns that over-reliance on 3 2-agonist therapy could be linked 
to increasing asthma morbidity and mortality (Sears et al, 1990; van Schayck, 
1991). 
The cost of asthma to the Australian community has been estimated at up to $720 
million per annum (NAC report, 1992). The National Asthma Campaign (NAC) 
was introduced in 1990 in response to rising morbidity and mortality with the 
goals of improving diagnosis and management and reducing preventable deaths 
from asthma. 
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The impact of the changing asthma management guidelines and the NAC on 
prescribing of anti-asthmatic drugs and morbidity and mortality within Tasmania 
was examined with the assistance of computerised pharmacy dispensing records. 
The background pathology, pharmacotherapy, current controversies and 
treatment guidelines in asthma are discussed in Chapter 2. Chapter 3 describes the 
relatively new discipline of pharmacoepiderniology, the study of drug use within a 
population (Hartzema, 1992; Henry, 1988). Pharmacoepidemiology, as the name 
suggests, is essentially the combination of pharmacology and epidemiology. 
Pharmacoepidemiology is used in Chapter 4 to assess the impact of the NAC on 
the prescribing of anti-asthmatic drugs within the Tasmanian population. 
Tasmanian prescribing trends were also compared with National prescribing 
trends. 
For patients unable to use metered-dose inhalers (MDIs), inhalation of nebulised 
respirator solutions is an integral component of the modern treatment of airways 
disease (Horsley, 1988; Johnson, 1989). Patients with severe asthma or chronic 
obstructive airways disease are often administered (3-agonist drugs in combination 
with ipratropium bromide, a quaternary anti-cholinergic drug (O'Driscoll et al, 
1989). It has been suggested that by mixing the drugs before administration both 
nursing time and time spent by the patient inhaling drug is reduced (Fry and 
Williamson, 1991). In addition it has also been suggested that patient compliance 
may also be increased because of the reduced administration time (Roberts and 
Rossi, 1993). 
This mixing of drugs, however, raises issues of compatibility. Compatibility issues 
between salbutamol (a commonly used 13 2-agonist) and ipratropium bromide have 
been addressed over short Storage periods (Iacono et al, 1987). The compatibility of 
bulk mixed drugs over a period of days, however, has not been addressed. 
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A single stability-indicating assay designed to measure concentrations of several 
common (32-agonists and ipratropium bromide in nebuliser solution was developed 
in Chapter 5. This assay was modified slightly in Chapter 6 to determine the 
stability of salbutamol and ipratropium bromide, such as in bulk mixed nebuliser 
solutions, over a period of days. 
Despite its wide spread use over many years there is surprisingly little published 
information on the pharmacokinetics of salbutamol, especially after inhalation 
which is mainly due to difficulties in detection. The pharmacokinetics of 
salbutamol, with emphasis on inhalation therapy, are examined in Chapter 7. 
Following inhalation salbutamol is excreted as free drug and metabolite in urine. 
(Morgan et al, 1986). Levels of drug and metabolite in urine are typically much 
higher than plasma due to urine acting as a reservoir for excreted drug. An assay 
using solid-phase extraction and UV detection was developed in Chapter 8 to allow 
the determination of salbutamol and indirect determination of the major 
metabolite in urine following administration of salbutamol by inhalation, either 
via MDI (metered dose inhaler), DPI (dry powder inhaler), or nebuliser. This assay 
was used to examine urine levels of drug in a relatively large sample of community 
and hospital patients in Chapter 9. The possibility of using single 'spot' urine levels 
as an indicator of possible over-use was examined as well as correlation with 
reported dosage. Limited pharmacokinetic data were also examined from the urine 
samples. 
The implications of the research presented in this thesis on the pharmacotherapy 
of airways disease are summarised in Chapter 10. 
CHAPTER 2 
Asthma Background 
2.1 SUMMARY 
It is now generally regarded that asthma is an inflammatory disease rather than simply 
bronchoconstriction. This has changed the rationale for therapy with less reliance on bronchodilator 
medication and more emphasis on anti-inflammatory medication. The pathophysiology of asthma, the 
rising morbidity and mortality of asthma, strategies for reducing the morbidity and mortality, asthma 
pharmacotherapy, and the controversies in therapy are outlined. 
2.2 ASTHMA AS AN INFLAMMATORY DISEASE 
Asthma is a chronic illness associated with widespread narrowing of the 
tracheobronchial tree and characterised by symptoms of episodic coughing, 
dyspnoea, wheezing and chest tightness, alone or in combination (McFadden and 
Gilbert, 1992). Asthma was once considered a disease associated with 
bronchoconstrictor mechanisms and possible airway smooth muscle abnormalities. 
However, in recent years it has been recognised that chronic asthma involves a 
characteristic inflammatory response in the airways (Barnes, 1989; Alpers 1991). It 
is now apparent that airways inflammation is present even in patients with mild 
asthma (Laitinen et al, 1985; Beasley et al, 1989). 
Histological changes in asthma include shedding of the airway epithelium, 
interstitial oedema, and sub-basement-membrane collagen deposition (Jeffery et al, 
1992). The unique pathological features of asthma are the lack of neutrophils and 
the large numbers of eosinophils in the exudative phase, the sparsity of phagocytic-
cell infiltrates and the absence of granulation tissue and fibrosis (McFadden and 
Gilbert, 1992). It has been suggested that asthma can be viewed as a chronic 
eosinophilic bronchitis (Barnes, 1989). The inflammation in asthma is different to 
that inflammation seen in bronchiolitis in smokers or during viral infections as the 
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airways are typically free of fibrosis, apart from collagen deposition below the 
basement membrane (McFadden and Gilbert, 1992). 
The root cause of airways inflammation in asthma still remains uncertain 
(McFadden and Gilbert, 1992; Frew and Holgate, 1993). The development of 
bronchial inflammation is complex involving eosinophils, mast cells, platelets and 
many different inflammatory mediators (Paterson et al, 1995). In addition, 
bronchial hyperresponsiveness, a characteristic of asthma (Barnes, 1989), is an 
exaggerated bronchoconstrictor response to many different stimuli and is related 
to both the extent of inflammation in the airways (Chung, 1986; O'Byrne et al, 
1987a) and the severity of the disease (Hargreave et al, 1981; Britton et al, 1988). 
In patients with active disease, acute exacerbations can occur on exposure to non-
specific stimuli such as physical exertion, cold air, and respiratory irritants 
(McFadden and Gilbert, 1992). The role of allergens in asthma is still not clear. It 
has been suggested that virtually all patients with asthma have an atopic 
component (Burrows et al, 1989; Sears et al, 1991). However, other estimates 
suggest that as many as one third of all patients with asthma are not atopic 
(Montogomery Smith, 1988) and that gene mutations may influence underlying 
asthma, even in the absence of atopy (van Herwerden et al, 1995). In addition, 
many patients with allergic rhinitis and well defined allergen sensitivity have no 
clinical evidence of asthma (Britton, 1992). 
The bronchospastic response to allergen inflammation typically consists of an 
early phase, due to the direct effect of mediators on bronchial smooth muscle, and 
late phase due to mucosal oedema and cellular infiltration 3 to 12 hours after 
inhalation of the allergen (Frew and Holgate, 1993). Recent research has shown 
that the CD4+ T-lymphocyte is important in the initiation of asthma and may be 
activated by exposure to antigens or other agents to release various cytokines 
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including interleukin 3, 4 and 5 (Kay, 1992; Paterson et al, 1995). The interleukin 
3, 4 and 5 cytokines activate B-lymphocytes and the recruitment of a mixed 
leucocyte infiltrate consisting of inflammatory cells such as eosinophils, 
macrophages, basophils and neutrophils (Beasley et al, 1989; Paterson et al, 1995). 
This is shown in Figure 2.1. 
The activated B-lymphocytes produce IgE (Kay, 1992). IgE can cause inflammation 
of the airways by binding with mast cells resulting in the release of mediators 
(associated with the immediate or early phase asthmatic response due to their 
direct effect on bronchial smooth muscle) and the recruitment of inflammatory 
cells typically associated with the late phase response (Djukanovic et al, 1990). 
These mediators include leukotrienes, histamine, prostaglandins, prostanoids, 
neuropeptides, endothelin-1, platelet-activating factor, eosinophil-derived cytotwdc 
peptides and neutrophil- and eosinophil-induced chemotactic factors of 
anaphylaxis (Wasserman, 1983; Kaliner, 1989; Drazen and Austen, 1987; Paterson 
et al, 1995). These mediators are responsible for constriction of bronchial smooth 
muscle, mucosal oedema, mucus production as well as interference in removal of 
mucus (Wasserman, 1983; Kaliner, 1989; Drazen and Austen, 1987) and may 
enhance both the immediate and late onset phases via a positive feed back loop 
(McFadden and Gilbert, 1992). In addition, allergen specific T-cells may be found 
in allergic persons (Kay, 1992). 
The role of mast cells remains unclear. While it is thought that mast cells may be 
important in the acute bronchoconstrictor response to an antigen (early phase) and 
possibly to exercise, the role of the mast cell in chronic asthma, particularly the 
late response and bronchial hyperresponsiveness, remains less certain (Barnes, 
1989). 
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Figure 21 	 Outline of the inflammatory pathophysiology of asthma. Adapted from 
Paterson et al, 1995. 
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In addition to the inflammatory mediators, neurogenic mechanisms have been 
implicated in asthma (Barnes, 1986a). Non-cholinergic non-adrenergic sensory 
nerves may release neuropeptides by an axon reflex that may have an important 
role in asthma (Barnes, 1989; Barnes, 1986b). These neuropeptides include 
substance P (a potent inducer of microvascular permeability and mucus secretion), 
neurominin A (a potent bronchoconstrictor) and calcitonin gene-related peptide 
(an effective and long-lasting dilator of bronchial vessels; Barnes, 1989). The roles 
of these various mediators in the pathogenesis of asthma will become clearer as 
more selective mediator antagonists are developed (Barnes, 1989). 
2.3 INCREASING ASTHMA MORBIDITY AND MORTALITY AND THE COST TO 
THE COMMUNITY 
There is ample evidence that over the last two decades asthma morbidity and 
mortality have increased in most industrialised countries (Sly, 1984; Benatar, 1986; 
Burney, 1986; Evans et al, 1987; Fleming and Crombie, 1987; Barnes, 1988; Jackson 
et al, 1988; Beasley et al, 1990; Weiss and Wagener, 1990). This is despite large 
increases in anti-asthmatic medication sales over the same period (Keating et al, 
1984; Hay and Higenbottam, 1987; Klaukka et al, 1991). 
The same pattern has occurred in Australia (Musk et al, 1987; Jenkins et al, 1988). 
Australian mortality rates from asthma are higher than England, Wales, Canada 
and the United States, although lower than New Zealand (Woolcock, 1986). 
Annual asthma deaths in Australia have risen from 2.3 deaths/100,000 population 
in 1978 more than doubling to 5.7 deaths/100,000 population in 1,989 (derived 
from data provided by the Australian Bureau of Statistics). There is, however, 
evidence that the mortality rate from asthma has begun to decline from the 1989 
peak shown in Figure 2.2 (source: Australian Bureau of Statistics). 
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Figure 2.2 	 Asthma mortality in Australia represented as asthma deaths per 100,000 
population. Source: Australian Bureau of Statistics. 
An estimated 1.4 milion Australians (9% of the population) reported experiencing 
asthma as either a recent or long-term condition in 1989-90 (National Health 
Survey 1989-90). The proportion of the population experiencing asthma as a long-
term condition rose from 2% in 1977-78 to 8% in 1989-90 with respiratory 
conditions, including the common cold, accounting for 24% of al days lost from 
work due to ilness or injury (National Health Survey 1989-90). The National 
Health Survey 1989-90 also found that asthma was more prevalent in younger 
people, with 12% of persons aged less than 25 reporting asthma. The asthma 
prevalence in children has been noted to be even higher at around 17% (Bauman et 
al, 1992a). 
Given the high morbidity and mortality due to asthma it not surprising that the 
cost to the community is high. It has been estimated that in 1991, the cost to the 
Australian community was between $585 to $720 milion per annum (NAG 
report, 1992). This estimate consisted of $320 milion in direct medical related 
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costs such as pharmaceuticals, medical consultations and hospitalisations, and 
between $265 to $400 million in indirect costs due to lost productivity such as 
absenteeism and reduced effectiveness at work (NAG report, 1992). Of additional 
interest is the fact that a person with poorly controlled asthma will incur greater 
costs than an asthmatic who is well controlled. Based on computer modelling, the 
more asthmatics who have their disease well controlled, the lower the total cost to 
the community (NAG report, 1992). 
It has been estimated that in Australia in 1990-1991, 4.0% of all encounters to a 
general practitioner resulted in a prescription for a bronchodilator, preventive 
agent (such as an inhaled corticosteroid or sodium cromoglycate) or methyl 
xanthine. Of all prescriptions written by general practitioners, 8.4% were for a 
bronchodilator, preventive agent or methyl xanthine (Bridges-Webb et al, 1992). 
In 1992, the top 10 drug list ranked by DDDs/1000 population/day in Australia 
included salbutamol with the highest level of community use of all prescription 
drugs (30.3 DDDs/1000 population/day), beclomethasone dipropionate (only 
inhaled preparations) in third position (12.3 DDDs/1000 population/day) and 
budesonide in sixth position (10.4 DDDs/1000 population/day; Anonymous, 
1994). The 1992 top 10 drugs by prescription counts included salbutamol with 
4,884,371 prescriptions in second position behind amoxycillin (Anonymous, 1994). 
The 1992 top 10 drug list ranked in order of cost to the government in Australian 
dollars included salbutamol in fifth position ($45 million), beclomethasone inhaled 
preparations in seventh position ($32 million), ipratropium bromide in eighth 
position ($30 million) and budesonide in ninth position ($28 million; Anonymous, 
1994). 
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2.4 STRATEGIES FOR REDUCING MORBIDITY AND MORTALITY IN 
AUSTRALIA 
Recognising the increase in asthma morbidity and mortality, an NHMRC working 
party (formed in 1987) on asthma-associated deaths released a report in June 1988 
with strategies for reducing morbidity and mortality in Australia (NHIARC 
report, 1988). This report made the recommendations shown in Table 2.1. 
Following an asthma awareness campaign in 1988, The National Asthma 
Campaign, a joint initiative of the Thoracic Society of Australia and New Zealand, 
the Royal Australian College of General Practitioners, the Pharmaceutical Society 
of Australia and the State and Territory Asthma Foundations, was established in 
1990 to combat the increasing morbidity and mortality from asthma in Australia. 
The 3 year goals of the National Asthma Campaign were that: (i) most people with 
asthma will be correctly diagnosed, (ii) most people with asthma will be using a 
recognised asthma management plan to help them manage their asthma, and (iii) 
there will be a decline in preventable deaths from asthma. 
The NAC and the asthma management plan were based on a publication of the 
Thoracic Society of Australia and New Zealand (Woolcock. et  al, 1989) which 
described a six point approach to asthma management as shown in Table 2.2. The 
plan provided guidelines for all doctors who treat patients with the hope that 
improved treatment will reduce morbidity and mortality from asthma in the 
future. Further guidelines have been published (Anonymous, 1992; Tse and 
Bridges-Webb, 1993) and it would seem sensible that new guidelines are published 
regularly in the future as understanding of the disease and therapeutic implications 
become clearer. 
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Table 2.1 	 Strategies for reducing morbidity and mortality from asthma in Australia. Based on 
NHMRC report (1988). 
Asthma in Australia 
Strategies for reducing morbidity and mortality 
(NH/VIRC working party report, June 1988) 
The immediate distribution of information about: 
curently agreed criteria for assessment of severity and management of 
patients with asthma; 
consumer (patient and parent) responsibility and roles in shared 
management of asthma as a chronic ilness. 
(i) The implementation of community based education programs through appropriate 
Commonwealth and State mechanisms. 
(ii) Having regard to the disincentives in curent fee schedules, the Health Insurance 
Commission be requested to explore methods of facilitating education of patients with 
asthma by medical practitioners. 
(iv) The RACGP, through its Family Medicine Program, be asked to consider making 
education about asthma a priority for doctors. 
(v) Fast lane procedures for admission to emergency care at hospitals be introduced. 
(vi) The urgent establishment of a National Asthma Mortality register with the capacity to 
conduct appropriate investigations. 
(vi)Research, aimed at providing beter understanding of the causes of asthma morbidity and 
mortality and their control, be made a priority area within the NHMRC grants scheme. 
(vii)Research be directed at defining the environmental factors presumed to act either as 
inducers of the disease or as triggers of atacks, in the Australian population. 
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Table 2.2 	 Asthma management plan based on Woolcock eta 1989. 
1.Assess severity of the asthma 
	
	 Assess when stable and not during an acute attack. Apply 
guidelines given in plan. 
2.Achieve "best" lung function 	 Use peak flow meter or spirometer and know "predicted" 
values; treat with bronchodilator and corticosteroid drugs 
by mouth until "best" value is found. 
3.Maintain "best" lung function by 
Home monitoring 	 Ensure patient records peak expiratory flow readings and 
continues to maintain "best" value. 
Therapy 	 Prescribe drugs including aerosol corticosteroid drugs, 
bronchodilator agents, cromoglycate and theophyline. 
Avoiding trigger and aggravating factors 	 Investigate and minimise (where possible) provoking 
stimuli and aggravating factors. 
4.Write an action plan 	 Write and discuss a plan, based on peak expiratory flow 
readings, to increase drug dosages and to gain rapid access 
to medical care. 
5.Educate the patient 	 Patient and family should understand the nature of the 
disease, relevant triggers, the aims of treatment, use of 
drugs and how to implement the action plan. 
6.Review regularly 	 Continue to care for the patient even when the asthma 
becomes mild. 
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Table 2.3 	 Anti-asthmatic drugs and some common adverse efects. 
Drug class Common adverse efects 
Bronchodilators 
Salbutamol 
Terbutaline 
Tremor, tachycardia, hypotension, nausea, hypokalaemia, sweating, muscle 
cramps, headaches, CNS disturbances, paradoxical bronchoconstriction, 
oral iritation. 
Inhaled corticosteroids 
beclomethasone dipropionate 
budesonide 
Oropharyngeal 	candidiasis, 	hoarsenes, 	throat 	iritation, 	paradoxical 
bronchospasm. 
Methyl xanthines 
Theophyline 
Aminophyline 
Choline theophylinate 
GI upset, CNS stimulation, tachycardia, palpitations, headache, insomnia, 
tremor, arhythmias, convulsions. 
Anti-cholinergics 
Ipatropium bromide 
Urinary retention, acute angle glaucoma, dry mouth, throat irritation, 
cough, visual accommodation disturbances. 
Anti-alergies 
Sodium cromoglycate 
Mild throat iritation, cough, transient bronchospasm. 
2.5 PHARMACOTHERAPY OF ASTHMA 
The pharmacotherapy of asthma relies mainly on 5 classes of drugs, 
bronchodilators, inhaled corticosteroids, methyl xanthines, ipratropium bromide 
and sodium cromoglycate. Table 2.3 shows the commonly used anti-asthmatic 
drugs in Australia, together with possible adverse efects. 
2.5.1 	 [32-Agonists 
In the past, asthma therapy has relied on achieving bronchodilation. Nebulised 
adrenaline became available in the 1930s (Gandevia, 1975), and was folowed by 
the development of non-selective P-agonists such as isoprenaline in the 1940s 
(Thompson and Watkins, 1994), and the development of [32-agonists during the 
1960s (Frew and Holgate, 1993). Stimulation of (32-receptors in the airway smooth 
muscle in humans results in the activation of adenylate cyclase and an increase in 
intracelular levels of cAMP. This leads to activation of protein kinase A which 
inhibits the phosphorylation of myosin and lowers the intracelular ionic calcium 
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concentration, resulting in smooth muscle relaxation (Barnes, 1989). Airway 
muscle in humans has only (32-receptors (Carstairs et al, 1985), hence stimulation of 
these receptors results in the smooth muscle relaxation. 
Mast cells also have 132-receptors (Butchers et al, 1980), and it has been suggested 
that 32-agonists also inhibit the release of mediators from mast cells in the airways 
(Butchers et al, 1980; Howarth et al, 1985; Church and Hiroi, 1987). [32-Agonists 
are known to be more potent mast cell stabilisers than sodium cromoglycate 
(Church and Hiroi, 1987). 132-Agonists may also inhibit the release of acetylcholine 
from postganglionic cholinergic nerves in the airway (Rhoden et al, 1988), reduce 
microvascular leakage and have beneficial effects on ciliary function and mucus 
production (Nelson, 1995). 
132-Agonists are the most effective bronchodilators in current use (Kemp, 1993) and 
protect against all bronchoconstrictor challenges (Barnes, 1989). Hence the term 
'reliever' is often used to describe (32-agonists due to their ability to relieve 
bronchoconstrictor challenges. They may be delivered by inhalation, or 
systemically by oral or intravenous routes (Thompson and Watkins, 1994). Inhaled 
therapy by either MDI or nebuliser is the most efficient means of delivering high 
local concentrations of drug to the airways, and minimising systemic side effects 
(Thompson and Watkins, 1994). 
Inhaled 132-agonists are indicated for the short-term relief of bronchoconstriction 
and are the treatment of choice for acute exacerbations of asthma (Barnes, 1989). 
They are highly effective against early phase exercise and allergen induced asthma 
bringing symptomatic relief (Skorodin, 1993). However, 132-agonists do not inhibit 
either the late response to allergens or the subsequent bronchial 
hyperresponsiveness (Cockcroft and Murdoch, 1987). Because of their 
symptomatic relief, it is now suggested that there is a danger that 13 2-agonists may 
15 
Chapter 2 
be used in worsening asthma to relieve symptoms, masking an underlying 
deterioration in the disease. Although there are beneficial non-bronchodilator 
actions of [32-agonists, for maintenance therapy in all but the mildest cases of 
asthma, it is essential that 13 2-agonists should be used in combination with inhaled 
corticosteroids or sodium cromoglycate, and if necessary, theophylline or 
ipratropium bromide (Thompson and Watkins, 1994). 
The past few years has seen the development of long acting r32-agonists including 
salmeterol, formoterol and bambuterol (Boulet, 1994). These agents have a later 
peak effect (typically 2-4 hours) and a significantly longer duration of action 
(typically greater than 12 hours) compared to the short acting (32-agonists such as 
salbutamol, terbutaline and fenoterol (peak effect usually 30-90 minutes after 
inhalation and duration of action 4-8 hours; Boulet, 1994). Longer acting i32- 
agonists have particular efficacy in nocturnal asthma and 'morning dippers', as 
well as reducing the overall [32-agonist load in comparison to salbutamol in 
conventional dosage regimens (Dalonzo et al, 1994; Thompson and Watkins, 
1994). In a twelve month comparison in moderate asthmatics, patients treated with 
salmeterol demonstrated a lower incidence of asthma and related events compared 
to patients treated with salbutamol (Britton et al, 1992). 
Long acting f32-agonists do protect against the late phase response but it has been 
suggested that this is due not to a clinically significant anti-inflammatory effect, but 
rather, to a prolonged functional antagonism (Taylor et al, 1992). It is currently 
recommended that long acting 132-agonists be used only in patients already 
receiving inhaled corticosteroids (Rees, 1991; Anonymous, 1992; Goldie et al, 
1995). There has been no evidence that long acting 32-agonists significantly 
influence the chronic inflammatory response (Barnes and Chung, 1992; Goldie et 
al, 1995). In addition, there have also been some questions regarding tolerance to 
protective effects against bronchoconstrictor stimuli in mild asthmatics despite 
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wel maintained bronchodilation (Cheung et al, 1992). It has been shown that 
patients using regular salmeterol treatment may also require higher doses of 
salbutamol when used for relief of acute symptoms (Grove and Lipworth, 1995a). 
The use of short acting 132-agonists for chronic therapy, not just acute symptomatic 
relief, has now been scrutinised. It would folow, therefore, that over reliance on 
long-acting (32-agonists may also mask an underlying deterioration in a patient's 
asthma. This wil also be discussed in Section 4.5. 
2.5.2 	 Glucocorticosteroids 
Corticosteroids are anti-inflammatory agents and have long been used in the 
treatment of asthma, although their mechanism of action is stil disputed (Barnes, 
1989). Corticosteroids produce a decrease in inflammatory cels, especialy 
eosinophils, inhibit leucocyte infiltration, inhibit activated T-lymphocytes, 
improve (32-adrenergic cel function, stabilise oedema, atenuate mediator release, 
especialy from activated eosinophils, and inhibit mast cel growth (Alpers, 1991; 
Gibson, 1992). Corticosteroids are the only available therapy which decrease the 
degree of bronchial hyperresponsiveness and reduce airway inflammation and 
oedema (Alpers, 1991). A reduction in bronchial hyperesponsiveness may take up 
to 3 months of continuous therapy (Woolcock et al, 1988). 
Corticosteroids also inhibit the late-phase response (Cockcroft and Murdoch, 1987; 
O'Byrne et al, 1987). In other words, unlike (32-agonists which provide 
symptomatic relief and may mask deterioration in the underlying disease, 
corticosteroids treat the underlying disease process (Paterson et al, 1995). Hence, 
corticosteroids are often termed 'preventers' in contrast to bronchodilator 
'relievers'. 
By the 1960s, it was realised that the long term use of oral corticosteroids was 
associated with significant adverse efects (Frew and Holgate, 1993). The adverse 
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effects of high dose glucocorticoids are shown in Table 2.4. Inhaled 
beclomethasone dipropionate was introduced in 1970 and rapidly established itself 
at the forefront of asthma treatment (Frew and Holgate, 1993). Because of its route 
of delivery, systemic side effects were reduced with the drug being delivered 
directly to the site of action. The efficacy and safety of inhaled corticosteroids now 
enable long term treatment with these drugs (Alpers, 1991). 
Systemic adverse effects from inhaled corticosteroids have been a controversial 
topic. With conventional inhalers, 85-90% of each dose is swallowed, of which 
some is absorbed. At doses greater than 1000 ,ug/day for adults ( > 400 Jug/day for 
children), biochemically detectable impairment of adrenal responsiveness to 
corticotrophin has been reported (Frew and Holgate, 1993). In the absence of 
previous or concomitant treatment with oral glucocorticoids, inhaled 
glucocorticoids in doses of 1500 ,ug/day or less in adults and 400 fig/day or less in 
children have little if any affect on pituitary-adrenal suppression related adverse 
effects (Barnes, 1995). Spacer devices, a recent development in MDI delivery, 
significantly reduce systemic absorption and should be used for drug delivery 
above these dosages (Frew and Holgate, 1993; Barnes, 1995). Fluticasone is a new 
inhaled corticosteroid which appears to be more potent than other corticosteroids 
with essentially no oral absorption and rapid hepatic metabolism (Thompson and 
Bremner, 1993). It is anticipated that this will allow the delivery of higher doses 
with reduced systemic effects (Thompson and Bremner, 1993; Lipworth, 1993). 
Health care providers and usually lay persons are aware that corticosteroids can 
cause serious side effects (Skorodin, 1993; Hanania et al, 1995). There have been 
some concerns about the possible side effects of inhaled corticosteroids, especially 
growth suppression in children (Frew and Holgate, 1993; Komodo, 1994). This has 
probably led to a reluctance to introduce inhaled corticosteroids into anti-
asthmatic regimens in the past, especially in patients with moderate asthma. 
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Because of the recent questions regarding the safety of long term r32-agonist use and 
a greater understanding of the pathogenesis of asthma as an inflammatory disease, 
there has now been general agreement towards a shift in the management of the 
disease with greater use of inhaled corticosteroids (Alpers, 1991; Frew and Holgate, 
1993; Paterson et al, 1995). Inhaled corticosteroids or sodium cromoglycate are 
now recommended much earlier in the disease for use as a regular maintenance 
therapy in al but the mildest cases of asthma (Barnes, 1989; Alpers, 1991; Larsen 
1992; Thompson and Watkins, 1994). 
Table 2.4 	 Adverse efects of high dose glucocorticoids. Adapted from Jackson and Bowman, 1995. 
• Hypertension (occurs in 80% of patients). 
• Osteoporosis and resulting fractures. 
• Impaired glucose tolerance and diabetes. 
• Suppression of immune function. 
• Poor wound healing and suppression of fibroblast activity. 
• Severe psychological disturbances, predominantly euphoria and depression. 
• Muscle wasting and central obesity. 
• Peptic ulcer disease. 
• Inhibition of linear growth in children. 
• Avascular necrosis. 
• Cataracts. 
• Electrolyte disturbances such as hypokalaemia. 
2.5.3 Methyl xanthines 
Methyl xanthines include theophyline, aminophyline (theophyline ethylene 
diamine) and choline theophylinate. Although theophyline has been used as a 
mainstay in asthma treatment for 50 years the mechanism of action is stil unclear 
(Persson, 1986). It was originaly thought that it caused bronchodilation by 
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inhibiting phosphodiesterase, leading to an increase in cAMP although this 
requires concentrations of drugs far exceeding the therapeutic range (Barnes, 1989). 
Other possible modes of action include adenosine receptor antagonism, although a 
closely related drug, enprofylline, has greater broncholidator potency but is not an 
adenosine antagonist (Cockcroft et al, 1989), inhibition of intracellular release of 
calcium and stimulation of catecholamine release (Barnes, 1989). 
Theophylline is a less effective bronchodilator than the 32-agonists (Barnes, 1989) 
but unlike 32-agonists, theophylline also inhibits the late phase response suggesting 
anti-inflammatory effects (Rogers et al, 1985; Mapp et al, 1987; Barnes, 1989; 
Alpers, 1991; Jenne, 1994). 
Intravenous aminophylline is an effective treatment for bronchospasm in acute 
severe asthma, however, there has been debate as to whether it has any additional 
benefits above those of the 132-agonists. Although there were no differences in 
spirometric response, Wrenn et al (1991) found that acute severe asthmatics who 
were treated with intravenous aminophylline in addition to bronchodilators 
recovered more quickly. 
There has been a shift away from the use of theophylline in recent years due to 
questions over its efficacy, its narrow therapeutic range and drug interactions 
(Alpers, 1991; Frew and Holgate, 1993; Paterson et al 1995). Continuous long-term 
therapy requires regular serum monitoring (Alpers, 1991) although xanthines are 
often prescribed without such monitoring (Rumbak and Self, 1992; Frew and 
Holgate, 1993). 
The therapeutic range of theophylline is 10-20 pg/ml. At serum levels over 
20 pg/m1 most individuals will experience toxicity consisting of tremor, nausea 
and CNS excitation (Frew and Holgate, 1993) and at higher plasma concentrations 
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more serious adverse effects such as cardiac arrhythmias and seizures may occur 
(Barnes, 1989). Despite these toxic effects, theophylline remains useful for some 
patients, especially those with nocturnal asthma (Alpers, 1991; Frew and Holgate, 
1993). For maintenance therapy, twice daily dosage of a slow release preparation 
should be used (Barnes, 1989). 
2.5.4 Ipratropitun bromide 
Cholinergic antagonists have been used for many centuries in herbal remedies for 
asthma but their adverse effects have proved unacceptable (Barnes, 1989). The 
development of ipratropium bromide, a quaternary ammonium derivative which is 
not readily absorbed from the gut and does not cross the blood-brain barrier, 
subsequently reducing the incidence of adverse effects, has renewed interest in this 
group of drugs (Barnes, 1989). 
Ipratropium bromide acts by blocking muscarinic receptors in smooth muscle 
leading to inhibition of vagal cholinergic tone, resulting in bronchodilation. 
Cholinergic antagonists provide various levels of protection against 
bronchoconstrictor challenges, are not particularly effective against allergen 
challenge, do not block the late phase response and do not inhibit the release of 
mediators from mast cells (Cockcroft et al, 1978; Howarth et al, 1985; Gross, 
1988). 
Ipratropium is less effective than adrenergic agonists in the treatment of asthma 
(Barnes, 1989) and should not be used as a first line drug or sole therapy for asthma 
(Alpers, 1991). The onset of action is slower than 13 2-agonists but the action is 
more prolonged, lasting up to 8 hours and may be of more benefit to patients with 
a major component of bronchitic symptoms (Barnes, 1989). The addition of 
ipratropium bromide to anti-asthmatic therapy may provide better therapeutic 
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coverage in some patients, especially those with severe acute asthma (O'Driscoll et 
al, 1989; Rees and Price, 1995a). 
2.5.5 Sodium cromoglycate 
Sodium cromoglycate has been classified as an anti-allergic agent. This is because of 
its prophylactic action by suppressing allergic response without possessing anti-
inflammatory properties (Paterson et al, 1995). The mechanism of action of 
sodium cromoglycate is still not clear. Because sodium cromoglycate inhibits the 
immediate response to allergens and exercise, it was originally thought that this 
was achieved by inhibiting the release of mediators (Cockcroft and Murdock, 
1987). 
It has also been suggested that sodium cromoglycate may act on other 
inflammatory cells such as macrophages or eosinophils because of its ability to 
inhibit the late response and bronchial hyperresponsiveness, whereas other mast 
cell stabilising drugs do not (Barnes, 1989). In addition, it has been suggested that 
sodium cromoglycate may act on sensory nerves in the airway involved in the 
neural mediation of bronchoconstriction (Barnes, 1989). 
There has been considerable recent promotion of sodium cromoglycate, given its 
anti-allergic properties, the very low incidence of adverse effects, an increase in 
dosage, and the current understanding of asthma as primarily a disease associated 
with airway inflammation due to antigen exposure. Sodium cromoglycate is now 
marketed in a 5 mg inhaler preparation in addition to the original 1 mg inhaler. 
Sodium cromoglycate, while having a long history of popularity for use in 
children with asthma, has now also become a recommended first-line therapy for 
these patients (Alpers, 1991; Breslin, 1993). Some adults may also benefit, 
particularly atopic patients and those with exercise induced asthma (McFadden and 
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Gilbert, 1993; Tse and Bridges-Webb, 1993). Despite its relative safety and efficacy, 
sodium cromoglycate is not effective in all patients and there seems to be no 
indicators to predict which patients will respond (Barnes, 1989). A trial of 4-8 
weeks is usually needed to determine if the patient will benefit (McFadden and 
Gilbert, 1993; Rees and Price, 1995a). Nedocromil sodium is closely related to 
sodium cromoglycate, with similar properties but has no advantages over sodium 
cromoglycate (Ruffin et al, 1987). 
2.5.6 Other drugs and new developments 
Other drugs used in the treatment of asthma include those drugs, not specifically 
anti-asthmatics, that act on the immune system such as methotrexate, gold salts, 
and troleandomycin, which have been shown to possess corticosteroid sparing 
activity (Barnes, 1989). Ketotifen, an antihistamine, showed some marginal benefit 
in a study by Hendy et al (1986) and cetirazine, another antihistamine, has shown 
some marginal benefit in exercise induced asthma (Ghosh et al, 1991). 
Zileuton, a 5-lipoxygenase inhibitor, blocks the synthesis of leukotrienes, 
mediators in the inflammatory cascade. It has been shown to be effective in 
improving airway obstruction and preventing associated symptoms (Israel et al, 
1993). Other drugs under development include anti-adhesion molecules (inhibit 
leucocyte recruitment), anti-cytokines (impair leucocyte activation, recruitment 
and survival) and anti-effector cells that act by temporarily removing T cells 
(Henahan, 1995). 
The search for a mediator antagonist or synthesis inhibitor is unlikely to result in 
the development of a new singularly effective asthma treatment (Paterson et al, 
1995). It is more likely that these new compounds may be combined with existing 
treatments to tailor medication to individual needs. 
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2.6 THERAPEUTIC CONTROVERSIES AND THE ASTHMA PARADOX 
As discussed earlier, there has been an alarming increase in asthma related 
morbidity and mortality in most industrialised countries, despite medication sales 
at an all time high. There have been numerous hypotheses to explain this 
paradoxical increase in morbidity and mortality. Environmental factors have been 
implicated, including pollution (Anonymous, 1989; Christie et al, 1992; Rennick 
and Jarman, 1992; Anto and Sunyer, 1995), occupational exposure to various 
compounds (Bernstein, 1992), pollens (Bellomo et al, 1992), and it is well 
documented that house dust mite is a trigger for asthma (Spector, 1991). Other 
studies have shown that there have been major misconceptions in the community 
about the disease in the past (Rubinfield et al, 1988) and a major degree of under-
recognition and under-treatment of asthma (Anonymous, 1993a; Bauman et al, 
1992b; Dales et al, 1992; Gibson et al, 1993a; Gibson et al, 1993b; Marks et al, 1994; 
Abramson et al, 1995), which could clearly contribute to asthma mortality. There 
has, however, been a disturbing suggestion that the increase in asthma drug sales, 
particularly bronchodilators, may not be a result of, but may rather be 
contributing to, increasing asthma morbidity and mortality (Barnes and Chung, 
1992). 
During the 1960s, isoprenaline, a non-selective P-agonist, was marketed in several 
countries in a high dose preparation (Isuprel Forte8). An epidemic of asthma 
deaths followed. Isoprenaline was implicated (Speizer et al, 1968) and mortality fell 
after the publicity and withdrawal of the over the counter preparation in Britain 
(Stony, 1972). There was, however, a similar rise in mortality of asthma in some 
countries which was not linked to the introduction of high strength isoprenaline 
inhalers (Barnes and Chung, 1992). 
A second epidemic followed in New Zealand in the 1970s with the introduction of 
fenoterol. It was suggested that there was a causal association between the 
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widespread use of fenoterol and asthma deaths (Crane et al, 1989a; Pearce et al, 
1990; Grainger et al, 1991) which was supported by a crossover study (Sears et al, 
1990) that showed worsening of asthma control with regular fenoterol use. Despite 
criticisms of these studies being confounded by disease severity, fenoterol use was 
clearly associated with an increased risk of death from asthma. 
It was suggested that fenoterol may have more adverse effects than related 
compounds due to less (32 selectivity and may have been marketed at a higher dose 
than related compounds (Wong et al, 1990). It was originally thought that these 
deaths were most likely due to cardiac arrhythmias induced by large doses of a less 
selective (32-agonist, given its effect of tachycardia after inhalation (Crane et al, 
1989b), but there is no direct evidence of this (Barnes and Chung, 1992). It has also 
been suggested that salbutamol can exert a cardiotoxic effect, evidenced by an 
increase in CKMB (creatinine kinase isoenzyme), when given by the intravenous 
route (Chazan et al, 1992). Although it is difficult to exclude arrhythmia as a 
precipitating cause of sudden asthma deaths (Barnes and Chung, 1992), Molfino et 
al (1991) found no evidence that arrhythmias are associated with near fatal attacks 
in patients admitted to hospital. 
It is still not clear as to whether fenoterol was responsible for the New Zealand 
epidemic or whether it was simply a marker, being a drug used in a high risk 
patient, and whether the potential problem was unique to fenoterol or common to 
all (32-agonists, and if so, if this is related to 132 selectivity or other mechanisms 
(Rubinfield, 1991). It is still argued that despite the limitations, the New Zealand 
time trends of asthma deaths are consistent with fenoterol being the main cause of 
the New Zealand asthma mortality epidemic (Pearce et al, 1995). 
Following the fenoterol controversy, Page (1991) hypothesised that the regular use 
of all 132-agonists, due to their nature of bronchodilation, permit antigen to 
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penetrate deeper into the airways. This is suggested to result in histological 
inflammatory changes and increased bronchial hyperresponsiveness, thus 
accelerating airways inflammation, leading to increased morbidity and mortality 
(Page, 1991). Studies have shown that regular treatment with 132-agonists can lead 
to reduced protection against constrictor challenges, including antigens and 
exercise (Cheung et al, 1992; Cockcroft et al, 1993; Grove and Lipworth, 1995b). 
After the acute protective effects (decreased bronchial hyperresponsiveness) of 1 2- 
agonist administration have worn off, there may be a rebound increase in 
bronchial hyperresponsiveness with regular p2-agonist use (illustrated in Figure 2.3 
after a single dose of a p 2-agonist; Wahedna et al, 1993). It has also been suggested 
that tachyphyla2ds may develop due to down regulation of 13 2-receptors, but this 
effect does not appear to occur readily (Barnes and Chung, 1992). Although 
tolerance to anti-bronchoconstrictor effects has been shown, there is no conclusive 
evidence as yet, to suggest that tolerance develops to the bronchodilator effects of 
132-agonists (Grove and Lipworth, 1995b). Despite the hypothesis that regular 132- 
agonist therapy may worsen asthma control, there is still no convincing evidence 
explaining how this would happen (Fuller, 1994). 
There is no doubt that asthma morbidity and mortality are clearly associated with 
increased use of p2-agonists as patients with more severe asthma require greater 13 2- 
agonist rescue (Spitzer et al, 1992; Castle et al, 1993; Fuller, 1994). In a large case-
control study using linked health insurance data-bases consisting of a cohort 
population of 12,301 asthmatic patients, Spitzer et al (1992) reported that 
increasing use of P2-agonist was associated with an increased risk of mortality. In 
retrospect, it has been suggested that the headlines following the study by Spitzer 
et al (1992) were misleading and were based on an extremely weak association 
between 132-agonist use and death (Mullen et al, 1993). In addition, Suissa et al 
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(1994) showed that increasing use of P2-agonists in a patient should be regarded as a 
serious warning sign of an impending life-threatening atack. 
Time (hours) 
Figure 2.3 	 Diferences in bronchial hyperresponsiveness after a single dose ofP-agonist with 
regular and acutep-agonist use. (a) Diminished reduction in bronchial 
hyperresponsiveness (decreased protective efect) after regular administration of a (3- 
agonist. (b) A rebound increase in hyperresponsiveness may occur after the acute 
protective efect has worn of after regular administration of a 13-agonist 
(Adapted from Tatersfield, 1994). 
Two possible scenarios to explain the association between increasing (32-agonist use 
and increased risk of mortality have been proposed by Suissa et al (1994): the 13- 
agonist hypothesis' (132-agonist use causing worsening of asthma control) and the 
'severity hypothesis' (p2-agonist use acting as a marker for increasing disease 
severity). The asthma paradox and hypothesis of a possible causal link between 
increased 132-agonist use and increased morbidity/mortality are depicted in Figure 
2.4. 
The hypothesis of a causal link between 132-agonist use and an increase in disease 
severity obviously relies on showing that P2-agonist use worsens asthma control 
(Fuler et al, 1994). There have been several studies suggesting that regular (32- 
agonist use does worsen asthma control (Sears et al, 1990; van Schayck et al, 1991; 
Spitzer et al, 1992). These studies, however, are in contrast to those suggesting that 
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regular 132-agonist therapy does not lead to a deterioration in asthma control or can 
improve asthma symptoms (Britton et al, 1992; Pearlman et al, 1992; Castle et al, 
1993; Chapman et al, 1994; Dalonzo et al 1994). These studies are summarised in 
Table 2.5. In addition, asthma mortality in the United Kingdom has not increased 
in the past 10 years despite a doubling in the use of [32-agonists (Tatersfield, 1994). 
Increasing 1 2 -agonist use 
relief of symptoms 
Increased drug sales 
THE ASTHMA PARADOX 
Increased morbidity/mortality 
Worsening asthma control 
bronchoconstriction 
bronchial hyperresponsiveness L. 	 inflammation 
p-Agonist hypothesis 
Environmental factors 
Poor management 
Other factors Severity hypothesis 
Figure 2.4 	 The asthma paradox. Increased sales of anti-asthma drugs, in particular p2- 
agonists, have not reduced either asthma morbidity or mortality. Have E-32- 
agonists been contributing to worsening asthma control or have the increases in 
morbidity/mortality been due to other factors such as poor management and 
the environment? Suissa et al (1994) have described these passible causes as the 
13-agonise hypothesis and the 'severity' hypothesis respectively. 
The fact remains that there have been two epidemics of asthma deaths in the last 
40 years, both of which were associated with a high dose bronchodilator with less 
1-32 selectivity than related compounds, and both epidemics resolved once the drugs 
had been withdrawn (Tattersfield, 1994). Whether or not these drugs were solely 
responsible has never been determined (Barnes and Chung, 1992). What cannot be 
argued is that increasing (32-agonist use in a patient is closely associated with 
worsening asthma severity. This indicates the need for intervention in line with 
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Table 2.5 	 Studies (=mining regular versus as-needed bronchodilator therapy. 
Title 	 Study Outline 	 Authors 
Regular inhaled beta-agonist 
treatment in bronchial asthma. 
Bronchodilator treatment in 
moderate asthma or chronic 
bronchitis: continuous or on 
demand? A randomised controled 
study. 
Eighty nine subjects with stable asthma took part in a 	 Sears et al, 1990. 
double-blind, placebo controled, randomised crossover 
study over 48 weeks. Patients took either placebo or 
fenoterol by DPI for 24 weeks before swapping to the 
alternate DPI as wel as supplementary aerosol as necescary. 
Regular treatment with fenoterol was associated with 
deterioration of asthma control in the majority of subjects. 
Two hundred and twenty three patients participated in a two 	 van Schayck et al, 
year randomised controled prospective crossover study in 	 1991. 
which patients were assigned to receive continuous 
treatment or treatment on demand. Continuous treatment 
without anti-inflammatory treatment accelerated decline in 
ventilatory function. 
The use of 13-agonists and the risk 
of death and near death from 
asthma. 
Health insurance databases were examined in a cohort of 
12,301 patients for whom asthma medications had been 
prescribed between 1978 and 1987. An increased risk of 
death or near death was associated with the regular use of 
inhaled f32-agonists, especialy fenoterol. 
Spitzer et al, 1992. 
A twelve month comparison of 
salmeterol with salbutamol in 
asthmatic patients. 
A comparison of salmeterol with 
albuterol in the treatment of mild-
to-moderate asthma. 
Serevent nationwide surveilance 
study: a comparison of salmeterol 
with salbutamol in asthmatic 
patients who require regular 
bronchodilator treatment. 
Regular vs as-needed inhaled 
salbutamol in asthma control. 
Salmeterol xinofoate as 
maintenance therapy compared 
with albuterol in patients with 
asthma. 
Six hundred and sixty seven moderate asthmatics 	 Briton et al, 1992. 
participated in a double-blind, paralel group study taking 
salbutamol and salmeterol regularly for 12 months (as wel as 
supplementary bronchodilation when necessary). Both 
treatments were wel tolerated throughout the study period 
with a similar incidence of adverse efects. 
Two hundred and thirty four patients were divided into 	 Pearlman et al, 
three treatment groups (regular salbutamol, regular 	 1992. 
sahmeterol and placebo) as wel as supplementary 
bronchodilation over a 12 week treatment period. Regularly 
administered salbutamol was no more or less beneficial than 
salbutamol used on an as-needed basis. 
Treatment over 16 weeks with either salmeterol or 	 Castle et al, 1993. 
salbutamol was not associated with an incidence of deaths 
related to asthma in excess of that predicted. 
Three hundred and fourteen asthma patients were treated in 	 Chapman et al, 
a four-week, randomised, crossover trial of regular and as- 	 1994. 
needed salbutamol. Regular salbutamol in moderate 
asthmatics was associated with less frequent asthma 
symptoms. 
Three hundred and twenty two asthma patients were treated 	 Dalonzo et al,- 
with salmeterol, salbutamol or placebo for 12 weeks. No 	 1994. 
deterioration of asthma control was observed with the 
regular use of salmeterol. 
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current management guidelines (Anonymous, 1992; Tse and Bridges-Webb, 1993) 
to reduce the reliance on bronchodilator therapy, with greater emphasis placed on 
early introduction of anti-inflammatory therapy. Figure 2.5 shows the current 
international consensus toward the stepwise management of asthma. 
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inical features pretreatment a 
Step 1. Mild Asthma 
• Intermittent brief symptoms 
(<1-2/week) 
• <1-2 nocturnal symptoms/month 
• Asymptomatic between epidsodes 
• PEFR or FEVi >80% predicted, 
variability <20% 
Steps 2 and 3. Moderate Asthma 
• >1-2 exacerbations/week 
• Activity and sleep affected 
• Nocturnal symptoms (>2/month) 
• Almost daily need for inhaled beta-agonise 
• PEFR or FEV1 60-80% predicted and 
variability 20-30% 
Step 4. Severe Asthma 
• Frequent exacerbations 
• Continuous symptoms 
• Frequent nocturnal symptoms 
• Activities limited 
• PEFR or FEY' <60% predicted 
and variability >30% 
Particularly for 
nocturnal symptoms 
erapy, (NB. /!..1ust include pauent education about preveuuon en addleion co symptom control 
• Short=acting inhaled B.- 
agonist pro (not more than 
3 times/week) 
•Inhaled sOdium cromo-
glicat`e or short acting 
13.-agonisi before exercise 
or allergen exposure — 
• Inhaled coiticosteroid (200- 
500 microgram daily up to 
750 microvam daily if 
necessary) 
Or 
Sodium cromoglycatc 
• Short-acting inhaled B.- 
agonise (pro, up to 3=4/daily) 
• Inhaled corticosteroid (800- 
1000 microgram daily 
+ 
• Sustained release 
theophylline 
or 
• Oral I3i- agonist 
• Long-acting inhaled 
agonist (especially for 
nocturnal symptoms 
• Short-acting inhaled pz-
agonist (pm, up to 3-4/daily) 
• Inhaled corticosteroidp00- 
1000 Microgram daily) 
• Sustained release 
tlxeophylline 
and/or 
• Oral 132- agonist 
or .  
Long-acting inhaled 
agoixist (especiallifor 
nocturnal symptoms) 
with or without 
„oaigeged 
• Oral corticosteroid (altern-
ate day or single daily dose) 
• Short-acting inhaled B.= 
agonise (pm, up to 3-4/daily) 
ncFic'anciged 
Control 
eved 
1.11;COIlle : 
Control of asthma 
• Minimal (ideally no) chronic symptoms 
• Minimal (infrequent) episodes 
• No emergency visits 
• Minimal need for inhaled B.-agonises 
• Minimal (or no) adverse effects 
from medication 
NB. Once sustained control achieved, a step-down reduction in therapy may be 
carefully considered (to identify minimum therapy required to maintain control) 
Best possible results 
• Least symptoms 
• Least need for inhaled R.- agonists 
• Least limitation of activities 
• Best PEFR with least circadian variation 
• Least adverse effects from medication 
. One or more features may bc oreKqe; 
gatfnt itic t) most severe grade which any 
b icuipigclizgcosteroid dose refers to beclomethasone 
. May consider inhaled anti-cholinergic 
• No limitations of activities 
(including exercise) 
• (Near) normal PEFR and circadian 
variation <20% 
Figure 2.5 Stepwise approach to the management of asthma. Adapted from the International 
consensus report on the diagnosis and management of asthma (Anonymous, 1992). 
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Pharmacoepidemiology Background 
3.1 SUMMARY 
Pharmacoepidemiology is a relatively new discipline involving the study of the patterns and effects of 
therapeutic drug use within populations. The background and methodology of pharmacoepidemiology 
and its applications in improving therapeutic drug use are examined. In addition, the current state of 
drug utilisation data in Australia is discussed. The role of pharmacoepidemiology in monitoring asthma 
drug therapy, in light of the asthma paradox and shift in emphasis to preventive (anti-inflammatory and 
anti-allergic) medication is also discussed. 
3.2 BACKGROUND OF PHARMACOEPIDEMIOLOGY 
3.2.1 What is pharmacoepidemiology? 
Pharmacoepidemiology is a relatively new discipline involving the study of the 
patterns and effects of therapeutic drug use within populations (Hartzema 1992; 
Henry, 1988; Wertheimer and Andrews, 1995). Pharmacoepidemiology is 
essentially the merging of clinical pharmacology (the study of effects of drugs in 
humans) and epidemiology (the study of distribution and determinants of disease 
in populations; Strom, 1994). 
The methodology of pharmacoepidemiology has a three stage process. Firstly, a 
sample population of subjects is studied; secondly, the information obtained from 
this sample is generalised; and thirdly, a conclusion is drawn about the population 
in general (Strom, 1994). This conclusion is referred to as an association. There 
are four basic types of associations that can be observed in a 
pharmacoepidemiology study, as shown in Table 3.1. The basis of 
pharmacoepidemiological research is to differentiate between these associations 
(Strom, 1994). This usually involves statistical analyses to determine if the 
differences in outcomes may have occurred by chance. To find a true causal 
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association, all three types of errors (random error, bias and confounding) must 
be excluded (Strom, 1994). In addition, further criteria must exist for a causal 
association (Table 3.2). No single criteria is sufficient for a causal association. 
Analogously, it is not necessary to satisfy all criteria for a causal association 
(Strom, 1994). 
Pharmacoepidemiological study design may consist of randomised clinical trials, 
cohort studies, case-control studies, analysis of secular trends, case series and case 
reports (Strom, 1994). These studies are briefly described in Table 3.3. Case 
reports, case series, analyses of secular trends, case-control studies and cohort 
studies have been referred to as observational study designs (Strom, 1994). In 
observational studies, investigators do not control drug therapy but observe and 
evaluate the results of ongoing medical care (Strom, 1994). 
Analyses of secular trends can examine trends in disease and exposure over time 
or between different populations. These types of studies may be particularly 
useful in the postmarketing surveillance of drugs for observing rare drug effects 
that would not necessarily be observed in cohort studies due to the number of 
exposed patients that would be needed (Strom, 1994). For example, if an adverse 
drug reaction is suspected in 1 in 10,000 users, a sample size of approximately 
30,000 patients would be needed to provide 95% confidence in detection (Porta 
and Hartzema, 1991). A limitation of analyses of secular trends is that 
confounding variables cannot be controlled. Because these studies only observe 
groups, they lack data on individuals. Another limitation is that disease trends 
may not be ideally recorded. When examining trends in disease, there may be (i) 
trends in how frequently patients are diagnosed with a given disease dependent on 
factors such as disease awareness at the time of diagnosis, (ii) changes in diagnostic 
methods, (iii) advances in diagnostic technology allowing a more accurate 
diagnosis of previously hard to diagnose diseases, (iv) changes in coding systems, 
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(v) changes in population demographics, and (vi) difficulty in differentiating 
between incidence of disease and mortality rates (Strom, 1994). The inherent 
scientific weakness of analyses of secular trends (ecologic studies) must be 
remembered and should be regarded as being, at best, an hypothesis generating 
activity (Eisdaile et al, 1987). 
Table 3.1 	 Types of associations between factors studied (Adapted from Strom, 1994). 
Association type 	 Nature of association 
•none 	 independent 
•artifactual: 	 spurious or false 
random eror 	 unsystematic variation 
bias 	 systematic variation 
•indirect 	 confounded 
•causal 	 direct or true 
Table 3.2 	 Criteria for the causal nature of an association (Adapted from Strom, 1994). 
•Coherence with existing information (biological plausibility) 
•Consistency of the association 
•Time sequence 
•Specificity of the association 
•Strength of the association: 
quantitative 
dose-response relationship 
study design 
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Can study multiple 
exposures. 
Can study uncommon 
diseases. 
Logisticaly easier and 
faster. 
Les expensive. 
Can provide rapid 
answers. 
Control selection 
problematic. 
Possibly biased 
exposure data. 
No control of 
confounding factors. 
Easy quantitation of 
incidence. 
Inexpensive and easy 
method for generating 
hypothesis. 
No control group so 
cannot be used for 
hypothesis testing. 
Cannot be used for 
hypothesis testing. 
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Table 3.3 	 Types of pharmacoepidemiology study designs, their advantages and disadvantages 
(Adapted from Strom, 1994) 
Study design 	 Description 	 Advantages 	 Disadvantages 
Randomised clinical trials are essentialy 
experimental studies in which the 
investigator controls the therapy and 
randomly alocates patients between the 
study groups. Associations demonstrated in 
randomised clinical trials are more likely to 
be causal associations than associations 
shown in other study types. 
Cohort studies identify subsets of a defined 
population and observe them over time, 
generaly comparing patients exposed to a 
particular therapy with unexposed patients. 
Patients are recruited into cohort studies on 
the basis of presence or absence of exposure 
and their subsequent disease course is then 
studied. 
Case-control studies compare patients with a 
disease with controls without the disease and 
difer from cohort studies on the basis of 
patient recruitment. Patients recruited into 
case-control studies are selected on the basis 
of presence or absence of disease, prior 
exposures are then studied. 
Analyses of secular trends, or ecologic 
studies, examine trends in an exposure that 
is a presumed cause and examine trends in a 
disease that is a presumed efect and test 
whether the trends coincide. 
Case series are colections of patients, al of 
whom have single exposure, whose clinical 
outcomes are then evaluated and described. 
Case reports, as used in 
pharmacoepidemiology, are usualy reports 
that describe a single patient who was 
exposed to a drug and experienced an 
adverse outcome. Case reports are useful for 
raising hypotheses about drug efects that 
can be tested with more rigorous studies. 
Randomised 
clinical trial 
(experimental 
study) 
Cohort studies 
Case-control 
Analyses of 
secular trends 
Case series 
Case reports 
Most convincing 
design. 
Only design that 
controls for unknown 
or unmeasurable 
confounders. 
Most expensive. 
Artificial. 
Logisticaly more 
dificult. 
Ethical objections. 
Can study multiple 
outcomes. 
Can study uncommon 
exposures. 
Selection bias less likely. 
Unbiased exposure data. 
Incidence data available. 
Possibly biased 
outcome data. 
More expensive. 
May take years to 
complete if done 
prospectively. 
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3.2.2 Applications of pharmacoepidemiological studies 
Accurate population-based data on drug usage and effects are required to ensure 
that drugs are safe, effective and utilised appropriately (Jacobson et al, 1992). 
Investigation of prescribing patterns can be a powerful tool in rationalising drug 
use and creating greater economic efficiency in health care (Clark, 1986). 
Population based data on the usage and effects of drugs can be used for (i) drug 
utilisation research, (ii) studies of drug efficacy and/or adverse drug reactions, 
incorporating postmarketing surveillance (PMS), (iii) economic evaluations of 
drug therapies (Hurley and McNeil, 1988; Hurley et al, 1988) and, (iv) to define 
optimal therapy or establish prescribing guidelines (MacLeod, 1991). The 
advantages of using pharmacoepidemiology for PMS include factors such as large 
populations may be studied over long periods of time, relatively low cost 
compared to clinical trials, sample populations may include patients not normally 
included in clinical trials and uncommon adverse drug reactions may be observed 
(Strom, 1994). 
There have been several recent studies which illustrate the benefits of 
pharmacoepidemiology. These are shown in Table 3.4. Pharmacoepideraiology 
has identified causal associations between gastrointestinal bleeding with individual 
non-steroidal anti-inflammatory drugs (Rodriguez and Jick, 1994; Figueras et al, 
1994; Traversa et al, 1995) and possible links between oral contraceptive use and 
protection from Guillain-Barre syndrome (Stricker et al, 1994), inappropriate 
prescribing practices (Henry et al, 1991; Montanaro et al, 1992; Rosholm et al, 
1993) and differences in patterns of benzodiazepine use linked with morbidity and 
psychosocial problems (Ekedahl et al, 1993; Ruiz et al, 1993). From these 
examples it is clear that pharmacoepidemiology has already shown its ability to 
act as a basis to increase the rational use of drugs, and is likely to have an 
increasing impact on clinical medicine (Strom and Tugwell, 1990). 
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3.2.3 Problems in therapeutic comparisons: the role of the defined daily dose 
To allow any meaningful analysis of observational pharmacoepidemiology 
research, either within studies or between studies, there must be agreement on 
standardised units of comparisons for drugs (Cooke, 1991). For example, 
therapeutic comparisons between different drugs based on units of weight would 
not take into account factors such as molecular weight, potency, bioavailability 
and route of administration. The use of units of weight for drug comparison 
between a relatively potent and selective 132-agonist, such a salbutamol, and a non-
selective 13-agonist, such as orciprenaline, becomes difficult. 
Recognition of this dilemma of comparison of drugs has led the WHO (World 
Health Organisation) to recommend the adoption of the defined daily dose 
(DDD). The DDD is a unit of comparison between drugs and was originally 
introduced by the Nordic Medicines Commission where DDDs are defined as the 
average maintenance doses for the main clinical indication of the drug in adult 
patients. DDDs are not meant to be recommended doses but merely provide a 
standardised unit for comparative purposes (Cooke, 1991). In Australia in 1988, 
the Drug Utilisation Subcommittee (DUSC) was formed by the Pharmaceutical 
Benefits Advisory Committee (PBAC) to investigate ways of providing 
comprehensive and valid drug utilisation information in Australia (Birkett, 1993). 
DUSC adopted the now international unit of drug utilisation, the defined daily 
dose (DDD) per thousand population per day. 
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Table 3.4 	 Some recent pharmacoepiderniology studies. 
Author  
Birket and 
McManus, 
1995. 
Henry et al, 
1991. 
Montanaro et 
al, 1992. 
Ekedahl et al, 
1993. 
Rosholm et al, 
1993. 
Ruiz et al, 1993. 
Rodriguez and 
Jick, 1994. 
Figueras et al, 
1994. 
Title 
Modeling the market uptake of 
new drugs folowing listing for 
subsidy in Australia. A report 
from the Drug Utilisation 
Subcommitee of the Australian 
Pharmaceutical Benefits 
Advisory Commitee. 
Recent trends in the prescribing 
of cholesterol lowering drugs in 
Australia. 
Drug utilisation in general 
practice: prescribing habits of 
National Formulary drugs by 
GPs of Emilia Romagna (Italy) in 
1988 and 1989. 
Benzodiazepine prescribing 
paterns in a high-prescribing 
Scandinavian community. 
Outpatient utilisation of anti-
depressants- a prescription 
database analysis. 
Comparative study on 
benzodiazepine use in Canada 
and Chile. 
Risk of upper gastrointestinal 
bleeding and perforation 
associated with individual non-
steroidal anti-inflammatory 
drugs, 
Spontaneous reporting of adverse 
drug reactions to non-steroidal 
anti-inflammatory drugs- a 
report from the Spanish system 
of Pharmacovigilance, including 
an early analysis of topical and 
enteric coated formulations. 
Gastroduodenal toxicity of 
diferent nonsteroidal anti-
inflammatory drugs. 
Study Outline 
The market uptake of simvastatin, omeprazole, budesonide, 
fluoxetine and moclobemide were modeled using the sigmoid 
Emax model for drug-receptor binding. There were substantial 
diferences in uptake rates between drugs and good fits of the 
model to the data. 
The use of clofibrate increased to a greater extent than the 
prefered treatment for hyper-cholesterolaemia (cholestyramine 
and colestipol). 
It was found that there was over prescription of wel documented 
drugs such as H2-antagonists, ACE inhibitors, calcium 
antagonists and HMG-Co-A-reductase inhibitors. There was 
frequent inappropriate prescribing of some drugs. 
Higher than national average prescribing of benzodiazepines, 
possibly due to higher psychiatric morbidity, psychosocial 
problems and deviant prescribing habits. 
A large number of patients were found to be prescribed anti-
depressants in low doses suggesting that the drugs were being 
used for indications other than depression or that a large number 
of patients were not given a suficient dose. 
Although total benzodiazepine use was similar in both countries, 
there were striking diferences in the use of individual 
benzodiazepines, possibly due to diferences in the health care 
systems. These diferences in paterns of use may determine 
diferences in morbidity rates associated with these drugs. 
Users of azapropazone and piroxicam had a higher risk of upper 
gastrointestinal bleeding than patients using ibuprofen, naproxen, 
diclofenac, ketoprofen and indomethacin. Indomethacin and 
ibuprofen showed a substantial increase in risk from a low to a 
high daily dose. 
The study raised concerns about the relative safety of sustained - 
release and enteric-coated non-steroidal anti-inflammatory drug 
preparations in practice. 
Traversa et al, 	 The use of ketorolac caried a greater risk of gastrotoxicity than 
1995. 	 other non-steroidal anti-inflammatory drug preparations. 
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Table 3.4 continued. 
A case-control study of drugs and 	 Stricker et al, 
other determinants as potential 	 1994. 
causes of Guilain-Bare 
syndrome. 
A case-control study was performed to investigate the possible 
role of drugs and other determinants in the causation of Guilain-
Bare syndrome. There was significantly lower use of oral 
contraceptives in female cases of Guilain-Bare syndrome, 
suggesting that oral contraceptives may ofer a protective efect. 
3.3 AUSTRALIAN DRUG UTILISATION DATA 
It has been suggested that Australia is faling behind many other countries, 
particularly in Europe, in the important health care area of 
pharmacoepidemiology (Henry, 1988). Major deficiencies have existed in the 
routine sources of Australian pharmacoepidemiology data and in data colection 
(Hurley et al, 1988) with no single comprehensive source. As noted by Henry 
(1988), it is even dificult to answer simple questions concerning the number of 
patients in Australia who have received a particular drug. 
The main sources of drug utilisation data colection in Australia include the 
Pharmaceutical Benefits and Repatriation Pharmaceutical Benefits Schemes (PBS 
and RPBS), private marketing companies such as Intercontinental Medical 
Statistics (IMS), and the Australian Health Survey (Hurley et al, 1988). These and 
other sources are shown in Table 3.5. The lack of systematic methods of 
examining prescribing paterns has contributed to relatively litle drug utilisation 
research being performed in Australia. In addition, the limited research that has 
been performed has largely had to rely on increasingly incomplete data (Birket et 
al, 1991; Henry et al, 1991; Hurley et al, 1990; Jenkins et al, 1990), data provided 
by the questionnaires completed during the Australian Health Surveys of 1977-78 
and 1983-84 (Lockwood and Berbatis, 1990), on information obtained from 
private market research companies (Mant et al, 1988; Harvey, 1988) or on the 
National Survey of Morbidity in General Practice (Bridges-Webb et al, 1992). 
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The formation of DUSC has addressed 3 major problems in drug utilisation 
research in Australia: (i) the lack of a uniform drug coding or classification 
system, (ii) the need for an adequate unit of drug utilisation measurement, and (iii) 
the problem of obtaining comprehensive and continuing data on drug 
prescribing, drug dispensing and drug use (Birkett, 1993). 
The major limitations of drug utilisation data from the PBS/RPBS is that the data 
is incomplete. PBS data is only complete for listed drugs prescribed to pensioner 
or concessional patients, drugs costing more than the maximum patient 
contribution (presently $16.20) and drugs prescribed to general patients who have 
spent more than approximately $400 on PBS drugs in a calender year (under the 
'safety net' scheme). Drugs listed in the PBS schedule with a dispensed price 
below the maximum patient contribution are not recorded, such as most of the 
bronchodilator preparations and many drugs are not listed on the PBS or RPBS, 
with the patient responsible for full payment. Only about 60% of total 
prescription sales are currently PBS items (based on extrapolations from 1994 
Guild Digest data; Table 4.4) and this would be expected to decrease further as 
patient contributions increase. RPBS data only encompass patients entitled to 
treatment because of service in the Australian armed forces, accounting for 7-8% 
of all community pharmacy prescriptions (Hurley et al, 1988). To correct these 
deficiencies in PBS/RPBS drug utilisation data, the DUSC has collaborated with 
the Pharmacy Guild of Australia to obtain survey data on drugs not covered by 
the PBS or RPBS. Data is collected from computer dispensing data in a stratified 
random sample of pharmacies throughout Australia and is aggregated by drug 
code. These data provide information on all PBS and RPBS categories as well as 
private, general and S3 recordable items (S3Rs) and so is more comprehensive 
than PBS/RPBS data alone (Birkett, 1993). 
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Table 3.5 	 Some major sources of drug utilisation data within Australia* 
Source 	 Scope 	 Comments 
Pharmaceutical Benefits 
Scheme (PBS) 
Repatriation 
Pharmaceutical Benefits 
Scheme (RPBS) 
National Survey of 
Morbidity in General 
Practice. 
Community Pharmacy 
Dispensing Records 
Australian Medical Index 
(AMI) produced by 
Intercontinental Medical 
Statistics (IMS) 
Australian Pharmaceutical 
Index (API) produced by 
IMS 
Strategic Planning Index 
(SPI) 
Hospital pharmacy 
dispensing records 
•Only drugs Listed on PBS - mostly S4 items. 
•prescriptions dispensed in community pharmacies or by 
approved doctors in isolated areas. 
•community or private hospital patients (not public hospital 
patients). 
•drugs on restricted List. 
•prescriptions dispensed in community pharmacies (not 
repatriation hospitals). 
•patients entitled to treatment because of service in the 
Australian armed forces. 
•7-8% of community pharmacy prescriptions. 
•GP recorded details of doctor-patient encounters 
•Stratified random sample of GPs 
•details recorded such as patient age, sex, reasons for encounter, 
problems managed and drugs prescribed. 
•al prescriptions dispensed in community pharmacies. 
•indudes recordable S3 items. 
•quarterly publication with prescribing paterns for diagnosis 
and utilisation paterns for drugs. 
•based on Australian Morbidity Survey of GPs. 
•Data projected to give Australian estimates. 
•monthly publication 
•sales of pharmaceuticals to community pharmacies (not 
hospitals). 
•prescription and non-prescription drugs. 
•quarterly publication with prescribing paterns for diagnosis 
and utilisation paterns for drugs. 
•based on survey of GPs. 
•details of treatment substitutions, additions and 
commencements 
•al prescriptions dispensed in hospital pharmacies. 
•mostly S4 items. 
•no data on number of patients, patient's 
age or sex, dosages or diagnoses. 
•data set has diminished with recent 
increases in patient contribution. 
•no data on number of patients, patient's 
age or sex, dosages or diagnoses. 
•only performed in 1962-63, 1969-74 and 
1990-91. 
•data represented as percentages rather 
than DDDs. 
•not al drugs prescribed are dispensed. 
•this source has not been investigated in 
depth. 
•compatibility of diferent software may 
be a problem. 
•most non-prescription drugs exduded. 
•not al drugs prescribed are dispensed. 
•co-prescribing data limited, non-
prescription drugs exduded. 
•data availability restricted and may be 
costly. 
•no data on number of patients receiving 
a particular drug. 
•no data on patients, dosages or 
diagnoses. 
•data availability restricted. 
•diary data recording system. 
•not al drugs prescribed are dispensed. 
•data not projected. 
•the large number of drug coding systems 
would make merging of data dificult. 
•many diferent computer systems. 
•computerisation not universal. 
•unit sales and individual products not 
identified. 
•data availability restricted. 
Australian Pharmaceutical • quarterly report of dolar sales of pharmaceuticals to hospitals. 
Marketing Research Group • 80% of manufacturers participate. 
(APMRG) survey 
*Adapted from Hurley et al, 1988 
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3.4 ANTI-ASTHMATIC DRUGS: THE ROLE OF PHARMACOEPIDEM1OLOGY 
The benefits of monitoring anti-asthmatic drug consumption within the 
community are obvious given the history surrounding the epidemics associated 
with isoprenaline and fenoterol in the 1960s and 1970s. In addition, the Australian 
Adverse Drug Reaction Committee (ADRAC), through its parent committee, the 
Australian Drug Evaluation Committee (ADEC), first noted the latest increase in 
asthma associated deaths during the 1980s (NHMRC report, 1988). The matter was 
then referred to the NHMRC in 1988. Subsequent to the NHMRC report on the 
matter, an action plan and the NAC were developed, and it now seems that asthma 
mortality may be falling. 
Following the International Consensus Report on Asthma Management, 
Toogood (1993) stated that challenges for medical research include epidemiologic 
studies to critically assess the impact of recommended treatment regimens on 
therapeutic outcome. The following study examined regional anti-asthma 
medication sales, morbidity (indicated by hospital admissions) and asthma 
mortality (asthma deaths) in Tasmania. The objective of the study was to examine 
if anti-asthma medication sales were changing in line with current therapeutic 
guidelines (i.e. greater emphasis on anti-inflammatory and anti-allergic therapy), if 
there were any regional differences within the State and if there was any 
association between anti-asthmatic medication sales and asthma morbidity and 
mortality. 
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Anti-Asthmatic Pharmacoepidemiological Trends in 
Tasmania from April 1991 to April 1994 
4.1 SUMMARY 
Pharmacoepklerniological data on the use of anti-asthmatic medications in Tasmania were examined 
following the recent shift in emphasis to preventive therapy, and compared with national prescribing 
trends. The prescribing of anti-asthmatic drugs in Tasmania was studied at six-monthly intervals using 
data retrospectively obtained from computerised dispensing systems from almost one-third of all 
community pharmacies within the State. The data collection included all prescriptions dispensed in the 
pharmacies, irrespective of supply under the Pharmaceutical Benefits Scheme, the Repatriation 
Pharmaceutical Benefits Scheme, as a private prescription or as a recordable S3 item. 
Results of the pooled data were quantified by using the Defined Daily Doses (DDDs) dispensed Drugs were 
grouped into 13-agonists, inhaled corticosteroids, methyl xanthines, ipratropium bromide and sodium 
cromoglycate, then converted to Defined Daily Doses (DDDs)/1000 population/day by extrapolation to 
the entire Tasmanian population on the basis of prescription volume. National anti-asthmatic prescribing 
data was provided by the Drug Utilisation Subcommittee pusq and compared with Tasmanian 
prescribing trends. 
Tasmanian prescribing was generally similar to the national data, with large increases in the prescribing 
of inhaled corticosterokls (an increase of 61% to 22.8 DDDs/1000 population/day) and ipratropium 
bromide (an increase of 138% to 7.2 DDDs/1000 population/day), a decrease in theophylline usage (a 
decrease of 43% to 6.6 DDDs/1000 population/day) and an increase in sodium cromoglycate prescribing 
(an increase of 52% to 1.5 DDDs/1000 population/day) over the period of the study. The prescribing ofp-
agonists remained fairly stable over the period of the study although there was a large decrease of 36% in 
the ratio ofp-agonists:inhaled corticosteroidc DDDs dispensed. 
Recent trends in the prescribing of anti-asthmatic medications were found to be similar to national trends. 
Tasmanian prescribing of anti-asthmatic medications appear to be changing in line with current 
management guidelines with greater emphasis on the prescribing of inhaled corticoswoids. 
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4.2 INTRODUCTION 
As discussed earlier in Chapter 2, there has been an alarming increase in asthma 
related morbidity and mortality in most industrialised countries, despite 
medication sales being at an all time high. There has been a disturbing suggestion 
that the increase in asthma drug sales, particularly bronchodilators, may not be a 
result of, but rather may be contributing to, increasing asthma morbidity and 
mortality (Barnes and Chung, 1992). There are two hypotheses to explain this 
paradoxical increase in morbidity with increasing use of bronchodilators. The 
'severity hypothesis' suggests that increasing bronchodilator sales are an indicator 
of increasing disease severity whereas the '13-agonist hypothesis' suggests that (3- 
agonists are responsible for the adverse asthma outcomes independent of disease 
severity (Suissa et al, 1994). Current management guidelines suggest a reduction in 
the reliance on bronchodilator therapy with greater emphasis placed on the early 
introduction of anti-inflammatory therapy. 
Pharmacoepidemiology is a relatively new discipline involving the study of the 
patterns and effects of therapeutic drug use within populations (Hartzema 1992; 
Henry, 1988) and may be used to observe and evaluate the results of ongoing 
medical care (Strom, 1994). In this study analyses of secular trends were used to 
examine the asthma paradox and regional differences in prescribing of anti-
. asthmatics within Tasmania. In addition, prescribing trends were examined to see 
whether prescribing habits were changing as recommended by current guidelines 
(Anonymous, 1992; Tse and Bridges-Webb, 1993) with a greater emphasis on 
preventive (anti-allergic and anti-inflammatory) medication. 
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4.3 METHOD 
4.3.1 Collection of computerised pharmacy dispensing data 
Tasmania lends itself to pharmacoepiderniology studies well with a relatively 
stable population of around 470,000. The trends in anti-asthmatic medication 
prescribing within Tasmania were examined using community pharmacy 
computer based dispensing records. The majority of pharmacy dispensing 
computer systems used within the State are either Amfac-Chemdata IQ and IV 
(Canberra, ACT), or Tasmanian Pharmacy Computer Users Group (TPCUG; 
Lindisfarne, Tas) systems. Both of these systems offer a drug summary facility 
whereby all drugs dispensed over a designated time period can be counted from 
the stored computer records and printed out in a drug summary list. This list 
contains all PBS/RPBS, general, private and S3 recordable drugs (by brand name) 
and the number of unit quantities dispensed (an example is shown in Figure 4.1 
for both Amfac-Chemdata and TPCUG systems). This computer generated drug 
summary list is far more comprehensive than PBS/RPBS data alone as only 
concessional, pensioner and 'safety net' MDI prescriptions are recorded on 
PBS/RPBS databases. The method for obtaining drug summary lists from both 
the Amfac-Chemdata and TPCUG pharmacy dispensing computer systems are 
shown in Figures 4.2 and 4.3 respectively. 
All pharmacies dispensing PBS items within the State were sent a letter in May 
1992 explaining the project (Appendix 1), an outline for obtaining drug summary 
lists from both the Amfac-Chemdata and TPCUG pharmacy dispensing computer 
systems (identical to Figures 4.2 and 4.3 respectively), and a return postage paid 
envelope. The letter invited pharmacists to participate by sending monthly 
dispensing data (retrieved from their dispensing computer systems via the drug 
summary facility) for the months of April 1991, October 1991 and April 1992 in a 
return postage paid envelope to the Tasmanian School of Pharmacy. The drug 
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summary lists were then examined for the anti-asthmatic medications shown in 
Table 4.1 with the drugs and quantities entered into a spreadsheet for further 
analysis. This is discussed further in Sections 4.3.2 and 4.3.3. A virtually identical 
letter was sent out to all pharmacies dispensing PBS items within the State in May 
1993 which invited pharmacists to contribute October 1992 and April 1993 data. 
A notice asking for contributing pharmacies was also included in the TPCUG 
newsletter (Appendix 2). A final letter was sent out in May 1994 inviting 
pharmacies to contribute October 1993 and April 1994 data, as well as offering 
$10 in payment from a dedicated research grant to offset time and paper costs. 
The data were collected every six months during April and October to minimise 
any end of year bias associated with the 'safety net' scheme. 
It was not a requirement that the same pharmacies participate throughout the 
course of the study as all data were pooled for each month into two regions. This 
was stressed in both follow-up letters. Data were pooled into Southern Tasmania 
(002 telephone area code including Hobart) and Northern Tasmania (003 and 004 
area code encompassing Launceston, the North East and the North West of the 
State). 
Not all pharmacies were able to provide comprehensive prescription data, either 
due to technical difficulties in retrieving data from the computer or for perceived 
confidentiality reasons (in relation to total dispensing volumes). For calculations 
involving DDDs/1000 population/day it was necessary that the total 
prescriptions (dispensing volume) for each pharmacy be provided although it was 
not necessary that the collection period was a full month (see also Section 4.3.2). 
Unfortunately some pharmacies did not provide dispensing volumes, therefore 
their data could not be used for DDDs/1000 population/day calculations. 
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Table 4.1 	 Anti-asthmatic drugs (generic and brand name) shown with their 
Nordic defined daily dose (DDD) recorded from drug summary lists. 
Generic drug Brand names Nordic DDD Drug type 
Salbutamol Asmol®  10 mg Inhal. solution P-agonist 
Respolin° 0.8 mg Inhal. aerosol/powder 
Respax®  12 mg oral 
Ventolin®  12 mg parenteral 
Terbutaline Bricanyl®  20 mg Inhal. solution P-agonist 
2 mg Inhal aerosol/powder 
15 mg oral 
15 mg parenteral 
Salmeterol Serevent®  0.1 mg Inhal. aerosol/powder P-agonist 
(Pint listed on the PBS co-payment 
schedule as an authority item in 1995.) 
Fenoterol Berotec®  4 mg Inhal. solution P-agonist 
(MDI delisted from the PBS 
co-payment schedule in 1990.) 0.6 mg Inhal aerosol/powder 10 mg oral 
10 mg rectal 
Orciprenaline Alupent° 6mg Inhal. aerosol P-agonist 60 mg oral 
60 mg parenteral 
Beclomethasone dipropionate Aldecin®  1.5 mg Inhal. solution inhaled corticosteroid 
Becloforte®  0.8 mg Inhal aerosol/powder 
Becotide®  
Budesonide Pulmicort° 1.5 rag Inhal. solution inhaled corticosteroid 
(First listed on the PBS co-payment 
schedule in 1991.) 
0.8 mg Inhal aerosol/powder 
Theophyline Austyn®  0.4g oral methyl xanthine 
Elixophyline®  0.4 g parenteral 
Nuelie 0.4 g rectal 
Slo-bid®  
Theodur®  
Aminophyline Cardophylin®  0.6 g oral methyl xanthine 0.6 g parenteral 
0.6 g rectal 
Choline theophylinate Choledyl®  0.6 g oral methyl xanthine 
0.6 g parenteral 
0.6 g rectal 
Ipratropium bromide Atrovent®  0.12 mg Inhal. aerosol/powder anti-cholinergic 0.3 rag Inhal. solution 
Sodium cromoglycate haat° 80 mg Lahal. powder/solution anti-alergic 40 mg Inhal. aerosol (excluding inhaled corticosteroids) 
DDDs adapted from Anatomical Therapeutic Chemcial (ATC) classification index, January 1993, WHO Colaborating 
Centre for Drug Statistics Methodology, Oslo, Norway. 
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However, these data were used in the analysis of regional differences in 
prescribing since the relative dispensing ratios of different anti-asthmatic drugs 
were examined and dispensing volumes were not necessary for this analysis (see 
also Section 4.3.3). 
Those pharmacies that provided dispensing volumes for the entire month were 
compared with the average Australian dispensing volumes per month. This data 
was provided by the Pharmacy Guild of Australia from a random sample of 263, 
244, 271 and 273 pharmacies throughout Australia for 1991, 1992, 1993 and 1994 
respectively. These figures were compared with the Tasmanian dispensing volume 
per month using two-tailed one sample t-tests (Instate Ver 2.0, Graphpad 
Software, San Diego, CA, USA). 
4.3.2 Analysis of prescription data: calculation and analysis of Statewide DDDs/1000 
population/day 
The calculation of Statewide DDDs/1000 population/day required drug summary 
data from responding pharmacies to be extrapolated to the total Tasmanian 
population. It was not necessary that the data be complete for the entire month. 
This calculation of Statewide DDDs/1000 population/day was performed in two 
steps. Firstly, the drug summary data was converted to a ratio of anti-asthmatic 
DDDs dispensed per total prescription volume. The second step involved 
extrapolating this ratio to find the DDDs of anti-asthmatics dispensed to the 
entire Tasmanian population. These calculations are described in more detail in 
Sections 4.3.2.1 and 4.3.2.2. 
4.3.2.1 Calculation of DDDs dispensed per total prescription volume 
The unit quantities of anti-asthmatic drugs and the total prescription volumes 
(PBS/RPBS, general and private) from which they were dispensed were recorded 
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from the drug summary lists and entered into a spreadsheet (Microsoft Excel® 4.0, 
Microsoft Corporation, Redmond, WA, USA). An example of the spreadsheet 
layout is shown in Figure 4.4. The unit quantities of each drug dispensed were 
then converted into DDDs dispensed and grouped into one of five classes of anti-
asthmatic drugs. Drugs were grouped into p-agonists, inhaled corticosteroids, 
methyl xanthines, ipratropium bromide and sodium cromoglycate (see Table 4.1). 
Each of the five groups were then divided by the total prescription volumes from 
which they were dispensed giving a ratio of DDDs per total prescriptions for each 
of the five classes. This was repeated for each pharmacy that provided 
prescription totals with their drug summary data. Simple descriptive statistics 
including mean, 95% confidence limits of the mean and standard deviations were 
calculated for DDDs dispensed to total prescription volume ratios for each of the 
five groups. This procedure was repeated for each month of sampling. 
4.3.2.2 Extrapolation of DDDs dispensed to the Tasmanian population and calculation of DDDs/1000 
population/day 
Unfortunately, the Pharmacy Guild of Australia had only limited information 
regarding the number of total prescriptions dispensed per year in Tasmania based 
on samples of only 10, 20 and 13 pharmacies for 1991, 1992 and 1993 respectively. 
These sample sizes were less than the number of responding pharmacies in this 
study. While there is no published information of total prescriptions dispensed in 
Tasmania, there are reliable data on dispensing under the PBS within the State. 
Because of this, the number of total prescriptions dispensed per year in Tasmania 
was estimated by multiplying the number of Tasmanian PBS prescriptions per 
year by the ratio of Australian total prescriptions to Australian PBS prescriptions. 
Australian total prescriptions were provided by the Pharmacy Guild of Australia 
(based on random samples of 263, 244, 271 and 273 pharmacies throughout 
Australia for 12 months trading up until the 30th of June 1991, 1992, 1993 and 
1994 respectively). Australian PBS prescriptions (Government derived figures 
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published in the Pharmacy Guild of Australia Guild Digest) were obtained from 
the Pharmacy Guild of Australia. 
The estimated total Tasmanian prescriptions were then divided by 466.802, 
469.685, 471.400 and 475.100 for 1991, 1992, 1993 and 1994 respectively 
(Tasmanian population divided by 1000; 1994 population estimated at 30th June 
1994, source: Australian Bureau of Statistics) and 365 (days in a year) to give total 
prescriptions/1000 population/day. This number was then multiplied by the 
mean, 95% confidence interval and standard deviation DDDs dispensed:total 
prescription volume ratio for each class of anti-asthmatic drug to give the mean, 
95% confidence interval and standard deviation for DDDs/1000 population/day 
for each class of drug for each month. The calculation outline is shown in Figure 
4.5 with an example calculation. These Tasmanian DDDs/1000 population/day 
data for October 1991, 1992 and 1993 were then compared with DUSC national 
data from 1991 to 1993 using two-tailed one sample t-tests (Instat® Ver 2.0, 
Graphpad Software, San Diego, CA, USA). 
4.3.3 	 Analysis of prescription data: analysis of regional diferences in prescribing 
To calculate DDDs/1000 population/day, the amounts of drugs utilised by a given 
sample population must be divided by a known population size. DDDs/1000 
population/day could not be used as a measure of drug utilisation in both South 
and North regions as population boundaries were unable to be defined from the 
responding pharmacies and estimates of PBS prescriptions for each region were 
needed to calculate DDDs/1000 population/day. Regional diferences were studied 
by examining the relative prescribing of each of the five anti-asthmatic drug groups 
([3-agonists, inhaled steroids, methyl xanthines, ipratropium bromide and sodium 
cromoglycate). Drug summary data that did not include dispensing volumes (i.e. 
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Amfac-Chemdata 
Tasmanian Pharmacy Computer Users Group 
= = = ... M.MMEMM W O M M .1111.11 MMMM M MMMMMM M ITEM 	 (minimum I) 	 AMOUNTS 	 Dispensed On hand 
ATROM1D-S OAPS 500t 	 -, 2 Rxe = 200  ATROPT EYE DROPS 1 ATROYENT INHALER 	 > 5 Rxe 74 	 1 °"1---- % mL ==== ==7 t Rxe = 5 ATROVENT NEBUL SOLN 20mL monism> I' Rs = 21 ===i____ ATROVENT UOV 290mcg (30)  , 3 Rxt = 5 ---I____ ATROYENT UOV 500mtg (30) ====F==> 5 RxS = 	 6 AUGMENTIN FORTE SYR 75mL 	 7I---- ? 7 RX2 m 	 7 - -  AUOMENTIN PORTE TABS ,00010111,==ass, 16 Rs = 240 ===__ AUOMENTIN SYRUP 75mL 	 , 12 Rxs = 	 12 -;--1____ AUOMENTIN TABS ====whAw=t2====, 47 Rxs .7 769 ===1 AURORIX TABS 150r 	  S Rxs = SOO ---)____ AUSTYN CAPS 300m9 ==tins======> 2 Rxs = 200 ===1____ AVM TABS 50m9  	 1 Rxs = ID  AVOMINE TABS 25mg =======mw=m/ 10 Rx: a SOO  AVOMINE THEOC TABS 25mg 	 , 1 Rxs = 30 ---1____ BAOTRIA OS TADS =============> 5 Rxs - 	 50 •,0.41....._ SACTRIM SYPur inow. s/F  , 7 Rxe, - 8AOTROBAN OINT 15g 2% ======-=-› 3 Rss - 	 31 "i---- 8EOLOPOR7E INHALER 250 	 > 23 Rxs . 	 22 ---1____ OCCONASE AQ NASAL SPRAY 	 > 13 Rs t .m. 	 13 =...i...___ BECONASE NASAL SPRAY 3 ---]___- 	 > 3 Rx: BECOT1DE INHALER 100 47=0”=====> 24 Rxs ■, 24 "'I-- BECOT1DE INHALER eo SECOTIDE ROTAOAPS - 6ENADRYL CAPS 
Figure 4.1 	 An example of drug summary reports received from both Amfac- 
Chemdata and TPCUG pharmacy dispensing computer systems. 
eseammusubsistowsmmawm;sarm /A POE 	SI POE 	Order 
068950 	112456 	  083534 	040592 	  16062391 	318691 	  071021 	240283 	  379352 	354100 	  
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Insert Dual History Archive Disk in floppy drive. 
Archive Disk mounted. 
Dates run from : dd/mm/yy 
to : dd/mm/yy 
Number of Dual History records on disk : #### 
Amfac-Chemdata instructions: 
F2 - END DAY 
     
Do you want a cancelation report? 	 N - no. 
     
          
          
   
Select End of Day run type. 	 M - manual. 
  
      
F 
  
    
End of Day Procedure Options. 
R - reporting. 
  
 
* It is important to select 
the Fl option (From 
* 	 Archive) otherwise it is 
not possible to nominate 
a time period. 
OK to run reporting? 	 Fl - (FROM ARCHIVE) 
Summary to Labels printer, Repeats printer, Notes printer, Alternate printer, Screen. 
(Please select uvprupt 	late printer.) 
Which type of paper? 	 W - wide continuous. 
ISelect criteria for detailed printout 	 N - no script printout 
Drug summary printout required? 	 Y - yes. 
	
Enter dates for Summary : 	 Start Date 
to : 	 End Date 
	 I Fl - LONG SEARCH 
** 
Print ACCNT audit trail? 	 N - no 1„„,,4., IOK to print trading totals? 	 Y - yes I 
 
IQ - quit from End Day. 
 
** 
These are needed to calculate asthma prescriptions as the percentage of total prescriptions. If you are not prepared to divulge 
the sales figures, could you please forward the first two columns of Trading Totals - Table I (i.e. No. Items for G NI-IS, S NI-LS, 
Pens, Ent., Conc., Repot, D Bag, Gvtot, Priv., TOTAL). 
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Figure 4.2 	 Outline for obtaining drug summary lists from Amfac-Chemdata computer dispensing 
system. 
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Tasmanian Pharmacy Computer Users Group Instructions: 
It is essential that data from the entire month is analysed. 
i.e. al data for April 1993, October 1993 and April 1994. 
MAIN MENU 
I REPORTS 
DISPENSING REPORTS MENU 
Drugs Used/Reorder 	 1 
Enter commencement date : dd/mm/yy Enter finishing date 	 : dd/mm/yy 
IYou may elect to see the quantif es of [ 1 or more, Press [Enter] for al. 
IManufacturers code [ 1, Press [Enter] for al. 
Do you want genericaly dispensed items listed by brand name? Y - yes 
Do you want a hard copy? Y - yes 
Is above corect? Y - yes 
Any more? N - no 
N.B. It is advisable that the above procedure be caried out 
after closing to avoid tying up the computer. 
Figure 4.3 	 Outline for obtaining drug summary lists from TPCUG computer dispensing 
system. 
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1. List of anti-asthmatic drugs and unit quantities. 
2. Quantities of anti-asthmatic drugs dispensed for each individual pharmacy in each 
column. 
3. Anti-asthmatic DDDs dispensed for each individual pharmacy in each column. 
4. Anti-asthmatic DDDs dispensed and total prescription numbers for each individual 
pharmacy in each column grouped into 132-agonists, inhaled steroids, methyl 
xanthines, ipratropium bromide and sodium cromoglycate. 
5. Grouped anti-asthmatic DDDs dispensed for each individual pharmacy (from 4) 
divided by the coresponding total prescriptions for that pharmacy. 
6. Descriptive statistics performed on each class of anti-asthmatic (from 5). 
7. Descriptive statistics performed on total prescription numbers. 
Figure 4.4 	 An example of Exce1li) spreadsheet layouts used to calculate the 
DDDs dispensed per total prescription numbers. This was then used in the 
calculation of DDDs/1000 population/day for each sample month 
(shown in Figure 6.3). 
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I 	 4,530,184 
1 
365 	 - 
Estimated Tasmanian total 
prescriptions per year 
26 59 	 Tasmanian total prescriptions . per 1000 population per day 
x 	 0.5307 	
▪ 	
14.11 	 DDDs/1000 population/day 
x 	 0.074 	 1.96 	 DDDs/1000 population/day 
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Amfac-Chemdata 	 TPCUG 
drug summary 	 drug summary 
Step 1. Calculation of mean DDDs per total prescription 
numbers with 95% confidence limits for each class 
of anti-asthmatic drug 
 
 
Statewide mean DDDs per total prescription 
numbers with 95% confidence limits for each 
class of anti-asthmatics for each sampled 
month. 
(1) 
   
Data entered into speadsheet 
as shown in Figure 4.4 
   
Step 2. Calculation of Tasmanian DDDs per 1000 people per day 
Tasmanian PBS 
prescriptions 
Australian total 
prescriptions per year - Estimated Tasmanian total 	 (2) 
prescriptions per year 
Australian PBS 
prescriptions per year 
Estimated Tasmanian 
total prescriptions 
per year 
1 	 1 
(Tas. population /1000) 	 365 
Tasmanian total 
— prescriptions 
per 1000 population 
per day 
(3) 
Tas, total prescriptions 	 Tasmanian mean DDDs 	 DDDs per thousand 
	 (4) 
per 1000 population per 	 for each class of anti-asthmatics 	 population per day 
day 	 per total prescriptions 	 for each class of anti-asthmatic 
Tas. total prescriptions 
per 1000 population per 
day 
95% confidence limits on 
x Tasmanian mean DDDs 
for each class of anti-asthmatics 
per total prescriptions 
95% confidence limits on 
DDDs per thousand 
population per day 
for each class of 
anti-asthmatic 
(5) 
Example calculation for April 1991 inhaled corticosteroids. 
Mean DDDs per total prescription numbers - 0.5307 
95% confidence limits on mean DDDs per total prescription numbers — 0.074 
2,640,507 
4,530,184 	 x 
Mean: 
95% confidence: 
[165,217,476 
96,300,259 
1 
(466,802 / 1000) 
26.59 
26.59 
Figure 4.5 	 Outline of calculation of DDDs per thousand population per day with 
95% confidence limits. 
(from 1) 
(from 2) 
(from 3) 
(from 4) 
(from 5) 
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could not be used for calculation of DDDs/1000 population/day) were combined 
with data used for calculation of DDDs/1000 population/day for analysis of 
regional differences. The dispensed quantity of each dosage form for each drug was 
grouped into Southern, Northern and Statewide data and converted to DDDs. 
Drugs were grouped into the five classes of anti-asthmatics. Statewide prescribing 
trends for each class of compound were examined over the sampling period using a 
chi-square test for each region (Statview® 4.01, Abacus Concepts Inc., Berkeley 
CA, USA). 
The regional differences in prescribing between the North and South were 
examined for each class of compound using a chi-square test for each month. 
Southern and Northern prescribing trends with time for each class of compound 
were examined over the sampling period using a chi-square test for each region. 
4.3.4 Australian and Tasmanian asthma morbidity and mortality 
Tasmanian and Australian asthma mortality data were obtained from the 
Australian Bureau of Statistics. Tasmanian morbidity data (Statewide and 
regional; based on hospital admissions with asthma as the primary diagnosis) were 
obtained from the Tasmanian State Health Department for each month of 
sampling. Statewide hospital admissions included both public and private hospital 
admissions. Regional data only included public hospital admissions due to 
confidentiality agreements with the private hospitals. These Statewide and 
regional measures of morbidity were plotted with the Statewide and regional 
ratios of 13-agonist: inhaled steroid DDDs dispensed. A Spearman rank correlation 
test was used to test for any association between Statewide morbidity and the 
relative prescribing of relieving and preventive medication. 
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4.4 	 RESULTS 
4.4.1 	 Analysis of prescription data 
The numbers of responding pharmacies for each time period are shown in Table 
4.2. Australia-wide average dispensing volumes are shown in Table 4.3. The 
mean monthly dispensing volumes for responding pharmacies that included 
prescription totals were significantly lower than the Australian averages for 
community pharmacies (provided by the Pharmacy Guild of Australia) in 4 out 
of 7 sampled months. Significant diferences were found in monthly pharmacy 
prescription volumes for April 1991 (t = 3.05, df = 25, p < 0.01), April 1993 
(t = 2.05, df = 37, p <0.05), October 1993 (t=2.28, df =41, p <0.05) and April 1994 
(t = 3.42, df = 40, p <0.01). It should be noted, however, that the average 
Tasmanian monthly dispensing volumes from responding pharmacies could only 
be calculated from those pharmacies that provided complete monthly data with 
prescription totals. Therefore, these figures should only be seen as a guide to the 
dispensing volumes of al responding pharmacies in this study. In addition, true 
dispensing volumes per pharmacy may be lower in Tasmania than the national 
average as the Tasmanian population:pharmacy ratio is almost 7% lower than the 
national average (Guild Digest, 1994). 
4.4.2 Tasmanian prescribing trends from April 1991 to April 1994 
DDDs/1000 population/day for each of the 5 groups of anti-asthmatic 
medications and totals were calculated as outlined in Section 4.3.2. These are 
shown in Table 4.4. It was found that the total anti-asthmatic DDDs/1000 
population/day dispensed in Tasmania increased slightly over the period of the 
study with a peak in October 1992 but dropped in April 1994. 
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Table 4.2 The number of responding pharmacies, pharmacy dispensing volumes and total 
prescriptions analysed for anti-asthmatics in the North, South and Statewide over the 
course of the study. Data contributed by al pharmacies were used to examine regional 
relative diferences in prescribing. Data from those pharmacies that provided 
prescription totals were also used to calculate DDDs/1000 population/day. Data from 
pharmacies that included prescription totals and were complete for the entire month 
were used as a guide to the dispensing volumes of the responding pharmacies. 
April 91 October 91 April 92 October 92 April 93 October 93 April 94 
South contributing 15 21 23 22 21 24 23 
pharmacies' (20.0%) (28.0%) (30.7%) (29.7%) (28.3%) (32.4%) (31.1%) 
South total prescriptions" 21,663 37,719 44,330 46,74.0 40,467 50,897 43,579 
(13) (18) (21) (22) (21) (24) (23) 
South total prescriptions 1,666 2,096 2,189 2,168 1,986 2,121 1,955 
per month per pharmacy ± 584 ± 808 ± 1,075 ± 1,088 ± 664 ± 724 ± 743 
(mean ± SD)` (13) (18) (20) (21) (20) (24) (22) 
North contributing 15 16 24 20 20 19 20 
pharmacies' (20.5%) (22.9%) (34.2%) (28.6%) (28.6%) (27.1%) (28.6%) 
North total prescriptions" 28,340 33,033 54,286 47,989 47,787 48,022 46,064 
(13) (14) (22) (19) (19) (19) (20) 
North total prescriptions 2,180 2,360 2,468 2,525 2,535 2,595 2,372 
per month per pharmacy ± 844 ± 1,056 ± 1,130 ± 1,244 ± 1,173 ± 1,275 ± 1,209 
(mean ± SD)c (13) (14) (22) (19) (18) (18) (19) 
State contributing 30 37 47 42 41 43 43 
pharmacies' (20.2%) (25.5%) (32.4%) (29.2%) (28.5%) (29.9%) (29.9%) 
State total prescriptions" 50,003 70,752 98,616 94,729 88,254 98,919 89,643 
(26) (32) (43) (41) (40) (43) (43) 
State total prescriptions 1,923 2,211 2,335 2,338 2,246 2,324 2,148 
per month per pharmacy ± 758 ± 919 ± 1,100 ± 1,162 ± 967 ± 1,013 ± 996 
(mean ± SD)c (26) (32) (42) (40) (38) (42) (41) 
a 	 Number of pharmacies contributing data with the response rate shown in parentheses. Used for analysis of 
regional diferences in prescribing where prescription totals not needed. 
From pharmacies contributing data with prescription totals but not necessarily for the entire month. The 
number of responding pharmacies are shown in parentheses. Data from these respondents were used for 
DDDs/1000 population/day calculations. 
Dispensing volumes calculated only from those pharmacies that provided complete monthly data with 
prescription totals. The number of responding pharmacies with complete data are shown in parentheses. 
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Table 4.3 	 Australia-wide average dispensing volumes from community pharmacies provided by 
the Pharmacy Guild of Australia for the financial year. 
1990-91 1991-92 1992-93 1993-94 
Sample size 
(number of pharmacies) 
Average total prescription volume per year 
(PBS, RPBS, general and private) 
Average total prescription volume per week 
(PBS, RPBS, general and private) 
Average total prescription volume per month 
(PBS, RPBS, general and private)* 
*calculated from prescription volume per week 
263 
30,876 
594 
2,376 
244 
30,448 
586 
2,344 
271 
33,393 
642 
2,568 
273 
34,852 
670 
2,680 
Drug utilisation trends (in terms of DDDs/1000 population/day) for each of the 
five groups of anti-asthmatics are shown in Figure 4.6. It was found that the 
DDDs/1000 population/day of P-agonists dispensed in Tasmania was relatively 
similar for April and October 1991, fel slightly in April 1992, then increased in 
October 1992 before decreasing steadily for the remaining months up to and 
including April 1994. It was found that the DDDs/1000 population/day of 
inhaled corticosteroids increased steadily to a peak value in October 1992 before 
leveling out for the remaining months up to and including April 1994. The 
DDDs/1000 population/day of methyl Xanthines decreased steadily by 43% over 
the period of the study as shown in Figure 4.6. The DDDs/1000 population/day 
of ipratropium bromide increased steadily to a peak value in October 1993 before 
leveling out for April 1994 to remain at greater than twice the level of April 1991 
prescribing. It was found that the DDDs/1000 population/day of sodium 
cromoglycate increased steadily to a peak value in October 1993 (approximately a 
60% increase over April 1991) before leveling out for April 1994. 
Relative prescribing trends of each class of anti-asthmatic were examined for the 
State over the period of the study. Overal, there were relatively large increases in 
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inhaled corticosteroid and ipratropium use, an increase in sodium cromoglycate 
use and a decline in methyl xanthine use during the time period from April 1991 
to April 1994 (chi-square= 23088, df =24, p <0.0001). 13-Agonist use fell after 
April 1991 and was fairly stable for the remainder of the study. 
4.4.3 Tasmanian prescribing and comparison to Australia-wide DUSC data 
DUSC data is obtained from a stratified random sample of pharmacies 
throughout Australia. The data obtained from October for 1991, 1992 and 1993 
was compared with the DUSC data for 1991, 1992 and 1993 (Table 4.5 and Figure 
4.7). 
As can be seen from Figures 4.6 and 4.7, general similarities were found between 
the Tasmanian DDD5/1000 population/day and the DUSC data. These 
similarities included (i) a slight increase in 13-agonist DDDs/1000 population/day 
in 1992 before levelling out with the Tasmanian levels dropping slightly, (ii) large 
increases in the prescribing of inhaled corticosteroids and ipratropium bromide 
(iii) a decrease in methyl xanthine prescribing, and (iv) an increase in sodium 
cromoglycate prescribing. The total anti-asthmatics (both DUSC data and 
Tasmanian data) remained fairly stable over the period of the study. 
It was found that there were statistically significant differences in Tasmanian 
utilisation of anti-athmatics compared to the data obtained from DUSC. The 
prescribing of total anti-asthmatics in Tasmania were significantly higher than 
national DUSC data in 1991 (t=2.62, df = 31, p < 0.05) and 1992 (t = 2.93, df =40, 
p <0.01). These differences are clearly shown in Figure 4.8. 
The utilisation of 13-agonists in Tasmania was significantly higher than the DUSC 
national data for 1991 (t=3.35, df =31, p <0.01), 1992 (t=3.78, df=40, p <0.001) 
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and 1993 (t=2.40, df= 41, p < 0.05). These differences are clearly shown in Figure 
4.9. It should, however, be noted that the DUSC data for P-agonist DDDs/1000 
population/day displayed a dip in 1991 compared to the previous and following 
years, as can be seen in Figure 4.7. 
The dispensing of inhaled corticosteroids fluctuated in Tasmania in comparison 
to national DUSC data, with Tasmanian DDDs/1000 population/day 
significantly higher than DUSC figures for 1991 (t=2.71, df = 31, p=0.01). These 
differences are shown in Figure 4.10. The prescribing of methyl xanthines was 
significantly higher than national DUSC data for 1992 (t=2.36, df =40, p <0.05) 
as shown in Figure 4.11. There were no significant differences in Tasmanian 
prescribing of ipratropium bromide in comparison to the national DUSC data 
for the period of the study (Figure 4.12). The prescribing of sodium cromoglycate 
fluctuated in comparison to national DUSC data with Tasmanian DDDs/1000 
population/day significantly higher than DUSC data for 1992 (t=2.28, df =40, 
p < 0.05) and 1993 (t=2.18, df =41, p <0.05). These differences in sodium 
cromoglycate prescribing are shown in Figure 4.13. 
4.4.4 Regional prescribing trends 
Regional utilisation trends for each class of anti-asthmatic were examined over 
the period of the study. Southern Tasmania showed a large increase in inhaled 
corticosteroid use, a smaller increase in ipratropium bromide and sodium 
cromoglycate use and a decline in methyl xanthine use over the time period April 
1991 to April 1994 (chi-square= 10682, df =24, p <0.0001). (3-Agonist use fell after 
April 1991 and was fairly stable for the remainder of the study. 
Similarly, Northern Tasmania showed a large increase in inhaled corticosteroid 
use, an increase in ipratropium bromide and sodium cromoglycate use and a 
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decline in methyl xanthine use from April 1991 to April 1994 (chi-square= 13394, 
df =24, p <0.0001). p-Agonist use fell after April 1991 and was fairly stable for the 
remainder of the study. 
4.4.5 Regional differences in prescribing 
Regional differences in prescribing for each of the classes of anti-asthmatics are 
summarised in Table 4.6. Regional differences in the relative prescribing of anti-
asthmatic classes between the South and North of the State were examined using 
a chi-square test for each month of sampling. It was found that in April 1991 
among the anti-asthmatic drug classes there were significantly higher levels of 
prescribing of P-agonists in the South, and higher levels of methyl xanthine and 
ipratropium bromide prescribing in the North (chi-square =331, df =4, 
p < 0.0001). This same pattern continued in October 1991 (chi-square=439, df=4, 
p < 0.0001), April 1992 (chi-square= 1078, df=4, p <0.0001), October 1992 (chi-
square = 492, df =4, p < 0.0001) and April 1993 (chi-square= 1158, df = 4, 
p < 0.0001). In addition, in April 1993 there were relatively higher levels of 
sodium cromoglycate prescribed in the South of the State. In October 1993 there 
were higher levels of inhaled corticosteroids prescribed in the South, higher levels 
of ipratropium prescribed in the North with little significant difference in the 
prescribing of p-agonists, methyl xanthines and sodium cromoglycate (chi-
square= 1340, df =4, p < 0.0001). In April 1994, a similar pattern continued with 
significantly higher levels of prescribing of P-agonists and sodium cromoglycate 
in the South, and higher levels of methyl xanthines and ipratropium prescribing 
in the North (chi-square =1282, df = 4, p <0.0001). 
These regional differences are best illustrated in Figures 4.14, 4.15, 4.16, 4.17 and 
4.18 for p-agonists, inhaled corticosteroids, methyl xanthines, ipratropium and 
sodium cromoglycate respectively. These figures show the dispensing of each 
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class of anti-asthmatic drug, expressed as a percentage of total anti-asthmatic 
DDDs dispensed, in each region, and Statewide for each sampled month. It can 
be seen that in general terms there was a greater percentage of (3-agonists (Figure 
4.14), inhaled corticosteroids (Figure 4.15) and sodium cromoglycate (Figure 4.18) 
and less methyl xanthines (Figure 4.16) and ipratropium bromide (Figure 4.17) 
dispensed as a percentage of total anti-asthmatic drugs in Southern Tasmania 
compared to Northern Tasmania. 
4.4.6 Australian and Tasmanian asthma morbidity and mortality trends 
Australian and Tasmanian mortality data and Tasmanian morbidity data (based 
on hospital admissions) are shown in Table 4.7. It can be seen from Table 4.7 that 
Tasmanian and Australian asthma mortality death rates per 100,000 population 
(non age-standardised) are similar. A Spearman rank correlation test was used to 
test for an association between morbidity and the ratio of P-agonist:inhaled 
corticosteroid DDDs dispensed Statewide (Figure 4.19) but no association was 
found (Spearman r=0.04, n=7, p >0.05). There were no significant differences in 
mortality rates between Tasmanian and Australian data from 1991 to 1993 
(t=0.94, df = 2, p >0.05). Statewide and regional trends in morbidity, mortality 
and anti-asthmatic drug use are illustrated in Figure 4.20. 
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Table 4.4 	 Figures used in the calculation of total prescriptions per 1000 population and 
DDDs/1000 population/day of anti-asthmatics dispensed from Tasmanian 
community pharmacies. 
April 
91 
October 
91 
April 
92 
October 
92 
April 
93 
October 
93 
April 
94 
Australian average prescription volume 
per pharmacy per year (PBS, 11.PBS, 
general and private)a 
30,876 30,448 30,448 33,393 33,393 34,852 34,852 
Number of Australian community 
pharmaciesb 
5,351 5,091 5,091 5,018 5,018 4,980 4,980 
Estimated Australian total prescriptions 
per year` 
165,217,476 155,010,768 155,010,768 167,566,074 167,566,074 173,562,960 173,562,960 
Australian PBS prescriptions per year 96,300,259 94,120,245 94,120,245 105,952,602 105,952,602 115,041,099 115,041,099 
Tasmanian PBS prescriptions per yeard 2,640,507 2,603,906 2,603,906 2,963,280 2,963,280 3,199,956 3,199,956 
Estimated Tasmanian total prescriptions 
per year` 
4,530,184 4,288,487 4,288,487 4,686,484 4,686,434 4,827,786 4,827,786 
Tasmanian population' 466,802 469,685 469,685 471,400 471,400 475,100 475,100 
Tasmanian total prescriptions per 1000 
population per day` 
26.59 25.02 25.02 27.24 27.24 27.84 27.84 
Tasmanian DDDs per 1000 population per day 	(Al numbers in units of DDD/1000 population/day) 
13-agonists 
Mean 40.70 39.01 34.67 45.37 41.95 42.54 39.36 
95% confidence interval of the mean 3.85 3.65 3.26 4.50 4.72 3.99 3.52 
Standard deviation 10.02 10.52 10.92 14.71 15.23 13.36 11.78 
Inhaled corticosteroids 
Mean 14.11 18.32 18.16 25.41 21.43 25.12 22.75 
95% confidence interval of the mean 1.96 2.47 1.88 2.82 2.81 2.89 2.62 
Standard deviation 5.10 7.13 6.30 9.23 9.06 9.68 8.77 
Methyl xanthines 
Mean 11.61 10.58 8.86 10.34 7.69 7.81 6.58 
95% confidence interval of the mean 1.64 1.16 1.39 1.51 1.12 1.02 0.92 
Standard deviation 4.27 3.34 4.64 4.93 3.62 3.39 3.08 
Ipratropium bromide 
Mean 3.04. 4.47 3.55 6.83 6.28 8.05 7.23 
95% confidence interval of the mean 0.66 1.11 0.59 1.24 1.20 1.56 1.22 
Standard deviation 1.71 3.20 1.99 4.06 3.86 5.22 4.08 
Sodium cromoglycate 
Mean 0.97 0.96 0.84 1.50 1.34 1.67 1.47 
95% confidence interval of the mean 0.30 0.29 0.18 0.38 0.39 0.34 0.31 
Standard deviation 0.78 0.84 0.60 1.24 1.26 1.13 1.05 
Total Anti-asthmatics 
Mean 70.43 73.34 66.08 89.45 78.69 85.19 77.40 
95% confidence interval of the mean 8.42 8.67 7.31 10.46 10.24 9.79 8.60 
Standard deviation 17.63 21.69 19.81 29.24 29.41 29.39 25.70 
a Source: Personal Communication (Pharmacy Guild of 
Australia; Canbera). 
b Source: Personal Communication (Pharmacy Guild of 
Australia; Canbera). 
Estimation calculations outlined in Section 4.3.2 and 
Figure 4.5. 
d Source: Personal Communication (Department of Community 
Services and Health; Canbera). 
Source: Australian Bureau of Statistics. October 1993 and April 
1994 figures based on Australian Bureau of Statistics estimates. 
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Table 4.5 	 DDD/1000 population/day of anti-asthmatics dispensed from 
Australian community pharmacies provided by DUSC. 
1990 1991 1992 1993 1994 
13-agonists 39.98 32.78 36.68 37.60 35.14 
Inhaled corticosteroids 12.64 14.90 22.63 24.52 22.78 
Methyl xanthines 13.70 9.56 8.52 6.99 5.43 
Ipratropium bromide 4.66 5.17 7.17 8.99 9.62 
Sodium cromoglycate 1.07 0.87 1.06 1.29 1.28 
Totals 72.05 63.28 76.01 79.39 74.25 
Table 4.6 	 Total regional DDDs of anti-asthmatics dispensed from al Tasmanian 
community pharmacies that contributed data. The number of 
contributing pharmacies are shown in Table 4.2 
April 91 
p-agonists inhaled 
corticosteroids 
methyl 
zanthines 
ipratropium 
bromide 
sodium 
cromoglycate 
South 37,762 12,973 9,495 2,383 880 
North 51,118 18,473 15,328 4,742 1,144 
October 91 
South 63,888 29,995 16,786 6,050 1,457 
North 68,620 33,145 20,519 8,967 1,933 
April 92 
South 63,306 33,196 14,430 4,783 1,760, 
North 90,986 45,925 25,599 11,017 2,145 
October 92 
South 71,392 39,649 15,295 9,042 2,390 
North 83,115 47,784 20,059 14,225 2,890 
April 93 
South 55,896 29,684 8,953 6,658 1,840 
North 74,356 39,510 16,085 12,083 1,835 
October 93 
South 72,226 44,755 12,926 10,800 3,300 
North 75,800 42,361 14,533 16,683 2,620 
April 94 
South 61,460 34,324 8,675 8,775 2,290 
North 68,825 40,248 12,512 14,850 2,540 
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Table 4.7 	 Australian and Tasmanian mortality data and Tasmanian morbidity data based on 
hospital admissions. 
Australian Asthma Mortality 
Australian 
population* Deaths 
Total 
Deaths per 100,000 population 
Total 
1991 	 17,284,000 
1992 	 17,482,593 
1993 	 17,661,468 
335 	 415 	 750 
332 	 427 	 759 
326 	 451 	 777 
	
1.94 	 2.40 	 4.34 
1.90 	 2.44 	 4.34 
1.85 	 2.55 	 4.40 
Tasmanian Asthma Mortality 
Tasmanian 
population* Deaths 
Total 
Deaths per 100,000 population 
M 	 F 	 Total 
1991 	 466,802 
1992 	 469,685 
1993 	 471,400 
10 	 11 	 21 
9 	 6 	 15 
7 	 6 	 13 
2.14 	 2.36 	 4.50 
1.92 	 3.19 	 5.11 
1.48 	 2.76 	 4.24 
*estimated resident population at 30th June (Source: Australian Bureau of Statistics). 
Tasmanian Asthma Morbidity' 
Month 	 Year 	 Northern Tasmania 	 Southern Tasmania 	 Statewide 
Hospital admiqsionsa 	 Hospital admissionsa 	 Total Admissionsb 
April 	 1991 	 45 	 31 	 82 
October 	 1991 	 49 	 31 	 92 
April 	 1992 	 59 	 33 	 103 
October 	 1992 	 59 	 40 	 114 
April 	 1993 	 43 	 54 	 109 
October 	 1993 	 42 	 27 	 85 
April 	 1994 	 44 	 12 	 62 
# Source: Personal communication (Department of Community and Health Services; Hobart.) 
a based on admissions to hospital with ICD primary diagnosis of asthma in public hospitals only 
b based on acImicsions to hospital with ICD primary diagnosis of asthma in public and private hospitals 
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Figure 4.6 	 Defined daily dose of anti-asthmatic drugs per thousand population per 
day dispensed from Tasmanian community pharmacies. Error bars 
represent ± 95% confidence intervals. 
1990 	 1991 	 1992 	 1993 	 1994 
Figure 4.7 	 Defined daily dose of anti-asthmatic drugs per thousand population per 
day from Australia wide DUSC survey data. 
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Figure 4.10 	 Comparison of defined daily doses in inhaled corticosteroids per thousand 
population per day dispensed from Tasmanian community pharmacies 
(shown as a line plot with error bars representing ± 95% confidence 
intervals) with Australia wide DUSC data (broken line) 
Figure 4.11 	 Comparison of defined daily doses of methyl xanthina per thousand 
population per day dispensed from Tasmanian community pharmacies 
(shown as a line plot with error bars representing ± 95% confidence 
intervals) with Australia wide DUSC data (broken line) 
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Figure 4.14 	 [3-agonist DDDs dispensed as a percentage of total anti-asthmatic DDDs 
dispensed in Southern and Northern Tasmania. The Statewide average is also shown. 
Figure 4.15 	 Inhaled corticosteroid DDDs dispensed as a percentage of total anti-asthmatic 
DDDs dispensed in Southern and Northern Tasmania. The Statewide 
average is also shown. 
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Figure 4.17 Ipratropium bromide DDDs dispensed as a percentage of total anti-asthmatic 
DDDs dispensed in Southern and Northern Tasmania. The Statewide average is 
also shown. 
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4.5 	 DISCUSSION 
4.5.1 Pharmacoepidemiology, usefulness and limitations in monitoring prescribing trends 
Pharmacoepidemiology can be a useful tool to monitor prescribing trends, 
particularly those brought about by changes in disease understanding, as this 
current study demonstrates. Recent overseas pharmacoepidemiological studies 
have focussed on the prescribing of NSAIDs (Rodriguez and Jick 1994; Figueras et 
al, 1994; Traversa et al, 1995), anti-hypertensives (Manolio et al, 1995), antibiotics 
(Atanasova and Terzivanov, 1995), anti-arhythmic drugs (Avanzini et al, 1995) 
and prescribing within target groups such as the elderly (Lindberg et al, 1994; 
Davidson et al, 1995). These are several areas that could be targets for future 
Australian pharmacoepidemiology studies. 
Pharmacoepidemiology also provides a means of evaluating educational 
intervention programs aimed at improving prescribing practices, such as the use of 
academic detailing to modify the dosage prescribing of alopurinol (Peterson and 
Sugden, 1995) and the study presented here. In addition, a method of estimating 
disease prevalence using pharmacoepidemiological drug consumption data 
comparable to that achieved with conventional cross-sectional studies but at a 
lower cost has been suggested (Sartor and Walckiers, 1995). 
Economic considerations in the prescribing of drugs is another area in which 
pharmacoepidemiology has an important role, especialy as the cost of drugs 
increase and expensive drugs are brought onto the market. For example, Manolio 
et al (1995) recently questioned the widespread utilisation of ACE inhibitors and 
calcium channel blockers in the United States since their introduction in the early 
1980s. It was argued that without convincing evidence of the advantages of ACE 
inhibitors and calcium channel blockers, it was dificult to justify the large decline 
in the market share of less expensive anti-hypertensive agents, such as diuretics and 
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13-blockers, and that US$3.1 billion would have been saved had the prescribing 
practices of 1982 remained in effect in 1992 (Manolio et al, 1995). Although this 
example may be a little extreme, it does highlight the way in which 
pharmacoepidemiology can be used to monitor prescribing for maximum cost-
effectiveness. 
As outlined earlier, the cost of asthma in Australia in 1991 was estimated to be 
between $585 and $720 million (NAC report, 1992). In 1992, the supply of 
salbutamol, beclomethasone dipropionate, ipratropium bromide and budesonide 
cost the Australian government $135 million alone (Anonymous, 1994). Obviously 
the increases in the prescribing of inhaled corticosteroids will impact on 
government costs, since inhaled corticosteroids are significantly more expensive 
than the p-agonists in MDI formulations. Naish et al (1995), after a study 
examining asthma prescribing habits in East London, suggested that pressure to 
reduce costs of asthma prescribing may lead to a reduction in prophylactic 
treatment and lower the quality of care as cost consciousness and good clinical 
practice are not necessarily linked. This leads to pharmacoeconomic cost-
effectiveness issues that are beyond the scope of this present study. 
Like PBS data, the data presented in this study lacks patient identifying numbers. 
This means that only information regarding the number of prescriptions and 
quantities dispensed are available, and not the number of patients prescribed a 
drug, individual doses or combination therapy data. A major consideration with 
patient identifying numbers is patient confidentiality, which could be at risk if 
identifying numbers were used. Although PBS data and the data used in this study 
are less comprehensive (since they lack a means for patient identification) it is 
easier and less controversial to obtain data from these sources. 
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As discussed earlier, the method of using community based pharmacy 
computerised dispensing records, as used in this study, is more comprehensive than 
PBS data alone (Section 3.3). This is particularly so in this study as a major portion 
of anti-asthmatic therapy, the bronchodilator MDIs, are priced under the 
maximum patient contribution and for that reason, MDI prescriptions for general 
patients or S3R sales are not included in the PBS database. DUSC estimates of total 
prescribing are derived from PBS data supplemented with private prescription 
survey data obtained from computerised dispensing data from around 250 
pharmacies throughout Australia. DUSC data which has been supplemented in 
this way, like the data collected in this study, are more complete than PBS data 
alone. DUSC data only includes over the counter MDI sales of salbutarnol from 
those states where recording is required (Victoria, South Australia and Tasmania). 
For this reason there is a possibility that DUSC data may underestimate total anti-
asthmatic and 13-agonist utilisation. 
The impact of hospital outpatient dispensing on these drug utilisation figures 
would be expected to be minimal. Hospital dispensing in the past has been 
estimated at 12% of the Australian pharmaceutical market (Hurley et al, 1988; 
Henry et al, 1991). However, in recent years hospital out-patient dispensing has 
undergone considerable down-sizing and would now be expected to be much 
smaller than this figure. 
As explained earlier, the calculation of the Tasmanian DDDs/1000 population/day 
for all drugs relies on prescription volumes for the corresponding financial year 
from the Pharmacy Guild of Australia. These estimates of prescription volume 
were taken from a random sample of between 263 and 273 pharmacies throughout 
Australia. These estimations also rely on the ratios of PBS to total prescriptions 
being similar for Tasmania and the whole of Australia. 
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In addition, the unit of drug utilisation, in this case DDDs/1000 population/day, 
may not truly represent the true nature of exposure and should be used with 
caution when drawing conclusion. For instance, an exposure of 12 DDDs/1000 
population/day may indicate 6 people in 1000 taking 2 DDDs of drug per day, or 
12 people in 1000 taking 1 DDD each per day. DDDs/1000 population/day is a 
standardised unit of comparison and should only be used for comparisons such as 
between different studies, populations and drugs (Cooke, 1991). Analogously, an 
increase in anti-asthmatic medication DDDs/1000 population/day may indicate 
that the number of people taking anti-asthmatic drugs have increased (an increase 
in incidence) or prescribed dosages of anti-asthmatic drugs have increased 
(increasing severity and/or more vigorous treatment) or a combination of both 
(Paterson and Musk, 1990). Unfortunately, there have been few international anti-
asthmatic drug utilisation studies of this nature for comparison. 
A study by Klaukka et al (1991) examined the prescribing of anti-asthmatic drugs 
in Finland. However, asthma prevalence (self reported prevalence of 1.9% of the 
total population) and total anti-asthmatic utilisation (49 DDDs/1000 
population/day) were considerably less than presented here. Unfortunately the 
study did not describe prescribing trends for each of the anti-asthmatic medication 
groups. Factors that affect drug prescribing such as drug availability, drug cost, 
prescriber education/guidelines and disease incidence (diagnosis/recording) limit 
the usefulness of international comparisons in pharmacoepidemiology. 
Regardless of any possible shortcomings in these data due to reliance on various 
estimations, which is inherent in all drug utilisation studies of this nature, the data 
presented is of benefit in comparing national and Tasmanian prescribing trends to 
78 
Chapter 4 
observe whether prescribing practices are changing as recommended by recent 
management guidelines. 
As the full potential of pharmacoepiderniology becomes realised it is likely to 
become an important tool in the pharmacoeconomic and therapeutic evaluation of 
drug use and policy decision making within Australia. 
4.5.2 Comparison of Tasmanian and National Anti-asthmatic prescribing trends 
The prescribing of anti-asthmatic drugs has increased considerably since 1986. 
Jenkins et al (1990) found that the total prescribing of anti-asthmatic medication in 
Australia was around 34 DDDs/1000 population/day in 1986 compared to current 
levels of around 70-80 DDDs/1000 population/day. Care should be exercised, 
however, when comparing 13-agonist and total anti-asthmatic prescribing data (of 
which 13-agonist DDDs make up the majority) in this current study with that of 
Jenkins et al (1990). Given the lack of a comprehensive pharmacoepidemiology 
database at the time, the total P-agonist community consumption data from 
Jenkins et al (1990) relied on linear regression estimations from PBS/RPBS and 
IMS data, as not all community salbutamol inhaler sales were included in the PBS 
and RPBS databases. This 1986 estimate of 34 DDDs/1000 population/day is far 
less than current prescribing reported in this study, both in Tasmania (77 
DDDs/1000 population/day for April 1994) and nationally (74 DDDs/1000 
population/day for 1994). This increase in prescribing would also be expected 
given the rising incidence of the disease reported in the National Health Survey 
(1989-90) from 2% in 1977-78 to 8% in 1989-90. 
It must be remembered that disease incidence, as reported in the National Health 
Survey, is self-reported by the public. It is therefore likely that the incidence may 
be influenced by public awareness campaigns (such as the asthma awareness 
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campaign in 1988 and the NAG in 1990) so a strict comparison between 1977-78 
and 1989-90 asthma incidence may not be entirely valid. 
The trends seen in both the national and Tasmanian utilisation were not 
unexpected given the awareness campaigns and the therapeutic shift toward anti-
inflammatory in recent years. Following the fenoterol controversy in which 
concerns were raised that fenoterol may have been responsible for the New 
Zealand epidemic of asthma deaths in the late 1970s (Pearce et al 1990; Sears et al, 
1990) and the publication of studies suggesting that regular 132-agonist use may 
worsen asthma control (Sears et al, 1990; van Schayck et al, 1991; Spitzer et al, 
1992) the use of 132-agonists has been reassessed. Following this concern, fenoterol 
MDI and nebuliser solution were delisted from the PBS co-payment schedule in 
Australia in 1990. It is therefore not surprising that the national utilisation of 
fenoterol, which never had a large market share in Australia, has declined by 
almost 85% between 1990 and 1994 to 0.22 DDDs/1000 population/day or less 
than 0.7% of total P-agonist utilisation. 
There were concerns that any potential problem with fenoterol may be common 
to all 32-agonists (Rubinfield, 1991) and coupled with the developing 
understanding of asthma as an inflammatory disease, it was suggested that more 
emphasis should be placed on anti-inflammatory therapy with more prudent use of 
132-agonists (Barnes, 1989; Barnes and Chung, 1992; Lipworth and McDevitt, 1992). 
Current management guidelines now suggest that additional preventive therapy 
(inhaled corticosteroids and/or sodium cromoglycate) must be considered in all 
but the mildest cases of asthma (Anonymous, 1992; Tse and Bridges-Webb, 1993; 
Thompson and Watkins, 1994; Rees and Price, 1995a). 
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Jenkins et al (1990) found that the total utilisation of P-agonists (inhaled and 
systemic) doubled from 10.9 DDDs/1000 population/day in 1980 to 22.6 
DDDs/1000 population/day in 1986. This contrasts with a decrease of almost 11% 
to 35.1 DDDs/1000 population/day for national utilisation of P-agonists from 
1990 to 1994 (DUSC data) and a fall of around 3% to 39.4 DDDs/1000 
population/day between April 1991 and April 1994 for Tasmanian utilisation of 
13-agonists. It should be noted, however, that there were considerable fluctuations 
in both Tasmanian and DUSC data as shown in Figures 4.6 and 4.7 respectively. 
Although there was a greater fall in the national dispensing of 13-agonists, it must 
be remembered that both national and Tasmanian 13-agonist utilisation figures 
fluctuated by more than 18% and 24% respectively. The smaller decline in the 
utilisation of 13-agonists in Tasmania should not necessarily be interpreted as 
Tasmanian prescribing being more reliant on 13-agonists, but maybe due to 
fluctuations as outlined above. These data suggest that both national and 
Tasmanian p-agonist prescribing has passed a peak and is now stable or declining. 
As reported earlier, the National Health Survey has reported a rise in the incidence 
of asthma since 1972 and asthma mortality had been increasing over the last 20 
years (Section 2.2) until a recent decline (which may be part of natural 
fluctuations). Even though P-agonist dispensing did not decline over the period of 
the study, this does not necessarily suggest that patterns of P-agonist use are similar 
to those prescribing practices before the change in emphasis to the earlier 
introduction of anti-inflammaiory therapy. Firstly, despite monthly fluctuations, 
p-agonist use did not increase over the period of this study. Secondly, if the 
incidence of asthma has been increasing over the period of the study at a rate 
similar to that between the 1977-78 and 1989-90 National Health Surveys, more 
people would have been expected to be using bronchodilator therapy with drug 
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utilisation levels increasing toward the end of the study. Thirdly, public and 
prescriber awareness due to the NAC would suggest that more people may have 
recently been diagnosed with asthma. These people may be more likely to have 
asthma of a milder nature (i.e. disease not previously diagnosed, treated or 
recognised) and if so, would be more likely to be prescribed bronchodilators than 
anti-inflammatory therapy. It is therefore surprising and encouraging that p-
agonist use, despite changing prescribing practices in asthma, did not increase over 
the period of the study. The most likely scenario is that individual patient reliance 
on P-agonist therapy has decreased. 
There has been concern surrounding the change in Poisons scheduling for 
salbutamol MDIs in Australian States. Once an S4 item requiring a prescription 
from a doctor, salbutamol MDIs have been available over the counter after 
consultation with a pharmacist in all Australian states since 1985. Salbutamol 
MDIs are classed as S3Rs in Tasmania (i.e. S3 item that is required to be recorded 
by law). Concern has been expressed based on the possibility of infrequent medical 
consultation and under treatment of asthma (Gibson et al, 1993b) and the large 
increases in over the counter MDI sales observed by Jenkins et al (1990). 
Secondary to the drug summary data (that consisted of combined prescription and 
S3R sales), some drug summary lists also included the number of over the counter 
S3R items dispensed separately (available on the Amfac-Chemdata system). This 
enabled the percent of total MDIs dispensed as S3R over the counter sales to be 
calculated for a small number of pharmacies. Despite the concerns outlined above, 
it was found that only a small percentage (6.5%) of total salbutamol MDIs were 
sold over the counter as S3Rs. There are, however, large limitations with these data 
for two reasons. The estimate relies on the assumption that all S3R prescriptions 
were recorded by the pharmacist (as legally required), and there were only a small 
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number of pharmacies (less than 6% of all monthly lists, provided by only 7 
different pharmacies over the period of the study) that included this information. 
Most responding pharmacists removed this S3R information presumably because, 
unlike the drug summary lists, patient names and addresses were included with the 
S3R prescription information. Despite these limitations, this figure compares 
favourably with that of Comino et al (1995) who found that 11% of asthmatic 
respondents purchased over the counter bronchodilators in Hobart. Over the 
counter bronchodilator sales were found to be higher in Adelaide (15%), 
Melbourne (19%), Brisbane (26%), Perth (50%) and Sydney (57%; Comino et al, 
1995). 
There were only a few private prescriptions of the long acting 132-agonist 
salmeterol recorded in this study. Salmeterol (which was released on the PBS as an 
authority item in early 1995) accounted for less than 0.03% of the total national 
anti-asthmatic DDDs dispensed (1994 DUSC figures) and 0.12% of the total 
Tasmanian anti-asthmatic DDDs dispensed for April 1994 (representing only 5 
prescriptions). Perhaps in light of some concerns about development of tolerance 
to the protective effects of long acting 132-agonists (Cheung et al, 1992; Skorodin, 
1993; Grove and Lipworth, 1995), there is not a high level of utilisation of this 
drug at this early stage. It would be interesting to model the market uptake of 
salmeterol in a similar approach to that used by Birkett and McManus (1995). 
Inhaled corticosteroid utilisation increased by 80% to 22.8 DDDs/1000 
population/day between 1991 and 1994 nationally and by 61% between April 1991 
and April 1994 in Tasmania to 22.8 DDDs/1000 population/day. National 
utilisation of beclomethasone dipropionate (Aldecin®, Becotide®, Becloforte6) has 
fallen by almost 14% from 12.6 to 10.9 DDDs/1000 population/day between 1990 
and 1994. Budesonide (Pulmicort) utilisation has increased since its listing on the 
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PBS co-payment schedule in 1991 by over 5-fold from 2.4 to 11.9 DDDs/1000 
population/day between 1991 to 1994. Budesonide has several advantages over 
beclomethasone dipropionate which may explain its popularity. Budesonide is 
available in both a higher dose formulation (400 [ig per dose) and a breath activated 
device. Budesonide also appears to have a higher topical to systemic potency ratio 
than beclomethasone dipropionate (Brattsand et al, 1982) 
Theses trends of increased inhaled corticosteroid usage are consistent with current 
management guidelines. Inhaled corticosteroids are now advised in all but the 
mildest forms of adult asthma (McFadden and Gilbert, 1992; Anonymous, 1992; 
Skorodin, 1993; Tse and Bridges-Webb, 1993; Barnes, 1995; Paterson et al, 1995; 
Rees and Price, 1995a) and the recommended dosages of inhaled corticosteroids 
have been increasing. There has been some concern, however, that inhaled 
corticosteroids are being increasingly used for children with relatively mild 
asthma, perhaps at the expense of using sodium cromoglycate (Phelan, 1995). 
Beclomethasone dipropionate was originally marketed as 50 in per inhalation in 
Australia, however, dosages have increased over the years. For example, in the 
original trials dosage schedules were formulated with a limit of 1200 lig/day. A 
250 p,g per inhalation MDI (Becloforte6) was listed on the PBS in late 1988 as an 
authority item (needing special approval to be prescribed) but as dosages have 
increased, it is now available without authority. 
The introduction of high doses of inhaled corticosteroids facilitated by a 250 [ig 
per dose inhaler (beclomethasone dipropionate) was a major therapeutic advance 
in the management of asthma (Douglass and Bowes, 1990). In addition, budesonide 
is also now available in a 400 lig per dose MDI. Despite the well documented risk 
of adrenal suppression with dosages above 1500 fig/day, high dose inhaled 
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corticosteroids (over 2000 ig/day) are now widely used to control more severe 
asthma and their use can alleviate or markedly reduce the need for oral 
glucocorticoid therapy (Kamada, 1994; Barnes, 1995). There is little evidence of 
glucocorticoid related side effects in doses up to 1500 lig/day (Barnes et al, 1995), 
however, doses exceeding 1000 lg/day do pose an increased risk of adrenal 
suppression (Kamada, 1994). 
The introduction of the higher dose formulation and spacer has improved the 
delivery of corticosteroids, allowing them to be prescribed to people who may 
have been unable or reluctant to take the drug in the past (Douglass and Bowes, 
1990). The use of spacer devices has been shown to reduce the incidence of oral 
candidiasis (Kong, 1985; Salzman et al, 1988), particularly so in patients who have a 
poor MDI technique. In addition, four times daily regimens of inhaled 
corticosteroids have been associated with a higher incidence of oral candidiasis 
than twice daily regimens (Toogood et al, 1984; Smith and Hodson, 1986). 
Although the current management guidelines place greater emphasis on the earlier 
introduction of anti-inflammatory therapy, the availability of higher dose MDIs 
needing fewer daily inhalations, and the introduction of spacer devices, have also 
helped make inhaled corticosteroids more popular by reducing adverse effects such 
as oral candidiasis and hoarseness. 
This increase in inhaled corticosteroid drug utilisation adds more evidence that 
prescribing practices have changed in line with management guidelines with the 
earlier introduction of preventive therapy. The Tasmanian utilisation of inhaled 
corticosteroids, although not displaying as great an increase, was virtually the same 
as 1994 national data with an April 1994 Tasmanian figure of 22.9 compared with 
the national data of 22.8 DDDs/1000 population/day. 
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It has been shown in England that 15% of patients receiving inhaled corticosteroids 
had a diagnosis other than asthma (Campbell et al, 1995). In addition 132-agonists, 
ipratropium bromide and theophylline are widely used in other diseases such as 
COPD (Section 2.5). Since the prescription data collected here was not linked to 
indication, due care should be exercised when interpreting the inhaled 
corticosteroid data. However, despite this data not being linked to indication, even 
when taking into account 15% variability, there has been a real increase in the 
utilisation of inhaled corticosteroids. 
Further supporting evidence of less reliance on bronchodilator therapy is that the 
ratio of 13-agonistinhaled corticosteroid DDDs dispensed has decreased from 7.3 
(or 4.1 not including general prescription and over the counter sales estimates) in 
1986 (Jenkins et al, 1990) to 1.5 (national data) or 1.7 (Tasmanian data) in 1994. 
The national ratio has decreased by 51% between 1990 and 1994 while the 
Tasmanian ratio has decreased by 40% between April 1991 and April 1994. As p-
ago nist utilisation has remained fairly stable over the period of the study, this 
increase in inhaled corticosteroid usage has been the main contributor to the 
decrease in the ratio of 13-agonist:inhaled corticosteroid DDDs dispensed. This 
suggests that prescribing practices have changed, with probably a combination of 
more people now receiving inhaled corticosteroid therapy and higher doses now 
being used. 
Theophylline and its xanthine derivatives have suffered a large decrease in 
prescriptions over the last 4 years. Jenkins et al (1990) reported total methyl 
xanthine utilisation as 6.8 DDDs/1000 population/day in 1986. DUSC data 
indicates 1994 utilisation as 5.4 DDDs/1000 population/day, down 60% from 
1990. Tasmanian utilisation has also fallen by a similar margin to 6.6 DDDs/1000 
population/day in April 1994, down 43% from April 1991. 
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Theophylline is no longer considered a first-line drug in asthma (Alpers, 1991). 
Current management guidelines now suggest less emphasis on the use of oral 
theophyllines for chronic asthma (Anonymous, 1992; Tse and Bridges-Webb, 
1993). Its popularity may have decreased for several reasons; the development of 
new drugs such as high dose inhaled corticosteroids and ipratropium bromide 
(Skorodin, 1993), studies questioning the use of theophylline in the emergency 
treatment of asthma (Littenberg, 1988) and dosage difficulties associated with its 
narrow therapeutic range and pharmacokinetic variability (Johnston, 1990; Jenne, 
1994). 
Despite recent questions regarding the efficacy of theophylline, it remains a potent 
and effective bronchodilator for asthma, and to a lesser degree, for COPD (Addis, 
1990; Skorodin, 1993). Theophylline is useful in the treatment of chronic 
persistent asthma that is difficult to control with maximum doses of inhaled 
corticosteroids (Breslin, 1993), nocturnal asthma (Alpers, 1991; Frew and Holgate, 
1993; Skorodin, 1993), patients with acute severe asthma who are progressing into 
respiratory failure (Addis, 1990; Jenne, 1994), and patients with severe COPD who 
are dependent on bronchodilators and oxygen (Jenne, 1994). In addition, 
theophylline has an additive or synergistic effect on bronchodilation when 
combined with [32-agonists and/or ipratropium (Jenne, 1987; Nishimura et al, 
1992; Thomas et al, 1992), may possess a mild anti-inflammatory action (Jenne, 
1994; Rees and Price, 1995a) and has positive effects on mucociliary clearance, 
diaphragmatic function and fatigue (Jenne, 1994). 
The negative aspects of theophylline use have been well documented. The variable 
clearance, narrow therapeutic index and the severity of the toxic reactions of 
theophyllines necessitate close attention to dosage regimens and subsequent 
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monitoring of plasma levels (Jenne, 1994) making theophylline a difficult drug to 
prescribe (Johnston, 1990). In addition adverse effects such as nausea, vomiting, 
and abdominal discomfort are common but headache, malaise and convulsions can 
also occur (Rees and Price, 1995a). 
Although expensive, immunoassay paper test strips for theophylline are now 
available providing a theophylline plasma level from a capillary blood sample 
within 30 minutes (Aronson et al, 1992). With plasma levels of theophylline in 
community patients now easily measurable, these adverse effects should be 
minimised with regular monitoring of levels. It is therefore a little surprising as to 
the magnitude of the fall in theophylline utilisation over the period of this study. 
Further studies into the relationship between the degree of theophylline plasma 
monitoring in the community, incidence of adverse effects, drug efficacy and the 
pharmacoeconomic aspects of prescribing of a relatively inexpensive drug should 
be examined. After all, theophylline is still of benefit in some asthmatics, has been 
a mainstay of asthma treatment for several decades and the tools are now available 
to better utilise this drug. 
There was a surprising rise in the use of ipratropium over the period of the study. 
Utilisation of ipratropium increased by 106% between 1990 and 1994 nationally 
and 138% between April 1991 and April 1994 in Tasmania. The large increase in 
ipratropium use may be 'associated with a combination of increased use in older 
patients with COPD and the fact that ipratropium may easily be added to an 
existing anti-asthmatic medication regimen. 
Ipratropium is more commonly of benefit in patients with chronic bronchitis or 
emphysema (Alpers, 1991; Kemp, 1993; Skorodin, 1993; Rees and Price, 1995). 
Ipratropium use in asthma is limited and is of most benefit to older patients, the 
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very young (Rees and Price, 1995a), or in patients with acute severe asthma 
(Bryant, 1985; Rebuck et al, 1987; O'Driscoll et al, 1989; Bendefy, 1991). 
Additional clinical benefit has been noted when ipratropium is combined with a 
132-agonist in COPD (Massey and Gotz, 1985; Mann et al, 1988). In addition, 
because the onset of action is slower but the action is more prolonged lasting up to 
8 hours, the addition of ipratropium to an anti-asthmatic regimen may provide 
better therapeutic coverage in some patients but it is not recommended as a single 
drug therapy in asthma (Alpers, 1991; Breslin, 1993). 
Comparison of ipratropium utilisation with that of Jenkins et al (1990) was not 
possible as the 1986 data in that study did not include ipratropium. Ipratropium 
was not released on the PBS co-payment schedule in Australia until 1985. 
It is unlikely that the rise in ipratropium use has offset or masked a lack of an 
increase in p-agonist bronchodilator use. Even when grouping ipratropium with 13- 
agonists as bronchodilators, the bronchodilator:inhaled corticosteroid ratio 
decreased between 1990 to 1994 from 3.5 to 2.0 (down 44%) nationally and from 
3.1 to 2.3 (down 27%) in Tasmania between April 1991 and 1994. 
One disturbing finding in this study was the relatively minor use of sodium 
cromoglycate in Australia. Both national and Tasmanian levels of utilisation were 
around 1 DDD/1000 population/day. This was similar to usage in 1986 (Jenkins et 
al, 1990). In addition, Jenkins et al (1990) noted a 39% fall in sodium cromoglycate 
usage between 1975 and 1986. 
In Canada, the use of sodium cromoglycate as well as inhaled corticosteroids began 
to rise in the late 1980s coinciding with the development of Canadian guidelines 
for asthma treatment (Toogood, 1983). This has not happened in Australia. 
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Prescribing of sodium cromoglycate in Finland has been reported at around 2 
DDDs/1000 population/day and as much as 7 DDDs/1000 population/day in 
some regions (Kluakka et al, 1991). Given that the Finnish utilisation of all anti-
asthmatics totalled 49 DDDs/1000 population/day (with a lower incidence of 
asthma), this represented over 4% of all anti-asthmatic DDDs. In the current 
prescribing environment in Australia, this would represent a utilisation of around 
3 DDDs/1000 population/day, double that found in this current study. 
Given that 12% of people under the age of 25 years reported asthma, accounting 
for 56% of all persons with asthma (National Health Survey, 1989-90), it seems 
peculiar that utilisation of a preventive drug with proven efficacy and which is 
recommended as first-line therapy in younger people (Alpers, 1991; Breslin, 1993; 
Skorodin, 1993; Rees and Price, 1995b) has remained relatively low. In addition, 
sodium cromoglycate is relatively free of harmful adverse effects (Skorodin, 1993) 
has been well promoted in current management guidelines (Anonymous, 1992; Tse 
and Bridges-Webb, 1993; Rees and Price, 1995a) and is now available in a higher 
dosage form (Intal Forte8). 
Taken regularly, sodium cromoglycate will control symptoms in about 60% of 
school age children with frequent symptoms (Rees and Price, 1995b). A trial period 
of at least 4-8 weeks of regular use should be allowed before sodium cromoglycate 
is dismissed as ineffective (McFadden and Gilbert, 1993; Skorodin, 1993; Price, 
1995a). To improve compliance, patients should be warned about this lag time 
(Skorodin, 1983) and this may be one reason why sodium cromoglycate is not 
utilised more. Sodium cromolgycate is not effective in all patients and there seem 
to be no indicators to predict which patients will respond (Barnes, 1989). In 
addition, sodium cromoglycate is generally not used together with inhaled steroids 
(Anonymous, 1992; Breslin, 1993). 
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The release of nedocronail sodium (Tiladeo) in Australia in April 1995 will be of 
interest given the surprisingly low market share of sodium cromolgycate (the only 
currently available anti-allergic medication) in a prescribing environment which 
should favour such drugs. Will the introduction of nedocromil sodium, the first 
non-steroid anti-inflammatory preparation specifically for adults (Brogden and 
Sorkin, 1993), promote greater interest in this class of drugs? The drug utilisation 
results found here suggest that more attention should be given to the prescribing of 
anti-allergic drugs. 
There is no doubt that utilisation patterns have changed over the three years of 
this study despite the fluctuations. The national utilisation of 13-agonists was low 
for 1991 compared with 1990 and 1992 while there was a large increase in 
utilisation of inhaled corticosteroids from 1991 to 1992. Tasmanian utilisation of p-
agonists dropped sharply between October 1991 to April 1992 while there was an 
increase in inhaled corticosteroid utilisation between April 1991 and 1992. These 
events occurred after the launch of both the NAC 's Medical Practitioners and 
Pharmacists Asthma Management Plans in 1991. It is difficult to conclude that 
these utilisation changes are due entirely to the awareness and educational 
intervention of the NAC, although studies have documented how patient and 
prescriber education can improve clinical outcomes in patients with asthma (ToeIle 
et al 1993; Pauley et al, 1995). The shift in prescribing emphasis may also have been 
contributed to by the publicity surrounding suggestions that 13-agonists may 
worsen asthma. There was, however, an increase in 1992 (nationally) and October 
1992 (Tasmania) in the utilisation of both inhaled corticosteroids and 13-agonists, 
before 13-agonist utilisation levelled out and declined slightly in Tasmania. The 
cause of this could be associated with an increased awareness of the disease, 
brought about by the NAC, resulting in more diagnoses, or natural fluctuations in 
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morbidity. However, there was no marked increase in asthma deaths during this 
period. 
The ratios of both bronchodilators ([3-agonist plus ipratropium bromide) and i3- 
agonist to inhaled corticosteroids are slightly higher in Tasmania than the national 
data which suggests there may either be still some room for improvement in 
prescribing practices in Tasmania or the higher ratios in Tasmania may reflect a 
higher disease incidence and severity. However, there were no significant 
differences in mortality rates between the Tasmanian and Australian data from 
1991 to 1993. 
The national DUSC figures, like the data presented in this study are merely 
estimations of drug utilisation. To place the accuracy of the data into perspective, 
the survey component of the DUSC estimations of prescribing presented here 
were collected from around 250 pharmacies Australia-wide initially, dropping to 
around 190 in 1993 (personal communication, Secretary of DUSC). This 
represented around one pharmacy sample per 69,000 people in 1991 rising to one 
sample per 93,000 people in 1993. In comparison, the Tasmanian data from 
October 1991 represented around one pharmacy sample per 13,000 people falling 
to around one sample per 11,000 people in October 1993 (calculated from 37 and 
43 pharmacies respectively). In addition DUSC estimations of prescribing only 
included over the counter MDI sales from Victoria, South Australia and Tasmania. 
This would suggest that the Tasmanian data presented in this study should be far 
more representative of prescribing practices within Tasmania than the DUSC data 
is representative of national prescribing. 
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4.5.3 Comparison of Tasmanian regional prescribing trends 
There were minor differences in prescribing within Tasmania. As discussed earlier 
(Section 4.4.5) there was slightly greater relative utilisation of inhaled 
corticosteroids and p-agonists in the South of the State and greater relative 
utilisation of ipratropium and methyl xanthines in the North. The ratios of p-
agonist:inhaled corticosteroid were very similar, except for October 1993 where 
the Southern Tasmania ratio was 1.6 compared to Northern Tasmania's 1.8. 
Asthma morbidity during the period of the study, as measured by hospital 
admissions in Tasmania, rose to a peak in October 1992, then fell for the 
remainder of the study. Utilisation of both P-agonists and inhaled corticosteroids 
increased at the same time. The cause of the increase in morbidity and drug 
utilisation is unclear but may have been associated with factors such as an 
influenza epidemic or a severe winter. However, given a lack of appropriate 
retrospective data and the limitations of analyses of secular trends, it is difficult to 
identify the reasons for these increases. 
The major contributor to the observed fall was Southern Tasmanian admissions 
while Northern Tasmanian admissions did not fall to the same extent. It is 
probably not valid to relate the fall in hospital admissions with the decline in the 
ratio of p-agonist:inhaled corticosteroid DDDs dispensed for the following reasons. 
The admissions numbers are small and susceptible to greater relative fluctuations 
and the degree of correlation 'between asthma morbidity in the general community 
and hospital admissions is unclear. 
It appears that in general, Southern and Northern Tasmanian prescribing are 
similar, and have followed a similar trend in line with the national data and 
current guidelines. 
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4.5.4 	 Does this data support either the 'severity' or '13-agonist' hypothesis? 
There also seems to be evidence that there may be now less reliance on P-agonist 
therapy. Despite an increasing incidence of the disease and greater awareness and 
diagnosis, 13-agonist utilisation has remained relatively stable (both nationaly and 
in Tasmania) and may be declining. This suggests that for a given individual within 
the population, the dose of (3-agonist used has decreased. In addition, a decrease in 
the dispensed DDDs ratio of P-agonist:inhaled corticosteroid has been observed. 
There has been a decline in national asthma mortality from the late 1980s. 
National and Tasmanian asthma mortality has stabilised over the period of the 
study. Tasmanian hospital admissions, a crude measure of morbidity, also appear 
to have stabilised over the period of the study and may be declining. 
The question arises, does this data support either the '13-agonist hypothesis' or the 
'severity hypothesis'. The 'severity hypothesis' speculates that increasing use of 13- 
agonists is a marker of greater disease severity, which itself is associated with an 
increased risk of fatal or near fatal asthma (Suissa et al, 1994). The 'P-agonist 
hypothesis' implies that the over reliance on 13-agonists is responsible for the 
adverse asthma outcomes independent of disease severity (Suissa et al, 1994). 
Unfortunately the data presented here have limitations, of which there are two 
diferent aspects. Firstly, there are wel documented limitations with analysis of 
secular trends, or ecological association studies as they are sometimes known 
(Eisdale et al, 1987; Strom, 1994). It is dificult to control confounding variables, 
they observe groups and so lack data on individuals, and disease trends may not be 
idealy recorded (Strom, 1994). As stated earlier (Section 3.2.1), to find a true causal 
association, random, bias and confounding (indirect) erors must be excluded. In 
addition there must be coherence with existing information (biological 
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plausibility), consistency and specificity of the association, a time sequence, and a 
strong association (Strom, 1989). 
Secondly, there are limitations with the use of DDDs/1000 population/day to 
measure drug utilisation as stated earlier, it provides no information on individual 
dosages. For example, without other supporting evidence, a static level of drug 
utilisation measured in DDDs/1000 population/day may suggest either (i) levels 
have remained stable, (ii) more people taking less drug, or (iii) less people taking 
more drug. Rises and falls in DDDs/1000 population/day utilisation figures 
further confound this problem. However, when combined with other 
information, this uncertainty can be minimised. As discussed earlier, it can most 
likely be inferred from this study that individual reliance on P-agonists has 
decreased. 
Like the study by Jenkins et al (1990), these limitations in using DDDs/1000 
population/day make this current study unable to support or disprove either the 
'13-agonist hypothesis' or the 'severity hypothesis'. This was noted by both 
Paterson and Musk (1990) and Jenkins and Bowes (1991), and in the study by 
Jenkins et al (1990). What this study does show is that there is now much greater 
utilisation of inhaled steroids and less reliance on 13-agonists as sole therapy which 
is in-line with current management guidelines. At the same time, mortality and 
morbidity appear to be stabilising or declining from the levels in the late 1980s. 
Further studies of this nature are required to monitor prescribing, asthma 
morbidity/mortality, and to assess the impact of recommended treatment regimens 
on therapeutic outcomes (Toogood, 1993). It is important not to become 
complacent and shift to other more topical issues. Asthma knowledge, drug 
therapy, morbidity and mortality have shown they are dynamic processes with 
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changes occurring in the past. It is likely there wil be changes in the future and 
observational studies such as analysis of secular trends are an ideal means of 
monitoring these trends. 
4.6 	 CONCLUSION 
In recent years it has been recognised that asthma should not simply be regarded as 
bronchoconstriction but involves a characteristic inflammatory response. This, 
together with concerns that 13-agonist may worsen asthma, have resulted in curent 
management guidelines placing greater emphasis on the earlier introduction of 
inhaled corticosteroids and anti-alergy drugs. 
Tasmanian prescribing trends of anti-asthmatic medications reflect these new 
guidelines and are similar to national prescribing trends. There has been a large 
increase, both nationaly and in Tasmania, in inhaled corticosteroid utilisation and 
13-agonist utilisation appears to have stabilised and may be declining. There was a 
surprisingly low level of utilisation of sodium cromoglycate, suggesting that 
greater atention should be given to the prescribing of sodium cromoglycate and 
the newly introduced nedocromil sodium. 
Australian and Tasmanian asthma mortality may have declined from levels in the 
late 1980s but it is difficult to atribute that this is entirely due to changes in 
prescribing and/or the NAC, or the changes may simply be part of natural 
fluctuations due to the limitations of secular trend analyses. 
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High Performance Liquid Chromatographic Assay for 
the Simultaneous Determination of Ipratropium 
Bromide, Fenoterol, Salbutamol and Terbutaline in 
Nebuliser Solution 
5.1 SUMMARY 
A reversed-phase ion-pair high performance liquid chromatography assay was developed for the 
simultaneous determination of ipratropium bromide, fenoterol hydrobromick, salbutamol sulphate and 
terbutaline sulphate in nebuliser solution. Chromatographic separation was achieved with a Nova-Pak® 
C18 4 pm 10 cm x 8 mm i.L Radial-pak® cartridge inside a Waters RCM 8 x 10 compression module 
using ternary gradient analysis. Detection was performed using UV detection at 220 nm. The standard 
curves were linear over the following ranges: ipratropium bromide 20.8- 250.0 pg/ml, fenoterol 
hydrobromide 27.8-500.0 pg/ml, salbutamol sulphate 34.7-2500.0 4 cg/m1 and terbutaline sulphate 69.5- 
2500 pg/ml. Inter-day and intra-day coefficients of variation for each compound ranged from 4.5-5.2% 
and 3.5-3.9% respectively. The assay procedure was developed to allow the accurate determination of 
constituents in various combinations of nebuliser solution, as well as being stability indicating. This 
provides a convenient means of testing long-term compatibility and stability following the post-
manufacture mixing of commonly used nebulised preparations. 
5.2 INTRODUCTION 
Inhalation of respirator solutions via nebuliser is an integral component of the 
modern treatment of airways diseases, particularly for patients unable to use 
metered dose inhalers (Johnson, 1989; Anonymous, 1987; Horsley, 1988). 
Nebulised drugs commonly used in the treatment of asthma include ipratropium 
bromide, which is a quaternary derivative of atropine, and the [32-agonists 
fenoterol, salbutamol, and terbutaline. The structures of these compounds are 
shown in Figure 5.1. 
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Figure 5.1 	 Structures of salbutamol, terbutaline, fenoterol and ipratropium bromide. 
While ipratropium bromide is not a first-line or sole drug for asthma, recent 
studies have advocated the use of ipratropium bromide in acute severe asthma in 
combination with 132-agonists (Bryant, 1985; Rebuck et al, 1987; O'Driscol et al, 
1989, Mann et al, 1988). The bronchodilator efect of ipratropium bromide in 
chronic bronchitis appears to be comparable, and may be superior in some cases, 
to that of the (32—agonists (Mann et al, 1988). In addition, in chronic obstructive 
pulmonary disease, various studies have shown additional clinical benefit is gained 
when ipratropium bromide is combined with other bronchodilating drugs (Barnes, 
1989; Massey and Gotz, 1985; Mann et al, 1988). 
The mixing of nebuliser solutions is a common practice (Caldwel et al, 1991; 
O'Driscol and Cochrane, 1987) which provides a means of shortening the time 
that patients spend nebulising inhaled drugs. It has been suggested that the 
convenience and reduced administration time resulting from mixing nebuliser 
solutions may increase patient compliance (Roberts and Rossi, 1993). The post- 
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manufacture mixing of these nebuliser solutions, however, gives rise to issues of 
compatibility and stability. Iacono et al (1987) showed that ipratropium was stable 
for a period of up to 1 hour after mixing with salbutamol and sodium 
cromoglycate, while longer term admixture stability and compatibility with 
fenoterol and terbutaline were not discussed. A need for a single assay that would 
alow testing of the compatibility and stability of diferent combinations of these 
132-agonists with ipratropium was evident. 
HPLC has many advantages over gas chromatography for the analysis of polar, 
non-volatile and thermaly labile compounds in aqueous matrices (Mehta, 1992). In 
this study, a reversed-phase ion-pair HPLC assay using Pic® reagent was developed 
to determine the concentrations of ipratropium, salbutamol, fenoterol and 
terbutaline present in a nebuliser solution, either alone or in any combination. 
Ion-pair chromatography was utilised because of the quaternary structure of 
ipratropium; this alowed retention of the neutral ion-pair on the reversed phase 
column. 
5.3 	 EXPERIMENTAL 
5.3.1 	 Materials 
Ipratropium bromide powder was kindly donated by Boehringer Ingelheim Pty. 
Ltd. (Ingelheim, Germany) for the development of the assay. 
The folowing were used in the assay procedure: ipratropium bromide (Atrovent® 
0.025% nebuliser solution; Boehringer Ingelheim Pty. Ltd., Artarmon, NSW, 
Australia), fenoterol hydrobromide (Berotec® 0.1% w/v nebuliser solution; 
Boehringer Ingelheim Pty. Ltd., Artarmon, NSW, Australia), salbutamol sulphate 
(Ventolin® 0.5% w/v nebuliser solution; Glaxo Australia Pty. Ltd., Boronia, Vic., 
Australia), terbutaline sulphate (Bricanyl® 1% w/v nebulising solution; Astra 
Pharmaceuticals Pty. Ltd., North Ryde, NSW, Australia), and mepivacaine 
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hydrochloride (Carbocaine® 1% w/v sterile injection, Winthrop Laboratories, 
New York, USA). 
Methanol and tetrahydrofuran (liquid chromatography grade) were purchased 
from Waters Associates, Lane Cove, NSW, Australia. The ion pair reagent (Pic® B-
8 Reagent Low UV; containing water, methanol, octane sulphonic acid and 
calcium acetate in undisclosed quantities) was purchased from Waters Associates, 
Milford, MA, USA. 
5.3.2 Equipment 
The HPLC system consisted of a Varian Solvent Delivery System Model 9010 
(Varian Chromatography Systems, Walnut Creek, CA, USA) and a Nova-Pak® 
C18 4 pm 10 cm x 8 mm i.d. Radial-pak® liquid chromatography cartridge (Waters 
Associates, Milford, MA, USA) inside a Waters RCM 8 x 10 compression module 
(Waters Associates, Milford, MA, USA). A Rheodyne injector Model 7161 
(Rheodyne Inc., Cotati, CA, USA) with a 10 1u1 external loop was used. Detection 
was performed using a Varian Variable Wavelength UV-VIS Detector Model 9050 
(Varian Chromatography Systems, Walnut Creek, CA, USA) set at 220 rim. 
Chromatographic peaks were digitised, integrated and recorded with a Varian GC 
Star Workstation (Varian Chromatography Systems,Walnut Creek, CA, USA). 
5.3.3 Method development 
The quaternary nature of the ipratropium molecule resulted in a fast elution with 
the solvent front in a normal reversed-phase HPLC system. Ipratropium bromide 
standard was used to confirm the retention time. This situation was easily solved 
with the addition of an ion-pair reagent to the mobile phase. The ipratropium ion 
formed an ion-pair with the hydrophobic counter-ion made available by the 
addition of an octane sulphonic acid ion-pair reagent. The relatively hydrophobic 
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ion-pair was retained to a greater extent on the non polar C18 column and hence, 
resolved from the solvent front. Hexane, heptane and octane sulphonic acid were 
investigated as ion-pair reagents. Octane sulphonic acid was finally chosen as the 
ion-pair reagent as the slightly longer hydrophobic tail resulted in a greater 
retention factor without the need to increase the ion-pair reagent concentration. 
The increased retention permitted more range for optimising the organic solvent 
components in the mobile phase. The addition of an ion-pair reagent also 
enhanced the resolution of the 132-agonists and mepivacaine with reduced peak 
tailing evident. Chromatograms of ipratropium, salbutamol and a blank distilled 
water sample are shown in Figure 5.2 with and without octane sulphonic acid ion-
pair reagent (Pic® B-8 Reagent Low UV) in the mobile phase, with an identical 
organic component in each mobile phase (25% tetrahydrofuran, 10% methanol in 
distilled water). 
Ternary gradient analysis was used to allow the satisfactory resolution of all five 
compounds. A solvent with relatively strong elution power such as 
tetrahydrofuran was required for the satisfactory elution of the hydrophobic ion-
pairs. Initially in the assay development, fenoterol was found to elute late in the 
chromatogram with a poor peak shape under the starting mobile phase conditions. 
This was corrected by two means. Firstly, the tetrahydrofuran concentration was 
increased after 7.7 minutes, which subsequently decreased the retention time and 
improved the peak shape of fenoterol. Secondly, an increasing methanol 
component after 7.7 minutes Was found to further decrease the retention time and 
improve the peak shape of fenoterol. 
5.3.4 Chromatographic conditions 
Ternary gradient analysis (mobile phases A, B and C) was used to achieve 
satisfactory solute elution. Mobile phase A was a solution of tetrahydrofuran - 
distilled water (40:60, v/v) containing 0.0025 M Pic® B-8 Reagent Low UV. This 
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Figure 5.2 	 Chromatograms of samples of salbutamol 5 mg/ml (1), ipratropium 250 pg/ml (2), 
distiled water blank (3) without an octane sulphonic acid ion-pair reagent in the 
mobile phase; and samples of salbutamol 5 mg/ml (4 ipratropium 250 pg/ml (5 
distiled water blank (6)with an octane sulphonic acid ion-pair reagent in the mobile 
phase 
was prepared by diluting the contents of one vial of Pic® B-8 Reagent Low UV in 
100 ml of distiled water. Fifty mililitres of this solution was then added to 400 ml 
of tetrahydrofuran and made up to 1000 ml with distiled water. This resulted in a 
solution containing 0.0025 M Pic ® B-8 Reagent Low UV which was half the 
recommended strength of 0.005 M (accompanying Pic® instructions). The level of 
ion-pair reagent was reduced to minimise the cost of the assay and did not impair 
performance under the conditions of this assay. Mobile phase B was distiled water 
and mobile phase C was methanol - distiled water (50:50, v/v). Al mobile phases 
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were filtered through a 0.5 pm filter (Lido Manufacturing Corp., Bensenville, IL, 
USA) using a vacuum flask before use. 
Flow was 2.0 ml/min of 50% mobile phase A and 50% mobile phase B up to 7.7 
minutes, then changing linearly to 60% mobile phase A, 15% mobile phase B and 
25% mobile phase C at 13.0 minutes. Run time was 13.0 minutes with a 5.0 minute 
equilibration time. 
5.3.5 Calibration curve 
An internal standard solution of mepivacaine was prepared by adding 2 nil of 
mepivacaine hydrochloride 1% to 8 ml of distilled water to give a solution of 
2.0 mg/ml. 
A 2 ml stock solution containing ipratropium, fenoterol, salbutamol and 
terbutaline nebuliser solutions (3:1:1:1, v/v/v/v) was prepared from the 
proprietary nebuliser solutions to give a solution containing ipratropium 
125 Jug/ml, fenoterol 167 pg/nal, salbutamol 833 ,ug/m1 and terbutaline 
1.67 mg/ml. Further dilutions of the stock solution were made; 200 ,u1 aliquots of 
the stock solution were added to appropriate volumes of distilled water to give 
concentrations of 66.7%, 33.3%, 16.7%, 8.3% and 4.2% of the stock solution 
concentrations. 
In addition, individual solutions of fenoterol 500 ,ug/ml, salbutamol 2.5 mg/ml, 
terbutaline 2.5 mg/ml (prepared from proprietary nebuliser solutions) and 
ipratropium 250 pg/m1 (proprietary nebuliser solution) were used to give 
maximum points on the calibration curves. 
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5.3.6 Sample preparation and calibration curve 
Three hundred microlitres of sample solution was added to 250 pl of internal 
standard solution and mixed using a vortex mixer (Super-Mixer, Lab-Line 
Instruments Inc., Melrose Park, IL, USA). Twenty microlitres of the mixture was 
injected for analysis and peak area to internal standard area ratios were calculated 
using the Varian GC Star workstation and a calibration curve for ipratropium, 
fenoterol, salbutamol and terbutaline constructed by computer using a linear least 
squares regression method (Cricket Graph® 1.3.2, Cricket Software, Malvern, PA, 
USA). 
	
5.3.7 	 Precision 
Intra-day variation was calculated by analysing five individualy prepared samples 
of 300 yl of stock solution mixed with 250 p1 of internal standard solution at 
evenly spaced intervals throughout the sampling day. The coeficient of variation 
was calculated for each drug from peak/ internal standard area ratios. 
Inter-day variation was calculated by analysing a daily prepared sample of 300 p1 of 
stock solution containing ipratropium 125 pg/ml, fenoterol 167 yg/ml, salbutamol 
833 pg/rn1 and terbutaline 1.67 mg/ml, mixed with 250 4u1 of internal standard 
solution each day over a five day period. The coefficient of variation was 
calculated for each drug from peak/ internal standard area ratios. 
5.3.8 	 Stability indicating nature of the assay 
Each of the four nebuliser solutions were degraded with four diferent conditions: 
heat, hydrogen peroxide, hydrochloric acid and sodium hydroxide. 
Heat degradation samples were prepared by adding 1 ml of each of the proprietary 
nebuliser solutions to separate glass ampoules, which were then sealed and heated 
at 200°C for 2 hours. After cooling, each heat degraded sample was diluted with an 
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appropriate volume of distilled water to give a theoretical maximum concentration 
equivalent to that in the stock solution (either ipratropium 125 yg/ml, fenoterol 
167 pg/ml, salbutamol 833 pg/m1 or terbutaline 1.67 mg/ml). 
Hydrogen peroxide degradation samples were prepared by adding 100 pl of 
hydrogen peroxide (35% w/w) to 200 pl of nebuliser solution in a glass vial and 
heating at 75°C for 20 minutes. After cooling, each nebuliser solution was diluted 
with an appropriate volume of distilled water to give a theoretical maximum 
concentration equivalent to that in the stock solution. 
Samples were degraded under acidic conditions by adding 100 pl of hydrochloric 
acid (2 M) to 200 pl of nebuliser solution in a glass vial and heating at 75°C for 20 
minutes. After cooling, each nebuliser solution was neutralised with 100 pl of 
sodium hydroxide (2 M). Fenoterol, salbutamol and terbutaline samples were 
further diluted with distilled water to give final theoretical maximum 
concentrations equivalent to that in the stock solution. 
Samples were degraded under basic conditions by adding 100 pl of sodium 
hydroxide (2 M) to 200 ,u1 of nebuliser solution in a glass vial and heating at 75°C 
for 20 minutes. After cooling, each nebuliser solution was neutralised with 100 pl 
of hydrochloric acid (2 M). Fenoterol, salbutamol and terbutaline samples were 
further diluted with distilled water to give final theoretical maximum 
concentrations equivalent to that in the stock solution. 
An aliquot of 300 pl was taken from each degraded nebuliser solution and added to 
250 /41 of internal standard. All degradation samples were chromatographed under 
identical conditions to the calibration curve samples. 
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5.3.9 	 Elution of preservatives 
Possible co-elution of drugs and preservatives contained in the proprietary 
nebuliser solutions was examined by comparing chromatograms of solutions of 
benzalkonium chloride 10.5 mg/ml, EDTA (ethylenediamine tetra-acetic acid) 
7.0 mg/ml and chlorbutol 6.6 mg/ml in distiled water with a chromatogram of a 
stock solution nebuliser solution containing ipratropium 125 pg/ml, fenoterol 
167 pg/ml, salbutamol 833 pg/m1 and terbutaline 1.67 mg/nil. The levels of 
preservatives were significantly higher than that typicaly encountered in 
proprietary nebuliser solutions. 
5.3.10 Chromatographic parameters 
Chromatographic parameters of capacity factor (k') and peak symmetry (A10) were 
measured for al compounds from the calibration curve stock solution containing 
ipratropium 125 pg/ml, fenoterol 167 pg/ml, salbutamol 833 pg/ml and 
terbutaline 1.67 mg/ml (Li Wan Po and Irwin, 1980). 
5.4 	 RESULTS AND DISCUSSION 
5.4.1 Chromatographic conditions 
The chromatogram of a stock solution sample containing ipratropium, fenoterol, 
salbutamol and terbutaline with mepivacaine as internal standard is shown in 
Figure 5.3. Retention times were as folows: salbutamol 3.2 minutes, terbutaline 
4.3 minutes, ipratropium 5.9 minutes, mepivacaine 8.2 minutes and fenoterol 12.7 
minutes. 
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Figure 5.3 	 Chromatogram of a stock solution sample containing ipratropium 125 sug/ml, fenoterol 
167 sug/m4 salbutamol 833 ,ug/ml and terbutaline 1.67 mg/ml with mepivacaine as 
internal standard (LS.). 
5.4.2 	 Calibration curve 
Calibration curves for ipratropium, fenoterol, salbutamol and terbutaline are 
shown in Figures 5.4, 5.5, 5.6 and 5.7 respectively. The calibration curve 
parameters are shown in Table 5.1. It can be seen that the standard curves were 
linear over the folowing ranges: ipratropium 20.8-250.0 jug/ml, fenoterol 27.8- 
500.0 ,ug/ml, salbutamol 34.7-2500.0 ig/m1 and terbutaline 69.5-2500 pg/ml. 
Ipratropium, fenoterol, salbutamol and terbutaline were al detectable at levels 
below the calibration range. 
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Figure 5.4 	 Calibration curve for ipratropium bromide. 
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Figure 5.5 	 Calibration curve for fenoterol. 
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Figure 5.6 	 Calibration curve for salbutamol. 
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Figure 5.7 	 Calibration curve for terbutaline. 
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Table 5.1 	 Calibration curve parameters of i pratropium, fenoterol, salbutamol and terbutaline. 
Linear Range 	 Regression Line Equation 
Correlation 
(y =Peak Area Ratio) 	 Coeficient 
(n) 	 (pg/ml) 	 (x = Concentration pg/ml) 	 ( r ) 
Ipratropium 6 20.8- 250.0 y = -0.000997 + 0.000192 x 1.00 
Fenoterol 6 27.8 - 500.0 y = 0.00251 + 0.000979 x 1.00 
Salbutamol 8 34.7 - 2500.0 y = 0.0168 + 0.000861 x 1.00 
Terbutaline 8 69.5 - 2500.0 y = 0.00392 + 0.000857 x 1.00 
	
5.4.3 	 Precision 
Intra-day variation was determined by calculating the coeficient of variation. The 
coeficient of variation for each drug was (al n=5): ipratropium 3.5%, fenoterol 
3.5%, salbutamol 3.9%, and terbutaline 3.9%. Inter-day variation was (al n=5): 
ipratropium 4.8%, fenoterol 5.1%, salbutamol 4.5% and terbutaline 5.2%. 
5.4.4 	 Stability indicating nature of the assay 
Peak areas of heat degraded samples of salbutamol and terbutaline were reduced to 
3% and 54% of the peak areas from the original stock solution respectively. A 
higher atenuation revealed that the original ipratropium peak at 5.9 minutes had 
been completely degraded under the heat degradation conditions with only a flat 
baseline remaining and a smal degradation peak at 5.0 minutes. Similarly, the 
original fenoterol was completely degraded under the heat degradation conditions. 
A minor degradation product of terbutaline with a retention time of 5.6 minutes 
shouldered the non-degraded ipratropium peak (retention time 5.9 minutes) but 
did not affect the accurate integration of this peak. None of the degradation 
products of ipratropium, fenoterol, salbutamol or excipients in their respective 
nebuliser solutions produced interference peaks with the stock solution containing 
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ipratropium 125 ,ug/rnl, fenoterol 167 ,ug/ml, salbutamol 833 4 ig/m1 and 
terbutaline 1.67 mg/ml. 
Peak areas of samples degraded by hydrogen peroxide were reduced to 36%, 71%, 
78% and 64% of the original ipratropium, fenoterol, salbutamol and terbutaline 
peak areas, respectively, with degradation product peaks in the solvent front and 
small peaks late in the chromatogram. Peak areas of samples degraded under acidic 
conditions were reduced to 88%, 79% and 69% of the original fenoterol, 
salbutamol and terbutaline peak areas, respectively, with small degradation 
product peaks late in the chromatogram. A lower attenuation revealed that the 
original ipratropium peak at 5.9 minutes had been completely degraded under 
acidic conditions with only a flat baseline remaining. 
Peak areas of samples degraded under basic conditions were reduced to 82%, 84% 
and 65% of the fenoterol, salbutarnol and terbutaline peak areas, respectively, with 
small degradation product peaks late in the chromatogram. A lower attenuation 
again revealed that the original ipratropium peak at 5.9 minutes had been 
completely degraded under basic conditions with only a flat baseline remaining. 
Chromatograms of degraded ipratropium, fenoterol, salbutamol and terbutaline 
samples under each of the degradation conditions are shown in Figures 5.8, 5.9, 
5.10 and 5.11 respectively. 
It was not feasible to establish mass balance for all of the drugs under all of the 
degradation conditions because of the many unknown decomposition products 
present in the samples. Furthermore, peak homogeneity could not be measured as 
the laboratory did not have a diode array detector. However, the assay was 
determined to be stability indicating for ipratropium, fenoterol, salbutamol and 
terbutaline under heat, hydrogen peroxide, acid and base degradation given the 
111 
Sal Ter 
V 
""'"'"•-•-up 
Chapter 5 
0.0 	 1!0 	 2.0 	 3.0 	 4!0 	 5.0 	 ?!0 	 8.0 	 9!0 	 10.0 	 11.0 	 125 	 13.0 
Retention Time (minutes) 
Figure 5.8 	 Comparison of chromatograms of non-degraded stock solution (1), and heat (2), 
hydrogen peroxide (3), acid (4) and base (5) degraded ipratropium nebuliser solution 
under identical atenuation and identical initial strength (125 pg/ml). See Section 
5.3.8. 
significant reduction in peak areas and the absence of interfering peaks from 
decomposition products. 
5.4.5 Elution of preservatives 
A chromatogram of possible interfering preservative excipients (benzalkonium 
chloride, EDTA and chlorbutol) is shown in Figure 5.12. It can clearly be seen that 
these preservatives, even at significantly higher levels than in proprietary nebuliser 
solutions, did not interfere with any of the chromatographic peaks of interest. 
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Figure 5.9 	 Comparison of chromatograms of non-degraded stock solution (1), and heat (2), 
hydrogen peroxide (3), acid (4) and base (5) degraded fenoterol nebuliser solution under 
identical atenuation and identical initial strength (167 pg/m1). See Section 5.3.8. 
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Figure 5.10 Comparison of chromatograms of non-degraded stock solution (1), and heat (2), 
hydrogen peroxide (3), acid (4) and base (5) degraded salbutamol nebuliser solution 
under identical atenuation and identical initial strength (833 pg/ml). See Section 
5.3.8. 
(1) 
114 
De
te
cto
r  
Re
sp
on
se 
 at
  2
20 
nm
  
(2) 
(3) 
(5) 
(4) 
Chapter 5 
Ter 
Sal 
Ipr 
. 
LS. 
 
Fen 
(1) 
       
00 	 1:10 	 2!0 	 3.10 	 4!0 	 50 	 6!0 	 ?!1:1 	 9.'0 	 leo 	 Lto 	 120 	 13.0 
Retention Time (minutes) 
Figure 5.11 Comparison of chromatograms of non-degraded stock solution (4 and heat (4 
hydrogen peroxide (3), acid (4) and base (5) degraded terbutaline nebuliser solution 
under identical atenuation and identical initial strength (L67 mg/ml). See Section 
5.3.8. 
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Figure 5.12 Comparison of chromatograms from a stock solution containing ipratropium 
125 pg/m4 fenotero1167 pg/ml, salbutamol 833 pg/ml and terbutaline 
1.67 mg/ml (I) with samples of distiled water blank (2), benzalkonium chloride 
10.5 mg/ml (3), EDTA ZO mg/ml (4) and chlorbutol 6.6 mg/ml (5). 
See Section 5.3.9. 
5.4.6 Chromatographic parameters 
The chromatographic parameters are shown in Table 5.2. There was significant 
peak asymmetry for mepivacaine. Peak symmetry of less than 1.5 is prefered for 
quantitative analysis; however, it is generaly accepted that severe peak tailing of 
basic drugs in reversed-phase chromatography is caused by interaction of solutes 
with free silanol groups in the packing (Vervoot et al, 1992). Vervoot et al (1992) 
also found that the addition of an ion pair reagent (sodium 1-hexanesulphonate) 
did not decrease peak tailing with some protonated basic drugs, as may be the case 
with mepiyacaine and the ion-pair reagent in this assay. The tailing of the 
mepivacaine peak was reduced considerably by using a relatively high proportion 
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of tetrahydrofuran in mobile phase A. The asymmetry of this peak did not afect 
assay performance. 
Table 5.2 	 Typical column parameters cakulated from a chromatogram of a stock solution 
containing zpratropium 125 pg/ml, fenoterol 167 ,ug/ml, salbutamol 833 pg/m1 and 
terbutaline 1.67 mg/ml with mepivacaine as internal standard. 
Retention time 	 Capacity Factor 	Peak Symmetry 
t (min) 	 k' 	 (A10) 
Salbutamol 3.2 1.6 1.13 
Terbutaline 4.3 2.5 1.75 
Ipratropium 5.9 3.8 2.11 
Mepivacaine 8.2 5.6 2.65 
Fenoterol 12.7 9.2 1.55 
5.5 	 CONCLUSION 
The assay provides a method of determining concentrations of drugs in common 
nebuliser solution admixtures. The assay is also stability indicating and provides a 
basis for assays to determine the stability of common nebuliser admixtures 
containing ipratropium and [32-agonists. 
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Stability of Ipratropium Bromide and Salbutamol 
Nebuliser Admixtures 
6.1 SUMMARY 
This study aimed to determine the physicochemical stability of an admixture of ipratropium bromide and 
salbutamol nebuliser solution (ipratropium bromide: salbutamol, 1:1 v/v). Solutions were stored for 5 days 
in a refrigerator at 40  C, at 22 ° C protected from light and at 22 ° C under 24 hour fluorescent lighting. 
Concentrations of ipratropium and salbutamol were periodically determined using a modification of the 
HPLC assay developed in Chapter 5. It was found that the nebuliser solution admixtures retained greater 
than 90% of their original concentrations of ipratropium and salbutamol for the duration of the study. 
Differences in losses between storage conditions were not statistically significant. An expiry period of 5 days 
for these admixtures would seem reasonable in practice. 
6.2 INTRODUCTION 
For patients unable to use metered dose inhalers, inhalation of nebulised respirator 
solutions is an integral component of the modern treatment of airways diseases 
(Anonymous 1987; Horsley, 1988; Johnson, 1989; Anonymous, 1993b). Drugs 
available as respirator solutions for the treatment of acute or chronic obstructive 
airways diseases in Australia include ipratropium bromide, fenoterol, salbutamol 
and terbutaline. 
The mixing of ipratropium and 132-agonist nebuliser solutions is a common practice 
(Iacono et al, 1987; O'Driscoll et al, 1987; Caldwell et al, 1991). The bulk mixing of 
ipratropium and 132-agonist nebuliser solution provides a means of shortening the 
time that patients spend nebulising inhaled drugs, as well as producing savings in 
costs and nursing time when compared to unit-of-use pre-diluted sterile nebules 
(Fry and Williamson, 1991). It has also been suggested that the convenience and 
reduced administration time resulting from mixing nebuliser solutions may increase 
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patient compliance (Roberts and Rossi, 1993). The post-manufacture mixing of 
these nebuliser solutions, however, gives rise to issues of compatibility and 
stability. 
Compatibility of ipratropium and salbutamol immediately prior to administration 
has been studied. Iacono et al (1987) showed that ipratropium in nebuliser solution 
retained greater than 90% of its initial concentration up to 1 hour after mixing with 
salbutamol and sodium cromoglycate solutions. However, long term compatibility 
and stability of admixtures of these solutions is not wel documented. 
Commencement of this study folowed enquiries from pharmacists involved with a 
district nursing service regarding the stability of ipratropium:salbutamol 
admixtures. The nurses provide drugs including nebuliser admixtures to out-
patients on a regular basis, typicaly several visits per week. Because of the common 
practice of mixing bulk solutions of drug, the objective of this study was to answer 
the clinicaly relevant question: do pre-mixed nebuliser admixtures of ipratropium 
and salbutamol retain greater than 90% of their initial concentrations if stored over 
a typical working week of 5 days? 
6.3 METHOD 
6.3.1 	 Materials 
Salbutamol sulphate (pure substance) was kindly donated by Glaxo Australia Pty. 
Ltd. (Boronia, Vic.) and ipratropium bromide (pure substance) was kindly donated 
by Boehringer Ingelheim Pty. Ltd. (Ingelheim, Germany). The folowing nebuliser 
solutions were used in the assay procedure: ipratropium bromide (Atrovent® 
0.025% w/v; Boehringer Ingelheim Pty. Ltd., Artarmon, NSW, Austalia), fenoterol 
hydrobromide (Berotec® 0.1% w/v; Boehringer Ingelheim Pty. Ltd., Artarmon, 
NSW, Austalia) and salbutamol sulphate (Vent°lin® 0.5% w/v; Glaxo Australia 
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Pty. Ltd., Boronia, Vic., Australia). Methanol and tetrahydrofuran (liquid 
chromatography grade) were purchased from Waters Chromatography Division 
(Millipore Australia Pty. Ltd., Sydney). Pic® B-8 Reagent Low UV (containing 
water, methanol, octane sulfonic acid and calcium acetate in undisclosed quantities) 
was purchased from Waters Associates (Milford, MA, USA). 
6.3.2 Assay procedure 
The high performance liquid chromatography (HPLC) system consisted of a 
Varian Solvent Delivery System Model 9010 (Varian Chromatography Systems, 
Walnut Creek, CA, USA) with a Rheodyne injector Model 7161 (Rheodyne Inc., 
Cotati, CA, USA) with a 10 external loop connected to a Varian Variable 
Wavelength UV-VIS Detector Model 9050 (Varian Chromatography Systems, 
Walnut Creek, CA, USA). Chromatographic peaks were digitised, integrated and 
recorded with a Varian GC Star Workstation (Varian Chromatography Systems, 
Walnut Creek, CA, USA). The analysis was performed using a Nova-Pak® C18 
4 jim 10 cm x 8 mm i.d. Radial-pak® liquid chromatography cartridge (Waters 
Associates, Milford, MA, USA) inside a Waters RCM 8 x 10 compression module 
(Waters Associates, Milford, MA, USA). 
Solute elution was satisfactorily performed using isocratic analysis. This assay was 
adapted from an assay for combinations of ipratropium and 3 2-agonist nebuliser 
solutions using reversed phase ion-pair chromatography with ternary gradient 
analysis (Chapter 5). Flow was 1.0 ml/min of a mobile phase containing 30% 
tetrahydrofuran, 1.9 mM octane sulfonic acid (from a dilution of Low UV Pic® B-8 
ion-pair reagent) and 5% methanol in distilled water. Run time was 10 minutes. 
Detector conditions were as follows: wavelength 272 nm at 0.5 AUFS until 4.1 
minutes changing to 220 nrn at 0.05 AUFS until 10 minutes. Retention times for 
salbutamol, ipratropium and the internal standard fenoterol were 3.5, 4.4 and 7.6 
minutes respectively. 
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An internal standard solution of fenoterol 100 [tg/m1 in distilled water was 
prepared from the proprietary fenoterol nebuliser solution (1 mg/ml). Calibration 
curves were constructed daily from freshly prepared admixtures of ipratropium 
bromide nebuliser solution 250 p,g/m1 and salbutamol sulphate nebuliser solution 
5.0 mg/ml over the following range: ipratropium 31-156 tig/m1 and salbutamol 
0.625-3.13 mg/mi. The concentration of the proprietary admixtures was verified 
both at the beginning and the end of the study using a calibration curve 
constructed from pure ipratropium bromide and salbutamol sulphate powder. The 
same fenoterol internal standard solution and ipratropium and salbutamol 
proprietary nebuliser solutions were used throughout the course of the study and 
were stored at 4°C and protected from light. 
Fifty microlitres of each sample was added to 25 pl of internal standard solution 
and mixed using a vortex mixer (Super-Mixer®, Lab-Line Instruments Inc., Melrose 
Park, IL, USA). Twenty microlitres of each sample was injected for analysis in 
duplicate and the results averaged. Peak area to internal standard area ratios were 
calculated using the Varian GC Star workstation and calibration curves for 
ipratropium and salbutamol constructed by computer using a linear least squares 
regression method (Cricket Graph® 1.3.2, Cricket Software, Malvern, PA, USA). 
Intra-day variation was calculated for each day of sampling by analysing five 
samples of ipratropium:salbutamol nebuliser solution (1:1 v/v; containing 
ipratropium bromide 125 ig/m1 and salbutamol 2.5 mg/ml) with internal standard 
at evenly spaced intervals throughout the sampling day. The coefficient of variation 
was calculated for each drug from peak area/internal standard area ratios. 
The stability indicating nature of the assay was validated by heat, acid and base 
hydrolysis, and oxidation. Heat degradation samples were prepared by placing 
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100 IA of salbutamol proprietary nebuliser solution, 100 pl of ipratropium bromide 
proprietary nebuliser solution or 100 pi of ipratropium:salbutamol nebuliser 
solution (1:1 v/v) into separate sealed glass ampoules. Ipratropium and salbutamol 
degradation samples were heated at 200°C for 1, 2 or 3 hours in a gas 
chromatograph oven. The combined ipratropium:salbutamol nebuliser solution 
(1:1 v/v) was heated for 2 hours at 200°C. 
Acid degradation samples were prepared by adding 50 1..t1 of 1 M HC1 to 100 pi of 
ipratropium:salbutamol nebuliser solution (1:1 v/v) in a glass vial. Samples were 
heated at 75°C for 20 minutes or 1 hour then neutralised by adding 50 1,A,1 of 1 M 
NaOH. Base degradation samples were prepared by adding 50 pi of 1 M NaOH to 
100 iAl of ipratropium: salbutamol nebuliser solution (1:1 v/v) in a glass vial. 
Samples were heated at 75°C for 20 minutes or 1 hour then neutralised by adding 
50 pl of 1 M HC1. Oxidation degradation samples were prepared by adding 50 IA of 
35% w/w hydrogen peroxide to 100 IA of ipratropium:salbutamol nebuliser 
solution (1:1 v/v) in a glass vial. Samples were heated at 75°C for 20 minutes or 1 
hour then diluted with a further 50 121 of distilled water. 
All degradation samples were allowed to cool. A 50 pi aliquot of each sample was 
added to 25 p.1 of internal standard solution and chromatographed under identical 
conditions to the calibration curve samples. Peak area ratios from chromatograms 
of degraded samples were compared with peak areas from freshly prepared 
standards that had been diluted to the same extent as the degraded samples. 
Chromatograms were also examined for any decomposition product peaks 
interfering with the ipratropium, salbutamol or internal standard peaks. 
Known excipients in the proprietary nebuliser solutions, benzalkonium chloride 
and ethylenediamine tetra-acetic acid (EDTA), were tested for possible co-elution 
with the peaks of interest. Solutions of benzalkonium chloride 10.7 mg/ml in 
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distiled water and EDTA 7.0 mg/ml in distiled water were chromatographed 
under identical conditions to the calibration curve samples. 
6.3.3 	 Stability study 
A 20 ml admixture of ipratropium bromide and salbutamol sulphate nebuliser 
solutions (1:1 v/v; containing ipratropium bromide 125 pg/ml and salbutamol 
2.5 mg/ml) was mixed thoroughly. Aliquots of 2 ml were taken and placed into 
nine pre-weighed 6 ml clear glass vials (Miniature Vial®, Canberra-Packard Pty. 
Ltd., Mount Waverley, Vic., Australia) and then re-weighed. Three vials were then 
stored under each of the folowing conditions: (i) refrigerated at 4 ± 0.5°C; (i) 
shalow immersion in an orbital shaking water bath (Model OW 1412, Paton 
Industries Pty. Ltd., Stepney, South Australia) at 22 ± 0.25°C protected from light 
by aluminium foil; and (ii) shalow immersion in an orbital shaking water bath at 
22 ± 0.25°C subject to continuous fluorescent lighting for the duration of the 
study. Lighting was provided by an 18 W fluorescent light suspended 
approximately 20 cm above the solutions. Samples exposed to light were tilted at 
approximately 45° so that the nebuliser solution admixtures were in the direct path 
of light and not protected by the opaque vial caps. The solutions stored at 22°C in 
the water bath were gently shaken at 20 oscilations per minute. 
Nebuliser solutions were sampled initialy, and on days 1, 2 and 5. Samples were 
analysed in the same manner as the calibration curve samples. The concentrations 
of drugs remaining in the nebuliser solutions were calculated from the daily 
calibration curves. 
Potential loss of solvent through evaporation was checked by pre-weighing the 
storage vials, re-weighing the vials after addition of the 2 ml combined nebuliser 
solution, and weighing again at the completion of the study. The initial weight of 
solution in the sample vials, after correcting for the removal of a succession of 
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100 1AL aliquots, was compared with the final weight of solution in the sample vials 
after the completion of the study. 
6.3.4 Statistical methods 
Diferences in the losses of ipratropium and salbutamol between the solutions and 
sampling periods were statisticaly evaluated using repeated measures analysis of 
variance (Statview® 4.01 package, Abacus Concepts Inc., Berkeley, CA, USA, on a 
Macintosh® computer). 
6.4 	 RESULTS 
6.4.1 Assay procedure 
The range of intra-day coefficients of variation over the sampling days for 
salbutamol was found to be 2.5 - 4.2% (al n = 5). The range of intra-day 
coeficients of variation for ipratropium was found to be 2.6 - 4.9% (al n = 5). Al 
standard curves throughout the study had corelation coeficients (r) greater than 
0.996 on al days of sampling. A chromatogram of an ipratropium:salbutamol (1:1 
v/v) admixture is shown in Figure 6.1. Calibration curves are shown in Figures 6.2 
and 6.3. 
The heat decomposed salbutamol nebuliser solution was originaly clear which 
discoloured to a brown solution with precipitate after heating. The ipratropium 
solution remained clear without any precipitate. The assay was found to be 
stability indicating as degradation product peaks did not interfere with either the 
salbutamol, ipratropium or internal standard peaks (shown in Figure 6.4). 
The heat decomposed salbutamol retained approximately 16% of the original peak 
area after 1 hour which decreased to approximately 4% and 1% at 2 and 3 hours 
respectively. The heat decomposed ipratropium was degraded below the detection 
124 
Chapter 6 
limit after 1 hour with only a flat baseline remaining. No co-eluting peaks from 
decomposition products emerged at the retention time of the original ipratropium 
peak after 2 and 3 hours. This suggested that the peaks of interest in the 
chromatogram were free of any interference from primary or secondary 
decomposition products. 
The combined heat decomposition sample of ipratropium:salbutamol (1:1 v/v) 
admixture had similar decomposition chromatograms after 2 hours when compared 
to the individually heat stressed ipratropium and salbutamol nebuliser solutions 
suggesting no obvious decomposition interaction between the two components. 
Acid degradation of an ipratropium:salbutamol (1:1 v/v) admixture reduced 
salbutamol peak areas to approximately 49% and 45% of original peak areas after 20 
minutes and 1 hour respectively. The ipratropium peaks were degraded below the 
detection limit after 20 minutes with no peaks from primary or secondary 
decomposition products emerging at the retention time of ipratropium after 1 
hour. 
• Base degradation of an ipratropium:salbutamol (1:1 v/v) admixture reduced 
salbutamol peak areas to approximately 53% and 38% of original peak areas after 20 
minutes and 1 hour respectively. The ipratropium peaks were degraded below the 
detection limit after 20 minutes with no peaks from primary or secondary 
decomposition products emerging at the retention time of ipratropium after 1 
hour. 
Oxidation degradation of an ipratropium: salbutamol (1:1 v/v) admixture reduced 
salbutamol peak areas to approximately 92% and 87% of original peak areas after 20 
minutes and 1 hour respectively. The ipratropium peak areas were reduced to 
approximately 96% and 95% of original peak areas after 20 minutes and 1 hour 
125 
D
et
ec
to
r  
R
es
p
on
se
  
Chapter 6 
Retention Time (minutes) 
Figure 6.1 Chromatogram of an i pratropium : salbutamol (1:1 v/v) admixture. Inset shows 
pratropium and salbutamol peak separation with a 16-fold decrease in attenuation 
respectively. Salbutamol produced four significant decomposition products at 
retention times of 4.2, 4.9, 5.7 and 9.4 minutes after heat stressing at 200°C. The 
largest (at 5.7 minutes) had a peak height approximately 10% of the parent drug and 
twice as large as the peak due to ipratropium. The peaks at 4.2 and 4.9 minutes 
were of comparable height to the ipratropium peak. 
Ipratropium produced four significant decomposition products at retention times 
of 4.2, 4.9, 5.9 and 9.3 minutes after heat stressing at 200°C. The peak at 5.9 
minutes was comparable in size to that of the parent drug. The peaks at 4.2 and 4.9 
minutes were approximately 30% and 15% of the height of the parent drug. All 
decomposition product peaks had baseline separation from the peaks of interest 
and did not affect integration. These decomposition peaks were not seen during the 
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Figure 6.2 Calibration curve of ipratropium. 
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Figure 6.3 Calibration curve of salbutamoL 
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Figure 6.4 Chromatograms showing degradation of ipratropium (I) and salbutamol (2) at 200°C 
compared to a non-degraded ipratropium:salbutamol (1:1 v/v) admixture (3). 
course of the study and were only observed under heat stressing, acid and base 
hydrolysis and oxidation. 
Benzalkonium chloride and EDTA did not produce any significant peaks under the 
chromatographic conditions and hence, did not interfere with the chromatography 
of any of the peaks of interest. 
6.4.2 	 Stability study 
Degradation was expressed as the percentage of the measured initial drug 
concentration in the combined nebuliser solution immediately after mixing. The 
percentages of initial concentration of each drug remaining with time are shown in 
Table 6.1. Degradation profiles are shown in Figures 6.5, 6.6 and 6.7 for 
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ipratropium: salbutamol 1:1 v/v admixtures stored at 4°C (dark), 22°C (dark) and 
22°C (light) respectively. Al admixtures clearly retained at least 90% of their initial 
concentrations for the duration of the study. The nebuliser solution admixtures 
remained clear with no discolouration, cloudiness or precipitation throughout the 
course of the study. Evaporation loss was minimal with al solutions retaining at 
least 97.5% of their expected weight. 
Repeated measures analysis of variance for salbutamol revealed no statisticaly 
significant diference in loss between the storage conditions (F=0.29, 2 and 6 df, 
p > 0.50). There was a significant diference in the concentration of salbutamol with 
the storage periods (F=6.10, 3 and 18 df, p < 0.01), atributable to the initial slight 
fal between days zero and one. Similarly, repeated measures analysis of variance 
for ipratropium revealed no statisticaly significant diference in loss between the 
storage conditions (F=0.69, 2 and 6 df, p > 0.20), but a significant diference in the 
concentration of ipratropium with the storage periods (F=4.84, 3 and 18 df, 
p < 0.05). 
Table 6.1 	 Degradation of i pratropium and salbutamol (1:1 v/v) nebuliser solution admixtures 
over a five day period 
Storage at 4°C (Dark) 	 Storage at 22°C (Dark) 	 Storage at 22°C (Light) 
Salbutamol 	 Ipratropium 	 Salbutamol 	 Ipratropium 	 Salbutamol 	 Ipratropium 
Mean ± SD (% of initial concentration) Mean ± SD (% of initial concentration) Mean ± SD (% of initial concentration) 
Initial 2.43 ±0.09 (100.0) 129.2 ±5.4 (100.0) 2.43 ±0.09 (100.0) 129.2 ±5.4 (100.0) 2.43 ±0.09 (100.0) 129.2 ±5.4 (100.0) 
Day 1 2.34 ±0.05 (96.3) 127.6 ±2.4 (98.8) 2.34 ±0.07 (96.3) 127.9 ±5.0 (99.0) 2.37 ±0.05 (97.5) 129.7 ±2.4 (100.4) 
Day 2 2.35 ±0.03 (96.7) 126.0 ±2.1 (97.5) 2.41 ±0.06 (99.2) 127.8 ±3.1 (98.9) 2.39 ±0.02 (98.4) 127.6 ±1.3 (98.8) 
Day 5 2.43 ±0.08 (100.0) 126.2 ±5.5 (97.7) 2.35 ±0.06 (96.7) 123.1 43 (95.3) 2.41 ±0.12 (99.2) 127.6 ±5.7 (98.8) 
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Storage at 4°C (Dark) 
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Figure 6.5 Degradation profile of ipratropium:salbutamol (1:1 v/v) nebuliser admixture at 4°C and 
protected from light. 
Storage at 22°C (Dark) 
Days 
Figure 6.6 Degradation profile of ipratropium:salbutamol (1:1 v/v) nebuliser admixture at 22°C 
and protected from light 
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Storage at 22°C (Light) 
Figure 6.7 Degradation profile of ipratropium:salbutamol (1:1 v/v) nebuliser admixture at 22 ° C 
and exposed to light 
6.5 	 DISCUSSION 
The results indicate that admixtures of proprietary ipratropium and salbutamol 
(1:1 v/v) nebuliser solutions retain greater than 90% of their initial concentrations 
when stored for periods of up to 5 days. Ipratropium was found to be slightly less 
stable than salbutamol. There were no statisticaly significant diferences in stability 
between the storage conditions for either salbutamol or ipratropium. 
It was not the purpose of this study to determine a precise expiry period but 
merely to examine the stability over a typical working week of 5 days. These 
findings suggest that it would seem reasonable in practice to recommend that 
admixtures of ipratropium bromide (Atrovente) and salbutamol sulphate 
(Ventoline) nebuliser solutions (1:1 v/v) can be stored between 4°C and 22°C for 
periods up to 5 days. This would alow bulk admixtures to be prepared and stored, 
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resulting in reduced preparation time and drug costs when compared to unit-of-use 
pre-diluted nebules (Fry and Williamson, 1991). 
This study was based purely on physicochemical stability and did not take into 
account microbial contamination or clinical efficacy. Benzalkonium chloride is 
contained in Atrovent® (0.025%) and Ventolin® (0.01%) nebuliser solutions 
(Roberts and Rossi, 1993). Ipratropium nebuliser solution also contains EDTA 
(Roberts and Rossi, 1993). After these nebuliser solutions are combined to give a 
1:1 v/v admixture the overall concentration of benzalkonium chloride is 0.0175% 
(less than that present in proprietary ipratropium solution). Roberts and Rossi 
(1993) noted that the manufacturer was considering lowering the concentration of 
benzalkonium chloride in Atrovento so the importance of this dilution of 
preservative concentration in the ipratropium and salbutamol (1:1 v/v) nebuliser 
solution admixtures is unclear. Reliance on benzalkonium chloride as a 
preservative in nebuliser solutions has led to the nosocomial spread of 
microorganisms (Hamill et al, 1995). It is also worth noting that this storage period 
of 5 days would not apply to unit-of-use preservative free nebules. It is therefore 
important that patients are counselled and understand this difference, as well as 
being counselled about the appropriate storage and hygiene measures when using 
nebulised drugs (Anonymous, 1993b; Mathew, 1990). 
6.6 CONCLUSION 
Admixures of proprietary ipratropium bromide and salbutamol nebuliser solutions 
(1:1 v/v) retain greater than 90% of their initial concentrations if stored between 
4°C and 22°C for periods of up to five days. An expiry period of 5 days would 
seem reasonable in practice. 
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Background on Salbutamol Pharmacokinetics 
7.1 SUMMARY 
The pharmacokinetics of salbutamol are outlined in the folowing sections. The majority of an inhaled 
dose is swalo-wed, is absorbed from the gastrointestinal tract and is subject to extensive first-pass 
metabolism in the intestinal wal and liver. Only a relatively smal fraction of the dose that is inhaled 
exerts a local bronchodilatory efect in the lungs folowing systemic absorption. The only known 
metabolite of salbutczmol in humans is the sulphate ester metabolite, salbutamol4'-0-sulphate which is 
substantialy less pharmacologicaly active than the parent drug Salbutamol4'-0-sulphate is freely filtered 
from the kidneys. Active tubular secretion is thought to play a major role in the renal excretion of 
salbutamol. The ratio of unchanged drug to metabolite in urine varies with the amount of dose subject to 
the first-pass efect according to the route of administration. 
7.2 	 ABSORPTION 
Despite their efectiveness and widespread use over more than two decades, there is 
surprisingly litle information available on the pharmacokinetics of 132-agonists 
(Morgan, 1990). In the past, this has mainly been due to dificulty in measuring 
low serum or plasma concentrations, particularly with regard to inhalation 
therapy. This is because the inhalation route of administration delivers the drug 
directly to the site of action requiring smaler doses; in addition, the volumes of 
distribution of the 132-agonists are large (Chrysten, 1994). The combination of these 
two factors means plasma levels folowing inhalation in therapeutic doses are 
relatively low. 
In clinical practice, salbutamol is administered by inhalation, oraly and by 
intramuscular and intravenous injection (Morgan, 1990). Of these routes of 
administration, it is the inhalation route that is most efective (Alpers, 1991), by 
either MDI, DPI (such as the Ventolin Rotahaler8) or nebulisation 
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(Taburet and Schmit, 1994). Many factors may effect the bioavailability from 
inhalation and are discussed later. 
The bioavailability of salbutamol depends on the route of administration. With 
oral administration, the systemic availability of salbutamol has been found to be a 
relatively low 50% (Morgan et al, 1986). Because of the low systemic availability, 
the oral doses of P-agonists are generally 5 to 10 times greater than the parenteral 
doses (Morgan, 1990). Salbutamol is usually administered as a racemic mixture, 
however, there is evidence to suggest that the systemic availability of oral 
(+)-salbutamol is greater than that of (-)-salbutamol (Tan and Soldin, 1987; Walle et 
al, 1993a; Walle et al, 1993b). 
The size of aerosolised particles is critical in the bioavailability from inhalation. 
Aerosol particles may be solids or liquids, and tend to settle (sediment), adhere to 
each other (coagulate) and adhere to structures (deposit) such as tubing and mucosa 
and are generally heterodispersed with particles covering a range of sizes (Taburet 
and Schmit, 1994). Aerosol particles larger than 10 pm in diameter are mostly 
deposited in the oropharynx and swallowed while particles smaller than 0.5 1AM are 
likely to reach the alveoli or be exhaled (Stahlhofen et al, 1980; Taburet and 
Schmit, 1994). Particles with a diameter of between 1 and 5 p.m are most likely to 
be deposited in the lower respiratory tract and therefore be effective in the 
treatment of asthma (Newman, 1985). 
Surprisingly, the amount of drug reaching the lungs from inhalation is small and 
variable but typically less than 15% of the inhaled dose (Clay and Clarke, 1987). 
The majority of the inhaled dose is deposited on the pharynx upon inhalation and 
then swallowed (Morgan, 1990). Studies using y-scintigraphy have shown 
pulmonary delivery at around 10% from a pressurised MDI and around 20% from 
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a Turbuhaler® (Borgstrom and Nilsson, 1990; Borgstrom et al, 1992) although 
there is some confusion about these measurements (Melchor et al, 1990). A 
summary of lung deposition between different inhalation devices is shown in 
Table 7.1. Factors such as definition of lung deposition (total lung versus lower 
lung), mucociliary clearance, oral absorption and reliability of inhalation 
techniques al influence these estimates, which should be treated with caution. 
Despite these variations in quoted pulmonary deposition, the point to be made is 
that the majority of an inhaled dose never reaches the lungs. 
Table 7.1 	 Characteristics of inhalation delivery systems including pulmonary deposition. 
These figures should only be seen as a guide. 
Delivery System 	 Pulmonary Deposition 	 Reference 
(c/0 dose) 
MDI 	 9-15 	 Thorsson et al, 1993. 
Borgstrom and Nilsson, 1990. 
MDI + spacer 	 14-20 	 Vidgren et al, 1987. 
DPI 	 10-30 	 Thorsson et al, 1993. 
Borgstrom et al, 1992. 
Hindle et al, 1995. 
Nebuliser 	 2-19* 	 Hardy et al, 1993. 
* percent of dose initialy loaded into in the nebuliser. 
Smal diferences in inhalation techniques (between patients and inhalation devices) 
have also been shown to greatly alter the degree of deposition and the dose 
delivered (Newman et al, 1982; Vidgren et al, 1987, Taburet and Schmit, 1994). 
Variation in the degree of lung deposition can also be responsible for diferences in 
therapeutic response of the drug between patients with inappropriate MDI 
inhalation techniques responsible for many failed clinical outcomes (Taburet and 
Schmit, 1994). 
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The pharmacolcinetics of inhaled salbutamol can essentially be described by a 
combination of two separate mechanisms. Inhaled salbutamol consists of drug that 
reaches the lungs (approximately 10%) and drug that is swallowed (approximately 
90%). The swallowed fraction of dose is absorbed and metabolised in the same way 
as an oral formulation (high first-pass effect with a greater percentage of drug 
recovered in urine as metabolite) while the dose that reaches the lungs is absorbed 
into the blood stream and metabolised in the same way as an intravenous dose 
with a lower percentage of recovered drug excreted as metabolite (Jer= and 
Ahrens, 1987). 
A high ratio of metabolite to unchanged drug is seen in urine following inhalation 
and is similar to that after oral administration, consistent with a significant first-
pass effect from oral absorption of the majority of the dose (Morgan, 1990). This 
ratio is much lower following direct bronchial instillation of drug and resembles 
the ratio following IV administration, indicating avoidance of the first-pass effect 
(Laros et al, 1977). 
In the past bronchodilation by wet nebulisation has been considered the treatment 
of choice for in-hospital asthma therapy (Choo-Kang and Grant, 1975). The 
metabolite/unchanged drug ratio concentration in plasma and urine following 
nebuliser is less than that with MDI and oral administration indicating a larger 
proportion of the dose is absorbed via the lungs (Morgan, 1990). However, recent 
studies have found that administration of salbutamol from an MDI with a spacer 
(or holding chamber) can provide similar bronchodilation to that achieved by 
traditional wet nebulisation (Colacone et al, 1993; Gibson et al, 1995; Idris et al, 
1993). 
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In summary, the pulmonary bioavailability of salbutamol with inhalation therapy 
is low (around 10%) and highly variable with extensive first-pass metabolism of the 
swalowed dose. 
7.3 	 DISTRIBUTION 
Folowing bolus IV administration, the plasma concentration-time curve of most 
of the 13-agonists including salbutamol is characterised by 2 or 3 exponential 
phases, indicative of substantial tissue distribution (Goldstein et al, 1987). In 
keeping with this, salbutamol has a relatively large volume of distribution of 
around 156 litres (Morgan et al, 1986) and a low plasma protein binding of around 
7-8% (Morgan et al, 1986). 
The concentration of salbutamol found in plasma varies according to the means of 
administration. Peak plasma levels of 10-17 ng/ml were found 1-4 hours after a 
dose of salbutamol in subjects taking 4 mg of oral salbutamol three times a day 
(Morgan et al, 1986). The reported 'therapeutic range' of salbutamol is 10-20 ng/ml 
(Glaxo Ltd.; cited by Lewis et al, 1990). 
Plasma levels after inhalation are usualy much lower. A study by Lewis et al 
(1990) measured salbutamol plasma levels in patients presenting to hospital with 
acute asthma. It was found that patients who had been taking only inhaled therapy 
prior to admission had low plasma levels of salbutamol at less than 3 ng/ml (the 
lowest detectable limit) except for one patient who had taken 5 mg via nebuliser 2 
hours prior to admission and had a level of around 5 ng/ml. In comparison, 
patients who had been taking oral therapy had higher levels between 6 and 
34 ng/ml. 
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The pharmacological efect of 32-agonists corelates 'reasonably wel with plasma 
concentration of drug, however, there is large intersubject variation in the 
relationship between plasma concentration and response (Morgan, 1990; Taburet 
and Schmit, 1994). Therapeutic response and onset of adverse efects are the main 
determinants in dosage optimisation (Morgan, 1990). Plasma concentrations of (32- 
agonists are not regarded as a useful parameter for dosage adjustment (Morgan, 
1990). 
7.4 	 METABOLISM 
Salbutamol undergoes phenolic conjugation with sulphate by phenol 
sulphotransferase (PST) to the sulphate ester metabolite, salbutamol 4'-0-sulphate, 
identified by Lin et al (1977; Figure 7.1). Extensive literature searches have shown 
that the sulphate ester metabolite of salbutamol is the only metabolite that has 
been detected in humans. Even with relatively large IV and oral doses, no 
glucuronide conjugates were found in urine or plasma by Morgan et al (1986). The 
sulphate ester metabolite does not appear to possess significant pharmacological 
activity (Evans et al, 1973). 
CH3  
CH-CH- NH—F--CH 2 	 3 
OH 	 CH3  
Salbutamol 4-0-Sulphate 
Figure 7.1 	 Salbutamol 4'-0-sulphate, the only identified metabolite of salbutamol in man. 
Oraly administered salbutamol undergoes extensive first-pass metabolism, 
atributed entirely to sulphate conjugation (Morgan et al, 1986). There is evidence 
to suggest that most of the first-pass metabolism may take place in the wal of the 
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smal intestine (llet et al, 1980; Koster et al, 1985) but this has not been 
demonstrated unequivocaly (Morgan, 1990). PST is widespread in the body and 
platelet, hepatic and placental PST have also been shown to metabolise 13-agonists 
(Sodha and Schneider, 1984; Wale et al, 1993b). 
As mentioned earlier, salbutamol is administered clinicaly as a racemic mixture. 
As for most of the 13-agonists, the (-)-isomer is mainly responsible for the 
pharmacological activity of a racemic mixture of salbutamol (Britain et al, 1973; 
Waldeck and Widmark, 1985). Differences in the pharmacokinetics of the 
salbutamol isomers have also been described (Tan and Soldin, 1987). 
It has been suggested (Tan and Soldin, 1987; Wale et al, 1993a) that the systemic 
availability of oral (+)-salbutamol is greater than that of (-)-salbutamol due to 
preferential first-pass metabolism. This was confirmed by Wale et at (1993b) who 
found that sulphation efficiency of the pharmacologicaly more active (-)- 
salbutamol was approximately 10 times greater than (+)-salbutamol with hepatic, 
jejunal mucosa and platelet derived PST. PST enzymes, present in humans as the 
M form (monoamine substrates) and the P form (simple phenol substrates) were 
also examined in the same study. It was found that only the M form demonstrated 
sulphation of the salbutamol substrate ('Wale et al, 1993b). 
7.5 	 EXCRETION 
Salbutamol is both excreted from the kidneys unchanged and as the metabolite 
with elimination dependent on the route of administration. After intravenous 
administration most of the drug is excreted as unchanged drug whereas after oral 
administration, a greater proportion of the drug is excreted as the metabolite 
(Morgan et al, 1986), reflecting the first-pass efect. 
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132-Agonists are polar and basic and have a high renal clearance unaffected by pH 
(Chrysten, 1994). The protein binding corrected renal clearance of salbutamol is 
greater than the glomerular filtration rate suggesting active tubular secretion 
(Morgan, 1990). The sulphate ester does not appear to be actively secreted (Morgan 
et al, 1986). In addition, the active tubular secretion of salbutamol may be 
stereoselective as is the case with terbutaline (Borgstrom et al, 1989). 
Typically, urine levels of drugs excreted by the kidneys tend to be higher than 
plasma levels as the collection of urine in the body effectively acts as a reservoir for 
excreted drug. Urine levels of salbutamol have been reported at around 100 ng/ml 
following a 200 lig dose (Horn et al, 1989) and between 160-580 ng/ml after a 
400 1..tg dose of inhaled salbutamol from MDI (Hindle et al, 1993). Urinary 
salbutamol excretion has been used as a measure of relative bioavailability to the 
lung (Hindle et al, 1993). 
There is little biliary excretion of 132-agonists in humans (Nilsson et al, 1973) and 
only 1-12% of the dose has been recovered from faeces following administration of 
both oral and inhaled tritiated salbutamol (Walker et al, 1972). 
Common pharmacokinetic parameters of salbutamol are summarised in Table 7.2. 
and the fate of an inhaled dose of salbutamol is outlined in Figure 7.2. 
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1. The majority of drug is deposited in the 
oropharynx region and swalowed (90%). 
4.Plasma levels are highly variable, 
dependent on means of inhalation, 
and are typicaly less than 5 ng/ml. 
5.Systemic salbutamol is 
metabolised to the inactive 
sulphate metabolite in the 
liver. 
6.Salbutamol has a high renal clearance 
and is actively secreted from the kidneys. 
Salbutamol 4•-0- sulphate is freely filtered. 
2.About 10% of the inhaled dose reaches the 
lungs and exerts a local pharmacological efect. 
3.Swalowed drug is absorbed systemicaly but is subject 
to extensive stereosclective first-pass metabolism 
in the intestinal wal and liver by PST to 
the pharmacologicaly less active salbutamol 4.-0-sulphate. 
Salbutamol is also metabolised in the platelets by PST. 
I7. Les than 12% of the dose is recovered in faeces. 
Figure 7.2 	 Fate of inhaled salbutamol. Inhaled salbutamol basicaly folows two routes. The 
majority of drug (approximately 90%) is swalowed with metabolism in a similar 
manner to oral administration with substantial first-pass metabolism. The drug that is 
deposited in the lungs is metabolised in a similar manner to intravenous 
administration with less first-pass metabolism. 
Table 7.2 	 Common pharmacokinetic parameters of (±)-salbutamol. Adapted from Morgan, 1990. 
Plasma 
protein 
binding Cl C1R Vz 
(%) (L/h/kg) (L/h/kg) (L/kg) 
8 0.41, 0.28 1.9, 
0.38, 2.2, 
0.46 2.5 
Percentage of total drug and metabolites. 
b Percentage of absorbed dose. 
Cl — total plasma clearance. 
C1R — renal clearance. 
Unchanged 	 Excreted 
drug in 	 unchanged 
plasma' (%) 	 in urineb 	 Reference 
ti2 
(h) 
Df 
(%) IV PO IV PO 
3.2, 
3.9, 
4.0, 
5.0, 
6.0 
4 >50 25, 
25 
64, 
65 
20, 
32 
Evans et al (1973), 
Goldstein et al (1987), 
Martin et al (1971), 
Morgan et al (1986), 
Powel et al (1985, 1986), 
Walker et al (1972), 
Vaisman et al (1987). 
Vz= apparent volume of distribution during the terminal phase. 
ti/2 	 elimination half-life. 
Df = intravenous dose excreted in faeces. PO = oral. 
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Assay Development for the Determination of 
Salbutamol in Urine 
8.1 SUMMARY 
An assay was developed for the determination of salbutamol in the urine of asthmatic patients. Several 
solid-phase extraction (SPE) sorbents were tested and compared with liquid-liquid extractions. The SPE 
was then further refined by studying retention behaviour of salbutamol on the sorbent under different 
solvent compositions and modifications in SPE procedures. Analysis was performed  using reversed-phase 
HPLC with UV detection. The recovery of salbutamol from urine Was 48± 5.0% with a calibration range 
of 47.3 ng/ml to 1760 ng/ml. The detection limit was estimated at 15 ng/ml (SN ratio of 3 dB). Intra-day 
and inter-day coefficients of variation were 8.6% and 11.1% (at 473 ng/ml) respectively. Enzymatic 
hydrolysis was performed for 2 hours to determine total salbutamol levels (unchanged + metabolite) 
enabling indirect determination of salbuLamol metabolite levels. 
8.2 INTRODUCTION 
8.2.1 Background 
Extensive literature searches indicate that until recently, there has been little 
research investigating the monitoring of plasma or urinary levels of the inhaled (32- 
agonist bronchodilators in asthmatic patients, primarily because of the difficulties 
in measuring the low concentrations generally seen in clinical practice with 
inhaled therapy (Horn et al, 1989; Horn et at 1990). Preparations of salbutamol 
available include tablets, syrup and injection, but it is inhaled salbutamol that is 
most commonly administered (Jenkins et al, 1990). Inhaled salbutamol is available 
as a 100 In metered dose inhaler (MDI), 200 vg Rotacaps® (a dry powder inhaler; 
DPI) and a respirator solution and unit-of-use pre-diluted nebules (2.5 and 
5.0 mg/ml) which are delivered by nebuliser. 
Administration by MDI results in direct stimulation of 13 2-receptors in the 
bronchial smooth muscle. Because approximately 10% of the drug is delivered 
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directly to the site of action after inhalation (the remainder is subject to extensive 
first-pass metabolism as discussed in Chapter 7), a smaller dose of drug is usually 
required (usually 100 ,ug per inhalation) which results in fewer systemic side-effects 
than if the drug is given by the oral route. The smaller dose of drug delivered by 
MDI, however, poses problems for studies involving the determination of drug 
levels in biological matrices. 
Because of its hydrophilicity and the low concentrations found in plasma at 
therapeutic dosages, extraction of the drug free from interfering compounds is 
relatively difficult (Ong et al, 1989). Typically, urine levels tend to be higher than 
plasma levels as the collection of urine in the body effectively acts as a reservoir for 
salbutamol and its metabolite before being eliminated from the body. This makes 
measuring drug levels easier although the scope of pharmacokinetic parameters 
obtainable may be limited. 
The aim of this study was to develop an assay capable of determining salbutamol 
levels in urine following inhalation therapy. It was anticipated that to be clinically 
useful, this assay would need to measure salbutamol to a lower calibration range of 
around 20 ng/ml in urine. Horn et al (1989) found that in patients who had taken 
200 ,ug salbutamol from a MDI, samples taken 1 hour after administration 
contained 101 ± 77 ng/ml (n=20) of salbutamol. 
8.2.2 Previous methods of detection 
The isolation and measurement of organic compounds, in particular drugs at low 
concentrations in a biological matrix, is a significant analytical challenge 
(McDowall, 1989). Chromatography and immunoassays are the two principal 
techniques used for the measurement of drug concentrations in biological matrices 
(Mehta, 1992). In general, immunoassay techniques for drug analysis are expensive, 
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time consuming to develop, and can be used only for those drugs for which 
reagent kits are available, usualy only when a need for TDM has been clearly 
indicated (Mehta, 1992). For these reasons, an immunoassay technique for 
measuring salbutamol in this current study was not feasible, leaving 
chromatographic techniques as the most practical means of measuring salbutamol 
at therapeutic concentrations. Given the relatively polar nature of salbutamol, 
reversed-phase HPLC was chosen as the method of analysis, although high 
performance thin layer chromatography (HPTLC), gas chromatography (GC) and 
GC-MS have been used to measure therapeutic levels of salbutamol in the past 
(Horn et al, 1989). Advantages of reversed-phase HPLC compared to gas 
chromatography are shown in Table 8.1. 
Table 8.1 	 Advantages of reversed-phase HPLC compared to GC in relation to drug analysis, as 
adapted from Mehta (1992). 
1.HPLC is faster than GC and can be used for polar, non-volatile 
and thermaly labile compounds. This permits the 
determination of a wide variety of drugs including salbutamol. 
2.Unlike GC, derivatization is not necessary in most cases. 
3.HPLC does not destroy the sample alowing it to be recovered for additional studies. 
4.A wide variety of silica based stationary phases with diferent 
functionalities are available. In addition, new stationary phases 
have been developed that alow the direct separation of chiral 
drugs. 
5.Aqueous mobile phases are compatible with clinical samples. 
Several recent studies involving measurement of therapeutic levels of salbutamol 
are summarised in Table 8.2. It should be noted that most of these studies used 
HPLC for measuring therapeutic levels of salbutamol, however, the method of 
detection typicaly used amperometric or fluorescent detectors, not UV detection 
as used here. In general, UV detection ofers the advantages of being a robust and 
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relatively inexpensive means of detection but lacks the specificity and sensitivity of 
arnperometric and fluorescence detection (Mehta, 1992). 
8.2.3 Solid-phase extraction background 
To measure a drug in a biological matrix usually requires a clean up step to remove 
interfering endogenous compounds and in many cases, other drugs. This clean up 
step has been traditionally performed using liquid-liquid extractions whereby the 
drug is unionised by changes in pH in the aqueous phase allowing it to partition 
into a lipophilic organic phase. The partitioning of compounds from the biological 
fluid can be modified by changes in pH and organic phase to be more selective 
toward the drug of interest leaving possible interfering endogenous compounds 
behind in the aqueous phase. 
These liquid-liquid extractions can be very effective for the extraction of lipophilic 
drugs from biological matrices, however, as stated earlier, the extraction of 
relatively non-polar molecules such as salbutamol from plasma or urine, free from 
interfering compounds at therapeutic concentrations, is relatively difficult (Ong et 
al, 1989). 
An alternative method of isolating an analyte from a biological matrix is solid-
phase extraction (SPE). Solid-phase extraction separates compounds by utilising the 
principles of liquid chromatography which involves the analytes being separated 
according to the degree of which each component is partitioned or adsorbed by the 
stationary or solid-phase (McDowall, 1989). As the sample solution passes through 
the sorbent bed (usually under vacuum), the isolate is adsorbed onto the solid-
phase while other sample components pass through the solid-phase bed leaving a 
concentrated isolate (Van Horne, 1985). The isolate can then be selectively 
removed (or eluted) from the sorbent bed by using a minimum volume of a solvent 
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Table 8.2 	 Previous studies measuring therapeutic levels of salbutamol and other Pragonists. 
Detection 
Title 	 Extraction procedure 	 Detection 	 range 	 Author(s) 
Reversed-phase HPLC 
determination of salbutamol 
in rabbit plasma. 
Extracted onto a solid phase Sep-
Pak®  C18 cartridge using ion-pair 
reagent (heptane sulphonic acid). 
Recovery was 89.9 ± 2.8% 
(mean ± SD, n=3). 
Fluorescence 	 10- 300 	 Kurosawa et 
detection. 	 ng/ml. 	 al, 1983. 
Solid phase Sep-Pak®  C18 
cartridge then extracted into 
di(ethylhexyl) phosphate 
(DEHP) as an ion-pair solution 
(heptane sulphonic acid). 
Recovery was 79 ± 8.6% (mean 
± SD, n-12). 
Solid phase extraction using Sep-
Pak®  C18 cartridge (plasma) and 
Prep-1 type W XAD-2 cartridges 
(urine) and conversion to an 
indoaniline dye by reaction with 
dimethyl-p-phenylenediamine. 
Determination of salbutamol 
in human serum by reversed-
phase HPLC with 
amperometric detection. 
Determination of salbutamol 
in human plasma and urine 
by high performance thin-
layer chromatography. 
Ampero- 	 0.4 - 20 	 Tan and 
metric 	 ng/ml. 	 Soldin, 1984. 
detection. 
Absorption 	 20- 700 	 Colthup et 
microdensit- 	 ng/nal. 	 al, 1985. 
ometry at 650 
nm. 
Pre-column sample purification 	 Electro- 
and enrichment, 	 chemical 
detection 
Fluorescence 
detection. 
Ampero-
metric 
detection. 
Simultaneous determination 
of salbutamol and terbutaline 
at overdose levels in human 
plasma by HPLC with 
electrochemical detection. 
Measurement of terbutaline 
and salbutamol in plasma by 
HPLC with fluorescence 
detection. 
Plasma assay of salbutamol by 
means of HPLC with 
amperometric determination 
using a loop column for 
injection of plasma extracts. 
Application to the evaluation 
of subcutaneous 
administration of salbutamol. 
Solid-phase extraction on alkali-
treated Bond-Elut. 
Solid-phase extraction on Bond-
Elut®  C18 cartridge. Recovery 
was 93 ± 10.6% (mean ± SD, 
n= 9). 
1 - 100 	 Sagar et al, 
ng/ml. 	 1993. 
Calibration 
curve over 
the range 20 
- 100 ng/ml. 
Detection 	 McCarthy et 
limit 0.5 	 al, 1993. 
ng/ml. 
Calibration 
curve over 
the range 25 
- 125 ng/ml. 
0.5- 15 	 Tamisier- 
ng/ml. 	 Karolak et al, 
Calibration 	 1992. 
curve over 
the range 2.5 
- 15 ng/ml. 
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detection. 
0.5 ng/ml. 	 Ong et al, 
Calibration 	 1989. 
curve over 
the range 0.8 
- 6.4 ng/ml. 
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Table 8.2 continued. 
Fluorescence 
detection. 
Fluorescence 
detection. 
An HPLC method for the 
determination of albuterol 
(salbutamol) enantiomers in 
human serum using solid 
phase extraction and chemical 
derivatisation. 
Residue screening for the 13- 
agonists denbuterol, 
salbutamol and cimaterol in 
urine using enzyme 
immunoassay and HPLC. 
Analysis of albuterol in 
plasma based on 
immunoafinity 
chromatographic clean-up 
combined with HPLC with 
fluorescence detection. 
Determination of salbutamol 
enantiomers in human plasma 
and urine by chiral high-
performance liquid 
chromatography. 
Solid-phase extraction and 
derivatisation of racemic 
albuterol to a diastereomeric 
thiourea. 
Combined solid-phase extraction 
with C18 silica gel and enzyme 
immunoassay. 
Immunoafinity dean-up 
recovery was 96.1 ±1.1% (mean 
± SD, n=8). Overal recovery 
was 80.1 ± 5.3 % (mean ± SD, 
n-8). 
Solid-phase extraction with 
acetonitrile wash and methanol 
elution. 
1.0- 20.0 
ng/mL 
Calibration 
curve over 
the range 2.0 
- 20.0 ng/ml. 
1 ppb 
0.25-500 
ng/ml. 
Calibration 
curve Over 
the range 
1.25-500 
ng/ml. 
He and 
Stewart, 
1992. 
Meyer et al, 
1991. 
Boulton and 
Fawcet, 1995. 
for which the isolate has a strong afinity. The properties of the solid-phase sorbent 
bed (usualy consisting of a functional group covalently bonded to a silica 
substrate) determine the selectivity for the isolate (Van Horne, 1985). 
A list of common sorbents and their properties are shown in Table 8.3. Most of 
the recent research studies on measuring therapeutic levels of the 132-agonists have 
utilised SPE (as can be seen in Table 8.2). It was therefore decided to investigate 
SPE as a possible clean up step for separating salbutamol from an aqueous urinary 
matrix containing interfering endogenous compounds and other drugs. 
8.2.4 Outline of the rationale for assay development 
SPE was initialy compared with liquid-liquid extraction. Diferent sorbents were 
tested in Section 8.3.3. An analytical HPLC column was then used in Section 8.3.4 
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Table 8.3 	 Commercialy available solid-phase extraction sorbents, functional groups and their 
properties (adapted from Van Horne, 1985). 
Abbreviation 	 Functional Group 	 Polarity 	 Properties 
C18 	 Octadecyl 	 Non-polar 	 Most non-polar sorbent available and is the most 
retentive of al sorbents for isolates being retained by 
non-polar mechanisms. C18 does not retain polar 
molecules wel. C18 sorbents are not very selective 
which is often a benefit when the isolates vary widely in 
structure but final extracts may not be as pure as when 
more selective absorbents are employed. 
C8 	 Octyl 	 Non-polar 	 Similar properties to the C18 phase but not quite as 
retentive for non-polar isolates and a slightly higher 
potential for polar interactions than C18 due to its 
shorter chain length. 
C2 	 Ethyl 	 Non-polar/polar 	 C2 is a fairly polar sorbent due to is short chain length. 
C2's polarity is slightly greater than CN for polar 
interactions. 
CH 	 Cydohexyl 	 Non-polar 	 CH has approximately the same polarity as a C2 
sorbent. CH is a medium polarity sorbent that exhibits 
unique selectivities for certain isolates. 
PH 	 Phenyl 	 Non-polar 	 PH has approximately the same polarity as a C8 sorbent. 
Like CH, PH exhibits a slightly diferent selectivity 
from other non-polar sorbents due to the electron 
density of the aromatic ring. 
CN 	 Cyanopropyl 	 Non-polar/polar 	 CN is a medium polarity sorbent with many uses. The 
cyano group gives CN a unique selectivity. 
to examine the retention characteristics of salbutamol under diferent conditions of 
solvent and pH with the solid-phase chosen from Section 8.3.3. The SPE technique 
was optimised using this information in Section 8.3.5. Finaly the chromatography 
conditions from Chapters 5 and 6 were optimised for salbutamol urine extracts in 
Section 8.3.6. Internal standards were examined in Section 8.3.7. Calibration curves 
for salbutamol were examined in Section 8.3.8 and hydrolysis conditions in Section 
8.3.9. 
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8.3 METHOD 
8.3.1 	 Materials 
Salbutamol pure base was kindly donated by Glaxo Australia Pty. Ltd. (Boronia, 
Vic., Australia). Methanol and tetrahydrofuran (liquid chromatography grade) 
were purchased from Waters Associates (Lane Cove, NSW, Australia). The ion 
pair reagent Pic® B-8 Reagent Low UV (containing water, methanol, octane 
sulphonic acid and calcium acetate in undisclosed quantities) was purchased from 
Waters Associates (Milford, MA, USA). Decane sulphonic acid was purchased 
from the Sigma Chemical Co. (St Louis, MO, USA). [3- 
Glucuronidase/arylsulphatase (derived from helix pomatia) was obtained from 
Boehringer Mannheim, Germany. Al other chemicals used were laboratory grade 
reagents. 
8.3.2 Equipment 
The HPLC system consisted of a Varian Solvent Delivery System Model 9010 
(Varian Chromatography Systems, Walnut Creek, CA, USA) and a Rheodyne 
injector Model 7161 (Rheodyne Inc., Cotati, CA, USA) with a 10 sul external loop 
connected to a Varian Variable Wavelength UV-VIS Detector Model 9050 (Varian 
Chromatography Systems, Walnut Creek, CA, USA). Detection was performed at 
220 rim. Chromatographic peaks were digitised, integrated and recorded with a 
Varian GC Star Workstation (Varian Chromatography Systems, Walnut Creek, 
CA, USA). 
The analysis of salbutamol extraction procedures was performed on a Nova-Pak® 
C18 4 pm 10 cm x 8 mm i.d. Radial-pak® liquid chromatography cartridge (Waters 
Associates, Milford, MA, USA) inside a Waters RCM 8 x 10 compression module 
(Waters Associates, Milford, MA, USA). The retention behaviour of salbutamol in 
phenyl solid phases (Section 8.3.4) was examined using a ,uBondapak Phenyl 10 pm 
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300 mm x 3.9 mm i.d. steel chromatography column (Waters Associates, Milford, 
MA, USA). 
The following SPE sorbents were used in Section 8.3.3: C18, C8, C2 and phenyl 
1 ml volume disposable extraction columns from a Bond Elute Applications 
Development Kit (Analytichem International, Harbour City, CA, USA). Phenyl 
1 ml volume Baker Bond spe® disposable extraction columns UT. Baker Inc., 
Phillipsburg, NJ, USA) were used in Sections 8.3.5 to 8.3.9 and in Chapter 9. 
8.3.3 Initial investigation of the solid-phase recovery of salbutamol 
The solid-phase recovery and clean-up of salbutamol from both water and urine 
was investigated using several potentially suitable sorbents chosen from the 
characteristics outlined in Table 8.3. The SPE technique was compared with a 
liquid-liquid extraction and a SPE technique using an ion-pair reagent to aid 
retention. 
Analysis of samples was performed by injecting into a 10 pl fixed loop for HPLC 
analysis on a Nova-Pak C18 4 pm 10 cm x 8 mm i.d. Radial-pak liquid 
chromatography cartridge with a mobile phase consisting of 30% tetrahydrofuran, 
1.9 rnM octane sulphonic acid (from a dilution of Low UV Pic ® B-8 ion-pair 
reagent) and 5% methanol in distilled water. Flow rate was 1.5 ml/min with UV 
detection performed at 220 nm. 
8.3.3.1 Preparation of salbutamol standards and their use in the assessment of SPE technique 
A stock solution of salbutamol 500 ng/ml in distilled water was prepared from 
salbutamol base to spike water and urine samples in Sections 8.3.3.2, 8.3.3.3 and 
8.3.3.4 and was also used to estimate recovery in Section 8.3.8. The 100 pi aliquots 
of this 500 ng/rnl stock solution that were used to spike urine blanks contained 
50 ng of salbutamol. Assuming 100% recovery, this amount would be present in 
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the final sample extract and after reconstitution with 100 ill of distilled water, 
would be present in a concentration of 500 ng/ml, equivalent to the stock 
solution. The chromatograms obtained from Sections 8.3.3.2, 8.3.3.3, 8.3.3.4 and 
the recovery estimation in Section 8.3.8 were compared against a chromatogram of 
the 500 ng/ml stock solution representing maximum theoretical recovery. These 
comparisons enabled an assessment of the different SPE techniques against a 
standard reference (Sections 8.3.3.2, 8.3.3.3, 8.3.3.4) and an estimate of salbutamol 
recovery (Section 8.3.8). 
8.3.3.2 Comparisons of SPE, SPE using ion-pair, and liquid-liquid extractions 
Spiked samples were prepared by adding 100 pl of a 500 ng/ml salbutamol stock 
solution to 1 ml of distilled water and mixing thoroughly using a vortex mixer 
(Super-Mixer, Lab-Line Instruments Inc., Melrose Park, IL, USA). Liquid-liquid 
extractions were performed by adding 250 Jul of 1 M HC1, mixing, and discarding 
the organic phase (either ethyl acetate or hexane), adding 500 pl of 1 M NaOH and 
either 1 ml of ethyl acetate or hexane, mixing, collecting the organic layer, 
evaporating under nitrogen at 45°C and adding 100 Jul of distilled water. 
A simple SPE technique was performed using 1 ml volume C18 Bond Elut 
disposable extraction columns. The technique consisted of (i) sorbent conditioning, 
(ii) introduction of sample to the column, (iii) sorbent wash and (iv) solute elution 
steps. This procedure is illustrated in Figure 8.1. 
Sorbent conditioning was performed by allowing 1 ml of methanol to pass 
through the disposable extraction column followed by 1 ml of pH 6.7 phosphate 
buffer. After the buffer had passed through the column, the spiked sample was 
introduced while the column sorbent was still wet and allowed to pass through the 
column. The sorbent was then washed with 2 x 500 tel aliquots of pH 6.7 
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phosphate buffer. Once the washings had been removed the solute was eluted with 
2 x 500 pl aliquots of methanol, evaporated under nitrogen at 45°C and 100 pl of 
distilled water was added. All of the steps involving solvents passing through the 
disposable extraction columns were performed under slight vacuum. The column 
sorbent was not allowed to air-dry between sorbent conditioning and introduction 
of sample onto the column. 
SPE was also attempted using an ion-pair reagent (octane sulphonic acid) to aid 
retention on the column. The procedure was identical to the SPE technique above 
except 1 ml of octane sulphonic acid (0.005 M) was added to the spiked sample and 
used in the wash steps instead of pH 6.7 phosphate buffer. All samples were then 
analysed by HPLC under the conditions outlined in the beginning of Section 8.3.2 
and compared with the 100% theoretical recovery chromatogram. 
It was found that the SPE technique using C18 sorbent produced satisfactory 
recovery with good peak heights of a similar magnitude to the stock solution 
(theoretical 100% recovery; Section 8.3.3.1). Both of the liquid/liquid extractions 
recovered far less salbutamol than the C18 sorbent as would be expected given the 
relatively polar nature of salbutamol. The ion-pair SPE method also produced 
worse results than the C18 sorbent without ion-pair. Overlayed chromatograms are 
shown in Figure 8.2. 
8.3.3.3 Comparisons of the retentive properties of C18, C8, C2 and phenyl solid-phase sorbents 
in an aqueous matrix 
The retentive properties of C18, C8, C2 and phenyl solid-phases were examined 
using 1 ml volume Bond Elut disposable extraction columns. Spiked water samples 
were prepared by adding 100 pl of a 500 ng/ml salbutamol stock solution to 1 ml 
of distilled water then mixing thoroughly using a vortex mixer. A simple SPE 
technique was performed identical to that outlined above in Section 8.3.3.2. A 
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1. 	 2. 	 3. 	 4. 
Conditioning Sample Introduction Wash 	 Elution 
waste 	 waste 	 waste 
Sample 
• Urinary compounds 
0 Drug 
6. 
5. 
Figure 8.1 Solid-phase extraction (SPE) technique employed for comparisons of SPE, SPE using ion-
pair, and liquid-liquid extractions (Section 8.3.3.2). I. Sorbent conditioning with lx 
I ml of methanol and I x I ml pH 6.7 phosphate bufer. 2 Sample introduction to 
sorbent (I ml of urine added to sorbent). 3. Sorbent wash with 2x 500 /al of pH 6.7 
phosphate bufer. 4. Solute elution with 2x 500 pl of methanol. 5. Eluent evaporation 
under nitrogen with 45°C. 6. Sample reconstitution with 100 plof distiled water 
ready for HPLC analysis. 
strong additional elution consisting of 2 x 250 jul aliquots of tetrahydrofuran was 
used in an atempt to ensure that al the salbutamol was removed from the column. 
Extractions were repeated five times to examine reproducibility. Al samples were 
then analysed by HPLC under the conditions outlined in the beginning of Section 
8.3.3. 
Recoveries were examined by comparing the relative salbutamol peak areas. It was 
found that the secondary tetrahydrofuran elution removed a considerable amount 
of salbutamol in al cases. The mean relative recovery was greatest with the phenyl 
SPE column, of which very litle salbutamol was removed by the first methanol 
elution. The mean relative recoveries and reproducibility are shown in Figure 8.3. 
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Figure 8.2 	 Comparison of SPE, SPE with ion-pair and liquid/liquid Extractions are shown. 
(I) Liquid/liquid extraction with hexane. (2) Liquid/liquid extraction with ethyl 
acetate. (3) SPE with ion-pair reagent (octane sulphonic acid) used in extraction. (4) SPE 
without ion-pair reagent. (5) 500 ng/ml stock solution equivalent to 100% recovery (see 
Section 8.3.3.1). 
8.3.3.4 Comparison of the retentive properties of C18, C8, C2 and phenyl solid-phase sorbents in 
a urinary matrix 
Although the extraction properties of the various disposable extraction columns 
were investigated in Section 8.3.3.3 in extracting salbutamol from water, it was 
necessary to investigate the various extraction properties obtained from the same 
batch of spiked urine. This would enable the selectivity and clean-up properties of 
the various solid-phases with respect to salbutamol to be investigated. For example, 
a column that recovered 90% of the solute of interest but also retained 90% of 
interfering endogenous solutes in the chromatography may not be ideal, whereas a 
column recovering less of the solute of interest but without interfering compounds 
may be more suitable. This is discussed in more detail in Section 8.2.3. 
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The retentive and selective properties of C18, C8, C2 and phenyl solid-phases were 
examined using 1 ml volume Bond Elut disposable extraction columns Spiked 
urine samples were prepared by adding 100 ,t21 of a 500 ng/ml salbutamol stock 
solution to 1 ml of blank urine and mixing thoroughly using a vortex mixer. A 
simple SPE technique was performed identical to that outlined above in Section 
8.3.3.2 with the exception that the elution consisted of 1 x 250 jul aliquot of 
tetrahydrofuran. It was found that elution with 2 x 250 ,u1 aliquots of 
tetrahydrofuran resulted in a significant amount of interfering urinary solute. 
18 — 
16 — 
14 — 
12 — 
Mean Relative 10 — 
Recovery 
— 
6 — 
4 — 
2 — 
ICI Methanol Wash 	 •Tetrahydrofuran Wash 
C18 	 C8 	 C2 	 PH 
Figure 8.3 	 Comparison of mean salbutamol recovery from C18, C8, C2 and PH solid phases after 
methanol elution and an additional tetrahydrofuran elution.(Section 8.3.3.3). 
Coeficients of variation (al n =5) for initial methanol wash were as folows: 18%, 80%, 
25% and 18% for C18, C8, C2 and PH solid phases respectively. Coeficients of 
variation (al n= 5) for additional tetrahydrofuran wash were as folows: 25%, 67%, 
55% and 15% for C18, C8, C2 and PH solid phases respectively. 
Al samples were then analysed by HPLC under the conditions outlined in the 
beginning of Section 8.3.3 and compared with the 100% theoretical recovery 
chromatogram. 
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The retentive properties of C18, C8, C2 and phenyl solid-phase sorbents were 
found to vary mostly in their salbutamol selectivity. Extraction was as expected 
given the characteristics outlined in Table 8.3. The C18 sorbent retained a large 
number of diferent compounds with a relatively messy chromatogram and lower 
recovery of salbutamol which is not unexpected given the relatively polar nature 
of salbutamol. The C8 and C2 sorbents provided a progressively cleaner 
chromatogram with decreasing hydrocarbon chain length, each with similar 
salbutamol recovery. The phenyl sorbent provided both good salbutamol recovery 
and a high relative selectivity and was selected as the choice for the SPE procedure. 
Chromatograms of the diferent sorbents are shown in Figure 8.4. 
8.3.4 Behaviour of salbutamol in phenyl solid-phases 
Based on the results in Section 8.4.1 it was decided to perform the SPE of urinary 
salbutamol with disposable Bond Elut® phenyl solid phase extraction columns. In 
this section the behaviour of salbutamol on an analytical phenyl HPLC column 
was examined. It was hoped that the chromatographic column parameters 
measured for salbutamol on the analytical HPLC column could be utilised on the 
phenyl SPE columns to optimise the extractions. Capacity factors (k') were 
measured with varying methanol and tetrahydrofuran components in the mobile 
phase. The capacity factor is defined as the number of column volumes of solvent 
required to elute the solute. This is shown below. 
k' = capacity factor 
t 	 = solute elution time 
t o = elution time without retention i.e. solvent complex elution time 
k' = 	 t - to 
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The influence of pH on solute retention was also examined. It was hoped that this 
would enable a prediction of the behaviour of salbutamol in phenyl disposable 
extraction columns. This prediction would then alow tailoring of the organic 
components in the SPE wash and elution steps for optimum extraction using 
phenyl disposable extraction columns. 
1!0 	 2!0 	 3.0 	 9!0 	 5!0 	 1 6.0 	 7!0 	 9.0 	 3,0 	 10:0 
Retention Time (minutes) 
Figure 8.4 	 Comparison of the retentive properties of (2) C8, (3) phenyl, (4) C2, and (5) C18 solid- 
phase sorbents in a urinary matrix with a baseline ofset to aid display shown with (1) 
salbutamol standard (equivalent to theoretical 100% extraction). Inset; although 
confused shows the salbutamol peaks for the same chromatograms under a lower 
atenuation. The salbutamol peak is shown (Sal). 
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A solution of salbutamol 0.5 mg/ml in distilled water was prepared from 
salbutamol base. Twenty naicrolitres of this solution were injected into the HPLC 
connected to a phenyl column with UV detection performed at 220 nm (Section 
8.3.2). The organic component and pH of the mobile phase were then varied as 
described below and the respective t and t o parameters recorded. 
The effect of methanol on the retention behaviour of salbutamol on a phenyl solid 
phase was examined using eight different compositions of mobile phase consisting 
of 25, 40, 50, 60, 65, 75, 80 and 90% methanol in distilled water at a flow rate of 
1.0 ral/rain. Similarly, the effect of tetrahydrofuran on the retention behaviour of 
salbutamol on a phenyl solid phase was examined using mobile phases consisting 
of 3, 5, 10, 15, 20, 30, 40 and 60% tetrahydrofuran in distilled water at a flow rate 
of 1.0 ml/min. The capacity factor parameters for salbutamol were recorded under 
each of these conditions. 
The effect of pH on retention behaviour was examined using six different mobile 
phases consisting of 10% methanol in Walpole's acetate buffer APF (pH 3.9 and 
5.0), phosphate buffer (pH 6.1 and 8.1) and borate buffer (pH 8.1). The capacity 
factor parameters for salbutamol were recorded under each of these pH values 
with a flow rate of 1.0 ml/min. 
The effect of methanol on the elution of salbutamol on a phenyl column is shown 
in Figure 8.5. The fastest salbUtamol elution occurred with methanol percentages 
of between 40% and 70% in distilled water. Similarly the effect of tetrahydrofuran 
on the elution of salbutamol is shown in Figure 8.6 with fastest elution occurring 
with tetrahydrofuran percentages of between 10% and 30%. In terms of relative 
elution strength of salbutamol on a phenyl column, tetrahydrofuran was around 
15 times more powerful than methanol. 
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The efect of pH on elution of salbutamol on a phenyl column is shown in Figure 
8.7. The capacity values obtained should only be seen as a guide because diferent 
bufers were used which could also greatly afect the elution parameters. Faster 
elution was found with the lower pH values of the acetate bufer. Beter retention 
of salbutamol was found at higher pH values with the phosphate and borate 
bufers. 
20 	 30 	 40 	 50 	 60 	 70 	 80 	 90 	 100 
Percentage of Methanol In Mobile Phase 
Figure 8.5 	 Efect of methanol on the elution of salbutamol from a phenyl analytical column. 
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Figure 8.6 	 Efect of tetrahydrofuran on the elution of salbutamol from a phenyl analytical 
column. 
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Figure 8.7 	 Efect of pH on the elution of salbutamol from a phenyl analytical column. 
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8.3.5 Optimisation of extraction 
Various parameters in the extraction procedure outlined in Section 8.3.3 were 
changed to optimise the extraction procedure. Based on observations in Sections 
8.3.3 and 8.3.4, changes were made in the introduction of sample on to the 
disposable extraction column, sorbent wash and elution steps. Solutions containing 
10% tetrahydrofuran in pH 8.1 and 4.0 buffers were tested in sample A and F. It 
was hoped that this would provide a fast elution of salbutamol (given the low 
capacity factors illustrated in Figures 8.6 and 8.7) while leaving other endogenous 
products on the column. Samples B, C and D were given two washes of methanol 
in buffer and water (washing solutions with high capacity factors from Figure 8.5) 
in the hope of washing endogenous compounds off the column while leaving 
salbutamol behind. Sample E was given pre-treatment with a buffer before 
introduction onto the SPE column. The different SPE procedures are listed in 
Table 8.4. 
It was found that the SPE of sabutamol was improved by pre-mixing pH 8.1 
phosphate buffer with the urine before introduction of the sample onto the SPE 
column (sample E). It was also found that improvements were made over the 
control SPE method when the wash step was performed with 1x250 [11 of 10% 
methanol in pH 8.1 buffer followed by 1x250 IA of 80% methanol in distilled water 
(sample B). Both these improvements were incorporated into the final SPE method 
used for sample analysis in Section 8.3.8. No improvements over the simple 
control SPE were made in the elution step. These results are shown in Figure 8.8. 
8.3.6 Optimisation of chromatography 
The chromatography of a salbutamol stock solution (500 ng/nal in distilled water) 
was tested under different flow rates, ion-pair reagents and UV detection 
wavelengths to increase resolution, peak shape and detection response. The 
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Table 8.4 	 Solid-phase extraction steps tested to optimise the SPE of salbutamol in Section 8.3.5 
based on observations obtained from Sections 8.3.3 and 8.3.8. 
Sample 	 Sorbent Conditioning 
Control 	 2 x 250 pi methanol 
2 x 250 pi pH 8.1 bufer 
A 	 2 x 250 /41 methanol 
2 x 250 pi pH 8.1 bufer 
2 x 250 pi methanol 
2 x 250 pl pH 8.1 bufer 
2 x 250 pl methanol 
2 x 250 pl pH 8.1 bufer 
Sample Introduction 
1 ml urine added to SPE 
column 
1 ml urine added to SPE 
column 
1 ml urine added to SPE 
column 
1 ml urine added to SPE 
column 
Sorbent Wash 
2 x 250 pl pH 8.1 
bufer 
2x 250 pi pH 8.1 
bufer 
1 x 250 pl 10% 
methanol in pH 8.1 
bufer folowed by 
1 x 250 pl 80% 
methanol in water 
2 x 250 pl 10% 
methanol in pH 8.1 
bufer 
Elution 
1 x 250 pi 
tetrahydrohiran 
lx 100 pi 10% 
tetrahydrofuran 
in pH 8.1 bufer 
1 x 250 pi 
tetrahydrofuran 
1 x 250 pi 
tetrahydrofuran 
2 x 250 pl methanol 
2 x 250 pi pH 8.1 bufer 
2 x 250 pi methanol 
2 x 250 pi pH 8.1 bufer 
2 x 250 pi methanol 
2 x 250 pl pH 8.1 bufer 
1 ml urine added to SPE 
column 
1 ml urine + 500/41 pH 
8.1 bufer mixed and 
added to SPE column 
1 ml urine added to SPE 
column 
2x 250 pi 80% 
methanol in water 
2 x 250 pi pH 8.1 
bufer 
2 x 250 pl pH 8.1 
bufer 
lx 250 pi 
tetrahydrofuran 
lx 250 pl 
tetrahydrohiran 
1 x 100 pi 10% 
tetrahydrofuran 
in pH 8.0 bufer 
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Figure 8.8 	 Optimisation of solid phase extraction technique from samples outlined in Table 8.4 
summarised as folows. Improvements were found with Sample B and Sample E. 
(1)Control:  Sorbent conditioning with 2 x 250 pl of methanol and 2 x 250 il washes of pH 8.1 bufer, I 
ml urine added to SPE column, 2 x 250 pl washes of pH 8.1 bufer and elution with a lx 250 pl wash of 
tetrahydrofuran. 
(2)Sample A:  Sorbent conditioning with 2x 250 pl of methanol and 2 x 250 pl washes of pH 8.1 bufer, I 
ml urine added to SPE column, 2 x 250 pl washes of pH 8.1 bufer, and elution with a lx 100 yl wash of 
10% tetrahydrofuran in pH 8.1 bufer. 
(3)Sample B: Sorbent conditioning with 2 x 250 pl of methanol and 2 x 250 yl washes ofpH8. I bufer, 1 
ml urine added to SPE column, I x 250 pl wash of 10% methanol in pH 8.1 bufer folowed by 1 x 250 ,u1 
80% methanol in water wash and elution with a lx 250 pl wash of tetrahydrofuran. 
(4)Sample C: Sorbent conditioning with 2 x 250 yl of methanol and 2 x 250 pl washes of pH 8.1 bufer, I 
ml urine added to SPE column, 2 x 250 yl washes of 10% methanol in pH 8.1 bufer and elution withal 
x 250 pl wash of tetrahydrofuran 
(5)Sample D: Sorbent conditioning with 2 x 2541 of methanol and 2 x 250 pl washes of pH 8.1 bufer, 1 
ml urine added to SPE column, 2 x 250 yl washes of 80% methanol in water and elution with a 1 x 250 yl 
wash of tetrahydrofuran. 
(6)Sample E; Sorbent conditioning with 2 x 250 pl of methanol and 2 x 250 pl washes of pH 8.1 bufer, 1 
ml urine and 500 pl pH 8.1 bufer mixed and added to SPE column, 2 x 250 pl washes of pH 8.1 bufer 
and elution with a 1 x 250 pl wash of tetrahydrofuran. 
(7)Sample F; Sorbent conditioning with 2 x 250 pl of methanol and 2 x 250 pl washes of pH 8.1 bufer, I 
ml urine added to SPE column, 2x 250 pl washes of pH 8.1 bufer and elution with a lx 100 pl wash of 
10% tetrahydrofuran in pH 8.0 bufer. 
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commercial Low UV Pic B-8 ion-pair reagent was compared with a 0.0025 M 
decane sulphonic acid ion-pair reagent. 
The following mobile phases were used: 
(i) 20% tetrahydrofuran, 1.9 mM octane sulphonic acid (from a dilution of 
Low UV Pic® B-8 ion-pair reagent) and 5% methanol in distilled water with 
a flow rate of 1.5 ml/min. 
(ii) 20% tetrahydrofuran and 2.0 mM decane sulphonic acid in distilled water 
with a flow rate of 1.5 ml/min. 
(iii) 18% tetrahydrofuran, 18% methanol and 1.6 mM decane sulphonic acid in 
distilled water with a flow rate of 1.5 ml/min. 
(iv) Mobile phase identical to (ii) with a flow rate of 2.5 ml/min. 
Different wavelengths were also examined by injecting a 500 ng/rnl solution of 
salbutamol into the HPLC fixed loop injection port and comparing the detection 
response by measuring peak heights at 220, 225, 230, 235 and 240 rim. 
Salbutamol (500 ng/ml in distilled water) was best chromatographed using a 
mobile phase consisting of 20% tetrahydrofuran, 1.9 mM octane sulphonic acid 
(from a dilution of commercial Low UV Pic ® B-8 ion-pair reagent) and 5% 
methanol in distilled water with a flow rate of 1.5 ml/min, developed from 
Chapter 5. A comparison with the other mobile phases tested is shown in Figure 
8.9. It was also found that increasing wavelength dramatically reduced the relative 
absorbance of salbutamol as shown in Table 8.5. 
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Figure 8.9 	 Optimisation of the chromatography of salbutamol as described in Section 8.3.6. 
Mobile phases and flow rates were as folows: (1)20% tetrahydrofuran, 1.9 mM 
octane sulphonic acid (from a dilution of Low UV Pic® B-8 ion-pair reagent) and 5% 
methanol in distiled water with a flow rate of 1.5 ml/min. Salbutamol peak shown at 
4 minutes. (2) 20% tetrahydrofuran and 20 mM decane sulphonic acid in distiled 
water with a flow rate of 1.5 ml/min. Salbutamol peak shown at 8.4 minutes. (3) 18% 
tetrahydrofuran, 18% methanol and 1.6 mM decane sulphonic acid in distiled water 
with a flow rate 1.5 ml/min. Salbutamol peak shown at 6.5 minutes. (4) Mobile phase 
identical to (2) with a flow rate of 2.5 ml/min. Salbutamol peak shown at 4.5 minutes. 
Table 8.5 	 Relative absorbance of salbutamol with increasing frequency represented as the 
percentage of maximum absorbance. 
wavelength (nm) Relative absorbance (%) 
220 97 
225 100 
230 71 
235 32 
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8.3.7 Internal standard 
Several compounds were tested for suitability as an internal standard in the urine 
assay for salbutamol. It was preferred that other 132-agonists were not used as 
potential internal standards as some asthmatic patients could be using more than 
one generic type of [32-ago/list bronchodilator. The ideal internal standard would 
be recovered wel from the SPE technique and elute late in the chromatogram with 
litle interference from endogenous compounds and salbutamol. 
Drugs of a similar nature to salbutamol were tested for their suitability as an 
internal standard, that is relatively polar, basic drugs, with relatively low molecular 
weights. Several 13-blockers (which are contraindicated in asthmatic patients and 
would therefore not be expected to be administered to these patients), 
sympathomimetics (including the 13-agonists fenoterol, isoprenaline and 
terbutaline), local anaesthetics and ketamine were tested. These compounds were 
tested for retention and peak shape under the chromatographic conditions 
developed for salbutamol (identical to that used below in Section 8.3.8). These 
drugs are shown in Table 8.6. 
Table 8.6 	 Potential internal standards tested. 
13-blockers 	 miscelaneous 	 P-agonists 
atenolol 	 mepivacaine 	 fenoterol 
metoprolol 	 , ephedrine* 	 isoprenaline 
oxprenolol 	 ketamine 	 terbutaline 
pindolol 
propranolol 
timolol 
* a+13 agonist 
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All of the potential internal standards tested except fenoterol were found to be 
unsatisfactory under the given chromatographic conditions with a long retention 
time and peak tailing a major problem. 
8.3.8 Standard curve: method conditions, parameters and reproducibility 
A 100 ml stock solution of salbutamol in distilled water (194 p.g/m1) was prepared 
from pure salbutamol base. Two aliquots of 25 111 of this solution were then 
diluted 1:10 and 1:100 with distilled water to give stock solutions of 19.4 jig/m1 
and 1.94 a.g/ml. Aliquots of 25, 50 and 100 11.1 were taken from both of these 
solutions and each added to 1 ml of blank urine from a healthy subject with no 
prior use of any 13-agonist. These spiked urine samples with concentrations of 
salbutarnol between 47.3 ng/ml and 1.76 ig/m1 were used to construct a 
calibration curve. An internal standard stock solution of fenoterol (100 [ig/m1) was 
prepared from a proprietary fenoterol nebuliser solution (Berotec6). Fifty 
microlitres of internal standard was added to each sample and mixed using a vortex 
mixer. Calibration curves were constructed on each day of sampling and stock 
solutions were refrigerated at 4°C. 
The spiked calibration curve samples were then extracted using the following SPE 
method using 1 ml Baker Bond spe® disposable extraction columns. Five hundred 
microlitres of pH 8.1 phosphate buffer were added to 1 ml of spiked urine sample 
and mixed using a vortex mixer. The solid-phase sorbent was conditioned with 2 
washes of methanol (250 pi per wash) and 2 washes of pH 8.1 phosphate buffer 
under a slight vacuum to aid passage through the SPE column. The buffered 
samples were then introduced onto the columns and washed with 250 iAl of a 10% 
methanol in pH 8.1 phosphate buffer solution and 250 [1.1 of 80% methanol in 
distilled water. The columns were not allowed to dry in between steps and were 
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not re-used. Sample elution was performed with a 250 vl wash of tetrahydrofuran 
and the eluent concentrated to approximately half volume under nitrogen (unlike 
samples in Section 8.3.3 and 8.3.5 that were evaporated to near dryness). The 
concentrated samples were then centrifuged for 2 minutes at 15,000 rpm in a 
microcentrifuge (Heltich Mikrolitre, Type 2020). 
The chromatography was performed with the equipment outlined in Section 8.3.2. 
A mobile phase consisting of 20% tetrahydrofuran, 19 mM Low UV Pic B-8® 
(from a dilution of Low UV Pic B-8® ion-pair reagent) and 5% methanol in 
distilled water was used with a flow rate of 1.5 ml/min and detection performed at 
225 rim. Calibration curves were calculated from salbutamol:internal standard peak 
height ratios (obtained from the Varian GC Star Workstation 8). 
Standard curves were constructed from spiked urine samples on each day of 
sampling. Intra-day coefficient of variation was calculated from five salbutamol 
spiked urine samples of 47.3 ng/ml (lowest level of the calibration curve) and 
473 ng/ml. The 473 ng/ml solutions were also used to examine the recovery of 
salbutamol by comparing peak heights with a stock solution of salbutamol 
equivalent to 100% recovery (Section 8.3.3.1). Inter-day coefficient of variation was 
calculated from a 10 ml urine sample containing salbutamol (473 ng/ml) with 1 ml 
aliquots extracted on five separate days for analysis. The detection limit, based on a 
SN ratio of 3 dB, was also examined. 
An overlayed chromatogram showing a blank and spiked urine sample used for the 
calibration curve is shown in Figure 8.10. An example of the calibration curve is 
shown in Figure 8.11 together with daily calibration curve parameters used in 
Chapter 9. The calibration curve range was 47.3 ng/ml to 1760 ng/ml. Intra-day 
coefficients of variation were found to be 9.5% (n=5; 47.3 rig/ml) and 8.6% (n=5; 
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473 ng/ml). The inter-day coeficient of variation was 11.1% (n=5; 473 ng/ml). 
Recovery of salbutamol from urine was estimated at a disappointing 48 ± 5.0% 
(mean ± SD, n=5). This was much lower than early indications of around 70%. 
This decrease in recovery may have been due to variations in many minor factors 
in the SPE technique such as flow rates, temperature, pH, solvent compositions 
and handling errors. This highlights the delicate nature of SPE techniques. The 
detection limit was found to be 15 ng/ml (SN ratio of 3 dB) but inadequate clean-
up prevented calibration to that level. 
Retention Time (minutes) 
Figure 8.10 	 Overlayed chromatogram showing a spiked urine sample (1) with 473 ng/ml of 
salbutamol used for the calibration curve compared to a urine blank (2). Inset shows the 
salbutamol peak at a lower atenuation. 
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Regression line equations for calibration curves used in the analysis of samples. 
(x = concentration ng/ml, y = peak height ratio) 
y = 0.0402 + 0.0011x 	 r=0.999 
y = 0.0407 + 0.0013x 	 r=1.000 
y = -0.0300 + 0.0013x 	 r=0.986 
y = 0.0000 + 0.0014x 	 r=1.000 
y = 0.0805 + 0.0011x 	 r=0.972 
y = 0.0000 + 0.0011x 	 r=1.000 
Figure 8.11 	 Calibration curve of salbutamol in urine. Daily regression line equations and 
correlation coeficients from al curves used for analysis of samples are also 
shown. 
8.3.9 Hydrolysis of salbutamol and determination of the major metabolite of salbutamol 
The major metabolite of salbutamol, salbutamo1-4'-0-sulphate, was measured 
indirectly by subtracting the level of unchanged salbutamol from the total 
hydrolysed sample. Hydrolysis was performed enzymaticaly by incubating 
samples at 37°C with a mixture of p-glucuronidase (5.5 U/ml at 38°C; 
phenolphthalein-13-glucuronide as substrate) and arylsulphatase (2.6 U/m1 at 38°C; 
phenolphthalein disulphate as substrate) derived from helix pomatia. The 
hydrolysis procedure was similar to that used by Hildebrandt et al (1994) in the 
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analysis of fenoterol conjugates which was analogous to a method used for the 
analysis of ritodrine conjugates (Brashear et al, 1988). 
The time period necessary for hydrolysis was examined. The extraction procedure 
outlined in Section 8.3.8 was used to examine the salbutamol urine concentration 
in spot samples from both a community and a hospital patient. The community 
patient was a 13 year-old mild asthmatic with a reported salbutamol dosage of 
400 lig (via MDI) in the preceding 24 hours. The hospital patient was a 59 year-old 
severe asthmatic with a reported dosage of 20 mg (via nebuliser) in the preceding 
24 hours. Four 1 ml aliquots were taken from each sample and added to 500 pi of 
pH 8.1 phosphate buffer and 50 111 of internal standard solution. These samples 
were hydrolysed by addition of 50 pi of P-glucuronidase/arylsulphatase mixture 
and heated at 37°C in a water bath. Samples were removed from the water bath 
and extracted and analysed using the procedure outlined in Section 8.3.8, initally 
before hydrolysis and after 30 minutes, 1, 2 and 12 hours of incubation. 
Salbutamol:internal standard peak height ratios were compared with the non-
hydrolysed samples to determine an adequate hydrolysis time. 
A chromatogram of a urine sample from a community and hospital patient before 
and after 2 hours of hydrolysis is shown in Figure 8.12. The plot of measured free 
salbutamol (hydrolysed from salbutamol sulphate ester) versus hydrolysis time is 
shown in Figure 8.13 for both a community and hospital patient. This plot was 
used to determine an adequate time for hydrolysis. The levels of salbutamol in 
samples that were hydrolysed for 12 hours were unable to be measured because of 
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Figure 8.12 	 Overlayed chromatogram showing a community patient salbutamol sample before 
hydrolysis (1) and after 2 hours of hydrolysis (2) with a 90% increase in salbutamol 
kvels. 
Community Patient Sample 	 Hospital Patient Sample 
Figure 8.13 	 The efect of hydrolysis time on the amount of salbutamol measured in urine (shown 
here as drug / Ls. peak height ratio) from unchanged salbutamol eliminated by the 
kidneys as wel as salbutamol hydrolysed from the sulphate ester metabolite Error bars 
represent the intra-day coeficient of variation for hydrolysed samples (15.2%). 
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large co-eluting peaks, presumably from hydrolysis products from other urine 
constituents. 
A hydrolysis time of 2 hours was decided on for the analysis of the samples. More 
extensive hydrolysis appeared to produce interfering poorly chromatographed 
peaks and the hydrolysis appeared to be complete after 1 hour based on Figure 
8.13. The amount of hydrolytic enzyme added to the samples seemed adequate 
given that both the community and hospital sample (with a final salbutamol 
concentration approximately 70 times greater than the community sample) 
reached their peak at 1 hour. 
Hydrolysed spiked urine was examined to see if hydrolysis affected the calibration 
curve parameters. Spiked urine samples (92.4, 473 and 924 ng/ml) identical to those 
used for the calibration curve (Section 8.3.8) were added to 500 [II of pH 8.1 
phosphate buffer, 50 Ill of internal standard solution and 50 1.1.1 of 13- 
glucuronidase/arylsulphatase mixture. Samples were heated at 37°C in a water 
bath for 2 hours then extracted and analysed in an identical manner to that 
outlined in Section 8.3.8. These hydrolysed samples were compared with their 
non-hydrolysed counterparts (used for the calibration curve in Section 8.3.8 and 
analysed on the same day) for possible interference from either the (3- 
glucuronidase/arylsulphatase mixture or hydrolysis of endogenous compounds. 
The intra-day coefficient of variation for the hydrolysed samples was examined by 
hydrolysing five separate 473 ng/ml spiked urine samples. 
As mentioned above, the chromatography of the hydrolysed samples were less 
than ideal. As expected, this impacted on the intra-day coefficient of variation with 
an intra-day coefficient of variation of 15.2% (473 ng/ml), however, the 
hydrolysed spiked calibration samples were similar to their non-hydrolysed 
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counterparts (t =0.079, df = 2, p =0.942). An overlayed chromatogram showing a 
hydrolysed blank and spiked urine sample (473 ng/rnl) is shown in Figure 8.14. 
0.0 	 1:0 	 2:0 	 3.0 	 9.0 	 5.0 	 4.0 	 7.0 	 0.0 	 9.0 	 10.0 	 11.0 	 12.0 	 13.0 
Retention Time (minutes] 
Figure 8.14 	 Overlayed chromatogram showing a hydrolysed spiked urine sample (1) with 
473 ng/ml of salbutamol compared to a hydrolysed urine blank (2). Inset shows the 
salbutamol peak at a lower atenuation. 
8.4 	 DISCUSSION 
It was found that SPE can provide reasonable recoveries of salbutamol, a drug that 
is relatively dificult to extract from biological matrices given its relatively polar 
nature. The solid-phase sorbents provided greater recovery than liquid-liquid 
extractions from urine with a phenyl solid-phase sorbent giving the best clean-up 
and recovery for this application. The examination of drug retention on an 
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analytical column was found to be a useful tool in developing the overal SPE 
technique with regard to solvent compositions. 
Despite initial indications of levels of recovery around 70%, the final recovery was 
around a disappointing 50%, although this recovery was quite reproducible. The 
studies listed in Table 8.2 reported higher recoveries than in this current study, 
however, these studies were performed in plasma and recoveries of P-agonists can 
vary greatly between plasma and aqueous solutions (McCarthy et al, 1993). 
There was a major problem with interference in the chromatograms from poorly 
resolved co-elution peaks. This was particularly a problem with the hydrolysed 
samples. These interfering peaks were probably due to hydrolysed endogenous 
urinary compounds, both sulphate and glucuronide conjugates. This problem may 
have been reduced if arylsulphatase enzyme was used alone and not an 
arylsulphatase/13-g1ucuronidase mixture. Given that urine acts as a reservoir not 
only for drugs of interest but interfering compounds, a SPE technique procedure 
with more thorough sample clean-up would be preferable for further work in this 
area. 
8.5 	 CONCLUSION 
Further research would be wel served by using a more sensitive means of 
detection such as fluorescence detection which was unavailable in this laboratory 
at the time of this study. In addition, sample clean-up with the SPE technique 
requires further refinement if measurement of hydrolysed salbutamol is a 
requirement. Despite the shortcomings presented above, the calibration curve 
parameters presented here were satisfactory for the type of study described in the 
next chapter. 
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Investigation of Urinary Levels of Salbutamol in 
Asthmatic Patients 
9.1 SUMMARY 
Some studies have indicated that over-reliance on inhaled 13 2-agonist bronchodikztor therapy may worsen 
asthma control and increase morbidity. Urine levels of salbutamol were =mined as a potential indicator 
of over-use in asthmatic patients. Salbuktmol levels (unhydrolysed and hydrolysed)were measured in 'spot' 
urine samples in 102 asthmatic patients (64 community patients and 38 hospital in-patients) using the 
assay developed in the previous chapter. The correlation between levels and dosage in the preceding 24 
hours was =mined. Urinary levels were also corrected for dilution by expressing results per miligram of 
excreted creatinine. 
Median levels of unchanged and total drug were found to be 378 ng/ml (range 0-34.4 mg/ml) and 
255 g/ml (range 0-49.8 [ig/ml) for community and hospital groups respectively. When community and 
hospital groups were combinecl, modest correlations were found between salbuklmol levels and dosage 
(Spearman r=0.67 p< 0.005 and Spearman r =0.54, p< 0.005) for unchanged and total drug respectively. 
Correlations were only slightly improved when correcting for urinary dilution. The inter-patient 
diferences were large. Even when controling for dosage in the preceding 24 hours, there was a 380 and 
810-fold variation in levels for unchanged and total drug respectively. In addition there was evidence to 
suggest saturation of salbutamol metabolism at relatively low levels. Even when conceding the limitations 
of 'spot' urine analysis, the enormous inter-patient variability, which may be largely due to diferences in 
the pharmacokinetics and/or administration technique, may have clinical implications. Further work 
specificaly aimed at these findings is required to expand the work presented here. 
9.2 	 INTRODUCTION 
As discussed in Chapter 2, despite advances in drug therapy and delivery systems, 
asthma incidence and anti-asthmatic drug sales have increased in most 
industrialised countries over the last two decades (Barnes, 1988; Beasley et al, 1990; 
Hay and Higenbotam, 1987; Kluakka et al, 1991). Several studies have suggested a 
link between 13-agonist therapy and worsening of asthma symptoms and control 
(Sears et al, 1990; van Schayck et al, 1991; Spitzer et al, 1992). In addition, 13- 
agonists have been implicated in the asthma death epidemics in the United 
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Kingdom (isoprenaline) and fenoterol in New Zealand (Speizer et al, 1968; Pearce 
et al, 1990). 
Although there is no doubt that selective 132-agonists remain the most effective 
bronchodilators in acute asthma (Kemp, 1993) there have been concerns raised that 
this class of compounds may be over-used. It has been suggested in current 
management guidelines that there should be a greater emphasis on the earlier 
introduction of inhaled corticosteroids and less reliance on 13 2-agonists 
(Anonymous, 1992; Tse and Bridges-Webb, 1993). These issues were discussed in 
more detail in Section 2.5. 
Urine monitoring of salbutamol was investigated as a possible means of easily 
identifying over-use of 132-agonists in asthmatic patients. It has been noted 
previously that asthmatic patients appear to use more therapy than they admit to 
(Chryssidis et al, 1981; Horn et al, 1989). This study aimed to assess the inter-
patient variation of urinary salbutamol levels in a relatively large group of 
asthmatic patients. The correlation between reported dosage of inhaled drug and 
urine levels of salbutamol was examined to see whether monitoring urine levels 
would be of benefit in identifying those patients who may be over-using their 
medication. A single 'spot' urine sample was used to assess the urinary salbutamol 
level as multiple samples or measuring urine volumes would prove impractical in 
an out-patient community setting. 
Because the half-life of salbutamol is around 3-6 hours, it was decided that the 
dosage in the 24 hours preceding the urine sample would give a reasonable variable 
with which to correlate the urine data. Horn et al (1989) found that intervening 
micturition had little effect on measured salbutamol levels. Urinary levels were 
also found to be relatively constant for at least 4 hours after a single inhaled dose of 
salbutamol (Horn et al, 1989). Urinary levels of drug must not, however, be 
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considered equivalent to plasma levels with regard to the scope of obtainable 
pharmacokinetic parameters. The limitations of urinary data are discussed in 
Section 9.5. 
Urine levels of salbutamol would of course be subject to urinary dilution with the 
level determined by the degree of hydration and the urine volume. Biological 
monitoring of industrial solvents is widely used in the industrial health area to 
assess exposure of workers to solvents, usualy from pulmonary absorption. 
Because obtaining plasma samples for analysis of xenobiotics can be time 
consuming and levels can be influenced by peak exposures, 'spot' urine samples are 
often used to assess exposure (Bernard and Lauwerys, 1986). Results are typicaly 
corected for urine dilution by expression of the solvent metabolite found in urine 
per gram of creatinine, an endogenous waste product excreted in urine (Apostoli et 
al, 1982; Bernard and Lauwerys, 1986). The concentration of creatinine, like the 
metabolite of interest, varies with the degree of urine dilution. Regardless of 
dilution, the proportion of the metabolite of interest to creatinine remains 
unchanged. Urinary creatinine turnover is relatively constant over a wide range of 
renal damage and does not depend on urine flow rate or dietary protein intake 
(Koushanpour and Kriz, 1976). Urinary creatinine excretion does, however, vary 
with age and gender. Males aged 70-79 years excrete around 60% of the urinary 
creatinine of men aged 20-29 years and females excrete around 85% of the urinary 
creatinine of males (Kampmann et al, 1974). 
9.3 METHOD 
9.3.1 	 Patient recruitment and profiles 
Community patients were recruited by two means. Three government owned 
community health centres, each having several general practitioners, were 
contacted by telephone. A meeting was arranged to explain the project to the 
general practitioners working at the centres. A meeting was also organised at the 
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local university health centre. General practitioners were asked to briefly explain 
the project to asthmatic patients, obtain informed consent from the patient if they 
were interested in participating and fill in the brief questionnaire. A $5 
reimbursement was offered to each practice for each patient sample obtained. 
Questionnaire and informed consent forms were supplied to the practices as well 
as a supply 70 ml plastic sample bottles. 
Patients who agreed to participate (informed consent form shown in Appendix 3) 
were asked to provide details necessary for the questionnaire (Appendix 4) and a 
'spot' urine sample. It was requested that samples be provided by the patient at or 
as close to the time of the questionnaire interview as possible. To be eligible for 
recruitment into the project, patients must have used salbutamol by any means of 
administration within the previous 24 hours and be able to estimate their dosage. It 
was not feasible for patients to measure urine volume (allowing the amount of 
drug excreted to be calculated from volume and concentration), so only single 
'spot' samples were taken. 
Questionnaire forms included an assessment of disease severity based on 
bronchodilator use, patient history, peak expiratory flow rate and variability from 
current guidelines for asthma management (Tse and Bridges-Webb, 1993). The 
criteria for groupings are shown on the questionnaire form (Appendix 4). Most 
patients were grouped according to their patient history and bronchodilator use. 
Community patients were also recruited through advertisements in two local 
newspapers (Appendix 5) and posters placed on noticeboards around the 
University of Tasmania's Hobart campus (Appendix 6). Patients were asked to 
telephone the School of Pharmacy if interested in participating in the project. 
Appointments were made at either the School of Pharmacy or at the patient's 
home. Informed consent, questionnaire details and a fresh urine sample at the time 
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of interview were obtained from these patients. These patients were offered $5 
reimbursement for their time. Urine samples were frozen at -14°C until analysis. 
Hospital patients were recruited at the Royal Hobart Hospital by ward 
pharmacists identifying asthmatic inpatients prescribed salbutamol. In-patients 
identified as current salbutamol users were then approached and the project 
explained to each patient. If informed consent was given, patient details were 
obtained from the drug chart and the urine samples collected by the nursing staff, 
noting the time of sampling. Information sheets about the project were left on 
wards for the benefit of the nursing staff (Appendix 7). Drug charts were then 
examined retrospectively to obtain the dosage of salbutamol in the 24 hours 
preceding the sample. Four hospital patients who had been receiving large doses of 
salbutamol immediately prior to the 24 hours preceding the sample time were 
included in the study. Urine samples were frozen at -14°C until analysis. This 
project was approved by the Royal Hobart Hospital Research and Ethics 
Committees. 
9.3.2 Determination of salbutamol levels 
Salbutamol levels were determined by the assay developed in Chapter 8 and is 
summarised in Figure 9.1. Samples were gently thawed at room temperature ready 
for analysis. Samples were analysed in three batches on consecutive days with both 
salbutamol (unchanged) and total salbutamol (after enzymatic hydrolysis) being 
measured. Samples from patients using nebulised salbutamol were diluted 1:10 
with distilled water to assure the salbutamol level was within the calibration range. 
Other samples above the calibration range were appropriately diluted and re-
analysed. The urinary levels of the salbutamol metabolite were expressed as 
equivalent concentrations of salbutamol due to the nature of determination 
(unchanged salbutamol subtracted from total hydrolysed salbutamol) as discussed 
in Section 8.3.9. 
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Determination of unchanged salbutamol 
HYDROLYSIS 
Determination of total salbutamol 
50 s I of 13glucuronidase/arysulphatase mixture 
Incubation at 37*C for 2 hours 
1.Column conditioning:2x250t 1 methanol, 2x250 a 1 pH 8.1 phosphate bufer 
2.Sample introduced to 1 nil phenyl SPE column 
3.Column wash: 1x250 151 10% methanol in pH 8.1 phosphate bufer, 
1x250 sI 80% methanol in distiled water 
4.Sample elution with lx250g1 tetrahydrofuran 
Sample volume reduced under N2 
HPLC analysis with UV detection at 225 nm 
Urine Sample 
Community MDI patient 
Community nebuliser patient 
Hospital MDI patient 
Hospital nebuliser patient 
Aliquot diluted 1:10 with distiled water 
1 ml aliquot added to 500111 pH 8.1 phophate bufer and 50111 of internal standard solution 
Chapter 9 
Analysis 
Sample 
Preparation 
SPE 
technique 
Figure 9.1 	 Summary of the method of determination of urinary levels of salbutamol developed in 
Chapter 8 and used in Chapter 9. 
9.3.3 Determination of urinary creatinine 
The Jafe reaction (alkaline picrate) was the basis for measurement of urinary 
creatinine. Measurement was performed using a technique developed from Clarke 
and Thompson (1949) and Supaluknari et al (1987). A picric acid solution of 
13.60 g/1 in distiled water and a creatinine stock solution of 2.05 mg/ml in 0.1 N 
HC1 were prepared. The creatinine solution was then diluted 1:50 with distiled 
water to give a solution of 0.041 mg/ml. 
Picric acid was obtained from May and Baker Ltd., Dagenham, UK. Creatinine 
was obtained from Sigma Chemical Co., St. Louis, MO, USA. 
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This 1:50 dilution was then used to prepare calibration curve samples by taking 
aliquots of 10, 25, 50, 100, 250, 500 and 1000 ml and making up to 2.01 ml with 
distiled water (giving creatinine concentrations between 0.204 and 20.4 ilg/m1). 
An absorbance blank consisting of 2.01 ml of distiled water was also prepared. 
One mililitre of picric acid solution (13.60 g/l) and 500 1.1.1 of 1.4 N NaOH were 
added and the sample mixed with a vortex mixer. The sample was alowed to stand 
at room temperature for 15 minutes before the absorbance was read at 500 rim 
using a spectrophotometer (Spectronic 20, Bausch and Lomb, Rochester, NY, 
USA) against the absorbance blank. A calibration curve was then constructed and 
an intra-day coeficient of variation measured using samples containing 10.2 [tg/m1 
creatinine. 
Urine samples were diluted by adding 10 [11 of urine to 2 ml of distiled water. 
Analysis was then performed as for the calibration curve samples by adding 1 ml 
of picric acid solution (13.60 g/l) and 500 [II of 1.4 N NaOH and the sample mixed 
with a vortex mixer. The sample was alowed to stand at room temperature for 15 
minutes before the absorbance was read at 500 rim using a spectrophotometer 
(Spectronic 20, Bausch and Lomb) against the absorbance blank. 
9.3.4 	 Statistical analysis 
The statistical analyses were performed using Statview® 4.01 (Abacus Concepts 
Inc., Berkeley, CA, USA) for the Macintosh®. Non-parametric tests were used to 
examine both patient profiles and the relationships between levels of drug and 
metabolite with and without correction for urine dilution and reported dosage. 
The relationship between level and time since last dose was also examined in 
community patients. Urinary levels of salbutamol below the calibration limit of 
47.3 ng/ml were treated as 0 ng/ml for statistical purposes. 
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The relationship between the unchanged salbutamol level in urine corected for 
dose and creatinine clearance was examined to see if there was a link between renal 
function and urinary excretion of salbutamol. Serum creatinine levels were 
available close to the time of sampling for some hospital patients. Creatinine 
clearance was estimated using the Cockroft-Gault equation (Cockcroft and Gault, 
1976). 
9.4 	 RESULTS 
9.4.1 Patient recruitment and profiles 
One hundred and two patients were recruited, consisting of 64 community 
patients and 38 hospital in-Patients. There were 31 males and 33 females in the 
community group and 19 males and 19 females in the hospital group. There were 
no significant differences in either the disease severity or salbutamol dosage 
between genders. 
As would be expected, the hospital group were generaly older (Table 9.1), had 
greater disease severity (chi-square =36.4, df =2, p <0.005), received more 
salbutamol (Table 9.2) and were more likely to be receiving prophylactic therapy 
(chi-square= 10.4, df =1, p <0.005). The diferences in dosage are also shown in 
Figure 9.2. The community group consisted of 24 (38%) mild asthmatics, 29 (45%) 
moderate asthmatics and 11(17%) severe asthmatics. The hospital group consisted 
of 10 (26%) moderate asthmatics and 28 (74%) severe asthmatics. Thirty-eight 
(59%) of the community patients and 34 (89%) of the hospital patients were 
receiving prophylactic medication. 
The patients receiving prophylactic therapy were more likely to have greater 
disease severity (chi-square =27.5, df =2, p <0.005). Of the 30 patients not receiving 
prophylactic therapy, 17 (57%) were mild asthmatics, 9 (30%) moderate asthmatics 
and 4 (13%) severe asthmatics. Of the 72 patients receiving prophylactic therapy, 7 
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(10%) were mild asthmatics, 30 (42%) moderate asthmatics and 35 (49%) severe 
asthmatics. Because of the hospital patient characteristics (older patients with 
greater disease severity), it is not surprising that the patients receiving prophylactic 
therapy were more likely to be older (Table 9.3) and be taking higher doses of 
salbutamol (Table 9.4). 
Community Patients 	 Hospital Patients 
40 
30 
r; 20 
10 
  
t.t 	 C.! 
C•3 C O a 0.1 
CO •O• OA 03 
Dose in Preceding 24 hours (mg) 
Dose in Preceding 24 hours (mg) 
Figure 9.2 	 Distribution of salbutamol dosages for community and hospital patients. 
The patients using a nebuliser were more likely to be from the hospital group (chi-
square = 56.8, df =1, p < 0.005) with greater disease severity (chi-square = 49.5, df =2, 
p < 0.005). In addition, patients with more severe disease were more likely to be 
receiving higher dosages of salbutamol (Table 9.5) and were more likely to have 
had previous admissions to hospital with acute asthma in the past year (Table 9.6) 
Table 9.1 	 Diferences in age between community and hospital groups. 
n 	 Median (Range) years Mann-Whitney U 	 z 	 P Community 	 64 	 25.5 (11-77) 	 362 	 -5.92 	 <0.005 
Hospital 	 38 	 64 (18-83) 
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Table 9.2 
Table 9.3 
Diferences in salbutamol dosage (over the 24 hours prior to sample) between 
community and hospital groups. 
n Median (Range) tig 	 Mann-Whitney U 	 z 	 P 64 	 400 (100-15,000) 	 218.5 	 -6.74 	 <0.005 
36 	 20,000 (0-50,000) 
Diferences in age between patients receiving or not receiving prophylactic therapy. 
Community 
Hospital 
Prophylaxis 
No 
Yes 
 
• Median (Range) years 
30 	 21(18-74) 
72 	 61(11-83) 
Mann-Whitney U 
560 	 -3.82 	 <0.005 
 
Table 9.4 	 Diferences in salbutamol dosage (over the 24 hours prior to sample) between patients 
receiving or not receiving prophylactic therapy. 
Prophylaxis 
No 
Yes 
 
• Median (Range) tg 
30 	 300 (0-20,000) 
70 	 1,500 (0-50,000) 
Mann-Whitney U 
479 
  
  
-4.32 	 <0.005 
Table 9.5 	 Diferences in salbutamol dosage (over the 24 hours prior to sample) with disease 
severity. 
Severity 
Mild 
Moderate 
Severe 
 
• Median (Range) pg 
24 	 200 (100-1,000) 
38 	 800 (0-20,000) 
38 	 20,000 (400-50,000) 
 
Kruskal-Walis H 
59.4 
  
   
<0.005 
Table 9.6 	 Diferences in hospital admissions due to asthma in the last year with disease severity. 
Severity 
Mild 
Moderate 
Severe 
 
Median (Range) 
• number of admissions 
24 	 0 (0-0) 
39 	 0 (0-1) 
39 	 1(0-5) 
 
Kruskal-Walis H 
41.0 
  
   
<0.005 
9.4.2 	 Salbutamol levels 
The chromatograms for salbutamol in urine and hydrolysed salbutamol in urine 
are shown in Figures 9.3 and 9.4 respectively. The calibration curve and 
reproducibility parameters are outlined in Section 8.3.8. As stated in Section 8.3.8, 
the assay was not ideal with low sensitivity and interfering peaks a major problem, 
especialy with the hydrolysed samples. The salbutamol peaks were unresolvable 
for 17 unhydrolysed samples (3 community, 14 hospital) and 52 hydrolysed 
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samples (35 community, 17 hospital). Individual levels of salbutamol and 
metabolite together with patient profiles are shown in Appendix 8. 
The calibration curve for the measurement of creatinine in urine is shown in 
Figure 9.5. The intra-day coeficient of variation was found to be 2.1%. The range 
of the calibration curve was 204 ng/ml to 20.4 mg/mi. 
00 	 1.0 	 2.0 	 3.0 	 1.0 	 5.0 	 6.0 	 1.0 	 0.0 	 9.0 	 1.0 	 11.0 	 12.0 	 1 .0 
Retention Time (minutes) 
Figure 9.3 	 Chromatogram of a urine sample from a community patient (2) showing salbutamol 
(1261 ng/ml) and fenoterol internal standard (LS.) compared with a blank sample 
spiked with I.S. (1). 
The median level of unchanged salbutamol in urine was 378 ng/ml (range 0- 
34.4n/m1) and the median level of total drug (consisting of unchanged drug and 
metabolite) was 2552.4 ng/ml (range 0-49.8 Ag/m1). The community group had 
lower levels of unchanged drug (median 246.7 ng/ml; range 0-4713.8 ng/m1) than 
the hospital group (median 3.061 vg/m1; range 0.471-34.4 tig/m1), as would be 
expected from the diferences in dosage (Table 9.2). 
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Time since last dose (within 24 hours preceding the sample) was examined in 
community patients to see if this variable significantly afected the levels reported 
in the urine. There were no significant corelations between time since last dose 
and either salbutamol, metabolite or total levels corected for dose for either the 
community patients or those community patients using MDIs only. Similarly 
there were no correlations between time since last dose and either salbutamol, 
metabolite or total levels corected for both urinary dilution and dose for either 
the community patients or those community patients using MDIs only. Al 
Spearman r values were less than ±0.14. Time since last dose was not examined in 
hospital patients as dosing was more frequent. 
00 	 10 	 2:0 	 3:0 	 40 	 5:0 	 6:0 	 7:0 	 4:0 	 90 	 leo 	 1.40 
Retention Time (minutes) 
Figure 9.4 	 Chromatogram of a urine sample from a community patient after hydrolysis (2) 
showing salbutamol (767 ng/ml) and fenoterol internal standard (LS.) compared with a 
blank sample spiked with LS. (1). 
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Figure 9.5 	 Calibration curve for measurement of creatinine in urine. 
Urinary creatinine levels were also examined. It was found that creatinine levels in 
the community group were higher than the hospital group (Table 9.8). There was 
a negative corelation between age and creatinine level in urine (Spearman r=-0.38, 
n=102, p <0.005). There were no significant differences in creatinine levels 
between males and females. 
Table 9.7 	 Diferences in unchanged salbutamol levels between community and hospital patients. 
Median (Range) 
ng/ml 	 Mann-Whitney U 	 z 
Community 	 61 	 246.7 (0-4,713.8) 	 79 	 -6.38 	 <0.005 
Hospital 	 24 	 3061 (471-34,400) 
Table 9.8 	 Diferences in urinary creatinine levels between community and hospital patients. 
Median (Range) 
ng/ml 	 Mann-Whitney U 	 z 
Community 	 64 	 1.44 (0.216-5.23) 	 736.5 	 -3.32 	 <0.005 
Hospital 	 38 	 0.701 (0.25-3.52) 
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There was a weak correlation between salbutamol dosage in the preceding 24 
hours and unchanged salbutamol urine level for the community (Spearman 
r=0.42, n=61, p <0.005) group but no significant correlation within the hospital 
group (Spearman r=0.33, n=24, p=0.11). This is shown in Figure 9.6. The 
correlations between salbutamol dosage in the preceding 24 hours and unchanged 
salbutamol urine level were not improved for the community patients using MDI 
only (Spearman r=0.33, n=56, p=0.01) or hospital patients using nebuliser only 
(Spearman r=0.30, n=20, p =0.19). 
There were no positive correlations between the urinary level of the salbutamol 
metabolite (calculated as the equivalent weight of salbutamol) and dosage in the 
preceding 24 hours for either the community (Spearman r=-0.09, n=29, p=0.64) 
or hospital groups (Spearman r=-0.57, n=21, p=0.01) as shown in Figure 9.7. 
Again the correlations were not improved for the community patients using MDI 
only (Spearman r=-0.05, n=27, p=0.78) or hospital patients using nebuliser only 
(Spearman r=-0.44, n=16, p=0.09). 
No significant correlations were found between total salbutamol (salbutamol and 
metabolite) and dose for either the community (Spearman r=0.03, n=29, p=0.88) 
or hospital (Spearman r=-0.37, n=20, p=0.11) groups as shown in Figure 9.8. 
There were no significant correlations between salbutamol dosage in the preceding 
24 hours and total salbutamol urine level for the community patients using MDI 
only (Spearman r=0.01, n=27, p=0.98) or hospital patients using nebuliser only 
(Spearman r=-0.18, n=16, p=0.49). 
After correction for urinary dilution by expression of results per gram of 
creatinine, the correlations were still poor with large variation between dose and 
urine levels. There was a modest improvement in the correlation between 
salbutamol dosage in the preceding 24 hours and unchanged salbutamol per 
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milligram of creatinine in urine for the community group (Spearman r —0.50, 
n=61, p < 0.005) but not the hospital group (Spearman r = 0.23, n=24, p =0.27). 
This is shown in Figure 9.9. The correlations between salbutamol dosage in the 
preceding 24 hours and unchanged salbutamol urine level (corrected for urinary 
dilution) were not improved for the community patients using MDI only 
(Spearman r=0.41, n=56, p <0.005) but were improved slightly for the hospital 
patients using nebuliser only (Spearman r=0.26, n= 20, p =0.27). 
There were no positive correlations between the urinary level of the salbutamol 
metabolite (calculated as the equivalent weight of salbutamol) per milligram of 
creatinine and dosage in the preceding 24 hours for either the community 
(Spearman r=-0.02, n=29, p =0.92) or hospital patients (Spearman r=-0.47, n=21, 
p =0.04), as shown in Figure 9.10. There were no correlations between salbutamol 
dosage in the preceding 24 hours and salbutamol metabolite in urine (corrected for 
urinary dilution) for the community patients using MDI only (Spearman r=-0.02, 
n=27, p =0.93) or hospital patients using nebuliser only (Spearman r=-0.34, n=16, 
p = 0.18). 
No significant correlations were found between total salbutamol (salbutamol and 
metabolite) per milligram of creatinine for either the community (Spearman 
r=0.11, n=29, p=0.57) or hospital groups (Spearman r=-0.28, n=21, p=0.23) as 
shown in Figure 9.11. Similarly there were no significant correlations between 
salbutamol dosage in the preceding 24 hours and total salbutamol in urine 
(corrected for urinary dilution) for the community patients using MDI only 
(Spearman r=0.05, n=29, p=0.81) or hospital patients using nebuliser only 
(Spearman r=-0.21, n=16, p =0.41). The fact that there were several negative 
correlations highlights the large scatter associated with these comparisons. 
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When the hospital and community data were pooled as one group, giving a wider 
range of dosages and levels, the correlations between dosages and levels did 
improve. There were significant correlations between dosage in the preceding 24 
hours and salbutamol level (Spearman r=0.67, n=85, p <0.005), salbutamol 
metabolite level (Spearman r=0.35, n=49, p=0.01) and total (salbutamol and 
metabolite) recovered drug (Spearman r=0.54, n=49, p < 0.005). After correction 
for urine dilution, there were correlations between dosage in the preceding 24 
hours and salbutamol level (Spearman r=0.69, n=85, p <0.005), salbutamol 
metabolite level (Spearman r=0.41, n=49, p < 0.005) and total (salbutamol and 
metabolite) recovered drug (Spearman r=0.57, n=49, p < 0.005). The correlations 
were slightly stronger after correction for dilution, however, there was still a 
relatively large scatter. 
The percent of total recovered drug excreted as the metabolite was also examined. 
While the median percentage of total recovered drug as the metabolite was lower 
in the group that had used a nebuliser in the previous 24 hours compared to those 
who had not used a nebuliser the difference was not significant (Table 9.9). There 
was a weak negative correlation between total dose in the preceding 24 hours and 
the percent of total recovered drug excreted as metabolite for hospital and 
community groups combined (Spearman r=-0.29, n=46, p=0.05) and the 
community patients using MDIs only (Spearman r=-0.44, n=24, p=0.04), but not 
quite significant for hospital patients using nebuliser only (Spearman r=-0.49, 
n=16, p =0.06). This is shown in Figure 9.12. 
The relationship between amount of unchanged salbutamol divided by dose and 
estimated creatinine clearance was also examined (shown in Figure 9.13). There 
was no correlation with renal function and urinary excretion of salbutamol 
(Spearman r=-0.10, n=11, p=0.77). There were no significant 
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community/hospital diferences in salbutamol urine level corrected for dose as 
shown in Table 9.10. 
Table 9.9 	 Diferences in percentage of total recovered drug as metabolite between patients who 
had used a nebuliser in the previous 24 hours and those who had not 
Median (Range) 
Nebuliser use in 	 % of total recovered drug 
previous 24 hours? 	 n 	 as metabolite 	 Mann-Whitney U 	 z 	 P Yes 	 18 	 70.3 (0-95) 	 225.5 	 -0.78 	 0.44 
No 	 29 	 84.0(0-100) 
Table 9.10 	 Diferences in salbutamol urine level corrected for dosage between hospital and 
community patients. 
Median (Range) 
salbutamol level (ng/ml) 
divided by dosage (n) 	 Mann-Whitney U 
Community 	 61 	 0.42 (04.71) 	 559 	 -1.16 	 0.25 Hospital 	 22 	 0.25 (0.16-6.04) 
The inter-patient variation between urine level of unchanged drug, metabolite and 
total level corected for dosage in preceding 24 hours was examined. It was found 
that even when controling for stated dosage in the preceding 24 hours there were 
large variations up to around 400-fold in salbutamol levels, 1200-fold in metabolite 
levels and 800-fold in total levels (Table 9.11). Inter-patient variability between 
patients using MDI only and those using nebulised drug only was also examined. 
Variability, although reduced to some extent, remained relatively large (over 40- 
fold variation in salbutamol level corected for dosage in patients using MDI only 
and over 100-fold for patients using nebulised drug only), as shown in Table 9.11. 
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Table 9.11 	 Variation in urine levels, urine levels corrected for dosage in preceding 24 
hours and urine levels corrected for dilution. Variation calculated as maximum level 
divided by lowest detected level above the detection limit. Also shown is community 
inter-patient variation with patients taking MDI only and hospital inter-patient 
variation with those patients using nebulised salbutamol only. 
Variation in salbutamol urine levels 
Salbutamol Metabolite Total (salbutamol +metabolite) 
Community 93-fold 85-fold 15-fold 
Hospital 73-fold 19-fold 12-fold 
Community (MDI) 92-fold 85-fold 91-fold 
Hospital (Neb) 73-fold 18-fold 10-fold 
Variation in salbutamol urine levels corected for dosage 
Salbutamol 	 Metabolite 	 Total (salbutamol +metabolite) 
Community 262-fold 1028-fold 810-fold 
Hospital 378-fold 1170-fold 451-fold 
Community (MDT) 40-fold 241-fold 177-fold 
Hospital (Neb) 107-fold 69-fold 43-fold 
Variation in salbutamol urine levels corected for urine dilution 
Salbutamol 	 Metabolite 	 Total (salbutamol +metabolite) 
Community 319-fold 63-fold 100-fold 
Hospital 205-fold 36-fold 25-fold 
Community (MDI) 319-fold 63-fold 100-fold 
Hospital (Neb) 205-fold 24-fold 25-fold 
Variation in urine levels corected for urine dilution and dosage 
Salbutamol 	 Metabolite 	 Total (salbutamol +metabolite) 
Community 976-fold 549-fold 400-fold 
Hospital 747-fold 2049-fold 955-fold 
Community (MDI) 174-fold 146-fold 96-fold 
Hospital (Neb) 305-fold 146-fold 69-fold 
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Community Patients 
Dose In Preceding 24 hours (mg) 
Hospital Patients 
Dose In Preceding 24 hours (mg) 
Figure 9.6 	 Relationship between salbutamol concentration in urine and dose in the preceding 24 
hours for both community (Spearman r=0.42, p< 0.005) and hospital (Spearman 
r=0.33, p=0.11)patients. 
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Figure 9.7 	 Relationship between salbutamol metabolite concentration in urine and dose in the 
preceding 24 hours for both community (Spearman r=-0.09, p= 0.64) and hospital 
(Spearman r=-0.57, p= 0.01) patients. Salbutamol metabolite expressed as pg of 
equivalent salbutamol. 
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Community Patients 	 Hospital Patients 
Figure 9.8 	 Relationship between the concentration of total salbutamol (salbutamol + metabolite) 
recovered in urine and dose in the preceding 24 hours for both community (Spearman 
r =0.03, p= 0.88) and hospital (Spearman r=-O.37, p=al) patients. 
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Dose In Preceding 24 hours (mg) 
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Figure 9.9 	 Relationship between salbutamol in urine corrected for dilution (per mg of creatinine) 
and dose in the preceding 24 hours for both community (Spearman r=0.50, p< 0.005) 
and hospital (Spearman r=0.23, p=0.27) patients. 
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Community Patients 
Dose In Preceding 24 hours (mg) 
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Figure 9.10 	 Relationship between salbutamol metabolite in urine corrected for dilution (tier mg of 
creatinine) and dose in the preceding 24 hours for both community (Spearman r=•0.02, 
p= 0.92) and hospital (Spearman r= -0.47, p= 0.04) patients. Salbutamol metabolite 
expressed as tig of equivalent salbutamot 
Community Patients 	 Hospital Patients 
Figure 9.11 	 Relationship between total salbutamol (salbutamol + metabolite) in urine corected for 
dilution (per mg of creatinine) and dose in the preceding 24 hours for both community 
(Spearman r =an, p=0.57) and hospital (Spearman r=-0.28, p =0.23) patients. 
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Figure 9.12 . 	 Relationship between percent of recovered drug as metabolite and dose in the preceding 
24 hours. 
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9.5 	 DISCUSSION 
The recruitment of patients, especialy community patients, was surprisingly 
dificult given the widespread knowledge and incidence of the disease. Recruitment 
of community patients initialy relied on general practitioners to obtain patient 
consent, questionnaire details and a urine sample. Despite initial assurances of large 
recruitment numbers and many telephone cals to remind general practitioners, 
this avenue proved unsatisfactory. The time involvement appeared to be the main 
reason general practitioners failed to recruit suficient numbers of patients, with 
the $5 reimbursement proving an inadequate incentive. Around 50% of 
community patients were recruited from the advertisement placed in the local 
newspapers. This avenue proved to be the most effective means of patient 
recruitment for this study. 
The methods of recruiting community patients may have lead to this sample being 
somewhat unrepresentative of the community as a whole. The usage of salbutamol 
by community patients in this study was compared with a study by Westley-Wise 
et at (1993) which examined 319 pharmacy clients receiving 32-agonists in NSW. It 
was found that 44% of patients were prescribed less than or equal to 200 pg/day, 
30% prescribed greater than 200 pg/day and less than or equal to 600 pg/day and 
26% prescribed greater than 600 tig/day. Almost 60% of patients had been 
prescribed prophylactic therapy in the previous year. 
In this curent study, the 28%.of the community patients reported taking less than 
or equal to 200 ,ug/day of salbutamol, 28% received greater than 200 ,ug/day and 
less than or equal to 600 ug/day and 44% received greater than 600 pg/day. Of the 
64 community patients, 59% were currently taking prophylactic therapy. The 
community patients in this current study appear to have reported taking higher 
dosages of salbutamol than pharmacy clients in the study by Westley-Wise et at 
(1993). Previous studies have suggested that patients use more (32-agonists than they 
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admit or are prescribed (Chryssidis et al, 1981; Horn et al, 1989). This may account 
for the higher reported dosage seen in this study compared to the prescribed 
dosage reported by Westley-Wise et al (1993). 
The majority of patients in this study were either using salbutamol from MDI or 
nebuliser. One hospital patient (patient 69; Appendix 8) was using MDI in 
conjunction with a volumetric spacer but had not used it in the previous 24 hours. 
No patients reported using DPIs. 
As expected, the community patient group was quite different to the hospital 
patient group. It has been shown in Section 9.4 that hospital patients tended to be 
older, have more severe disease, were more likely to be receiving prophylactic 
medication, were receiving higher dosages of salbutamol and had lower creatinine 
excretion rates than the community group. For this reason, the community and 
hospital groups were treated as two distinct groups with regard to correlation data 
and inter-patient variability which is discussed later. 
Obviously the large numbers of unresolvable salbutamol peaks in the urine sample 
chromatograms was disturbing and reflected a major limitation of the assay. As 
discussed in Section 8.5, sample recovery, clean-up and detector sensitivity were 
relatively poor. Ideally, a more sensitive detection method such as fluorescence 
detection should have been used, however, this equipment was unavailable in this 
laboratory. Hydrolysis of urine samples also posed difficulties with large co-eluting 
peaks, presumably from endogenous urine products, that may not have been 
present to the same extent in plasma. This study did not examine the (+) and (-) 
salbutamol isomers but the racemic mixture. Pharmacokinetic differences between 
the isomers are discussed in Chapter 7. 
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The median free salbutamol levels from the community group were of a similar 
magnitude to that found by Horn et al (1989) and Horn et al (1990). The median 
salbutamol level of the community group in this current study was 246 ng/ml with 
a median dose of 400 ,ug over the preceding 24 hours. Horn et al (1989) found that 
previously healthy subjects with no recent drug exposure who had taken 200 jug of 
salbutamol had levels of around 100 ng/ml in urine for up to 4 hours after dosing. 
Horn et al (1989) also found that asthmatic patients who had reported taking 
200 ,ug of salbutamol on the same day prior to their sample had urine levels around 
200 ng/ml. Horn et al (1990) found that patients taking 1600 ,ug a day had median 
levels around 500 ng/ml. The median salbutamol level for patients in the hospital 
group in this current study was 3.1 ,ug/m1 with a median nebulised dosage of 
20 mg over the preceding 24 hours. These values were also similar to Horn et al 
(1990) who found that in a group of patients taking 8 mg of salbutamol per day 
(via specially prepared Rotacaps®), median urine levels of salbutamol were 
962 ng/ml. 
In this study urine volume determination, viewed as time consuming and messy, 
was not performed for two reasons. Firstly there was a relatively large number of 
patients, various settings, and sample collection relied heavily on help from people 
not directly involved in the study such as nurses and general practitioners. 
Secondly, the study aimed to examine if a single 'spot' urine sample was of benefit 
in identifying possible over-use of salbutamol. It was anticipated that this should 
be a quick test in an out-patient setting for maximum compliance. 
Unfortunately this meant that the determination of the actual amount of drug and 
metabolite excreted (calculated from concentration in a given volume) was not 
possible. A single concentration of drug in urine is obviously dependent on urine 
volume. Typical daily volumes of urine are around 1.2 litres but may vary between 
0.3 to 2.7 litres per day for adult males and females (Liappis, 1973). This variation 
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would be expected to affect the concentration of the metabolite or drug by a 
similar amount. 
The correlations between reported total dose in the preceding 24 hours and 
urinary salbutamol, metabolite and total levels were disappointing although most 
were statistically significant. This was not totally unexpected given the possible 
inter-patient variability in urine volumes, administration technique and 
pharmacokinetics. There was no indication of significant correlation between time 
since last dose (within 24 hours prior to the sample being taken) and either 
salbutamol level corrected for total dosage in the preceding 24 hours or salbutamol 
level corrected for total dosage in the preceding 24 hours and urinary dilution. 
From this it appears that total dosage within a 24 hour period may be a valid 
measure of 'average' exposure to salbutamol. 
As mentioned earlier, when monitoring levels of solvent metabolites in exposed 
workers, single 'spot' urine samples are often taken for convenience without 
measuring total urine volume (Bernard and Lauwerys, 1986). In an attempt to 
control for the effect of urine dilution, levels are usually expressed per gram of 
creatinine (Apostoli et al, 1982; Bernard and Lauwerys, 1986). Creatinine is an 
endogenous product . excreted from the kidneys in relatively constant amounts 
(Koushanpour and Kriz, 1976). Because the creatinine is diluted in urine to the 
same extent as the metabolite or drug, the effect of urine dilution is reduced. 
Creatinine excretion does decline with age (Kampmann et al, 1974). This effect is 
not so important with workers who are typically less than 60-65 years but 
becomes more significant in this study where older patients, in particular the 
hospital patient group, were compared with younger patients. Another limitation 
with the creatinine method used is this study it that the Jaffe reaction (alkaline 
picrate) is not entirely specific for creatinine. Glucose, aceto-acetic acid, acetone, 
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ascorbic acid and pyruvate can all potentially interfere with this colourimetric 
assay (Lentner, 1984). 
There was only a modest improvement in correlation between salbutamol in urine 
expressed per gram of creatinine and dose in the preceding 24 hours for 
community patients compared to the samples not corrected for urinary dilution. 
When community and hospital patients were combined as one group, the 
correlation between salbutamol level corrected for urinary dilution and dose in 
preceding 24 hours was slightly improved for unchanged salbutamol, salbutamol 
metabolite and total salbutamol. The community and hospital groups were 
distinctively different with regard to dosages, levels and creatinine excretion so 
these improvements in correlation when the two groups are combined together 
should be viewed with caution. 
Dosages in the preceding 24 hours were as reported by the community patients 
and may not have been accurate estimations. In the past it has been frequently 
noted that patients are unreliable with reporting dosages accurately (Sackett and 
Snow, 1979). Despite relying on community patients accurately reporting their 
dose of drug in the preceding 24 hours, it is unlikely that this was a major factor in 
the poor correlation. There were poor correlations between measured salbutamol, 
metabolite and total levels in urine and reported dose in the preceding 24 hours for 
both the community and hospital groups. The dose for the hospital patients was 
taken retrospectively from drug charts and did not rely on patients accurately 
reporting their dosage like the community groups, yet there was still large 
variation. Therefore it was most likely that the poor correlations were real and due 
to variations in the measured levels rather than errors in the reported dosages. 
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It is suggested that despite these limitations, correction for urinary dilution by 
expressing the level of drug per gram of creatinine may have a role in 'spot' sample 
testing of compliance. 
There was a surprisingly large inter-patient variation between levels especially after 
correction for dosage (Table 9.10). The variation was large for both community 
and hospital patients which suggests that this variation is not due to inaccurate 
reporting of dosage. 
Urine volume is increased with high water and salt intake and a protein rich diet; 
low water intake, a diet rich in carbohydrates and profuse sweating can lower 
urine volume (Lentner, 1981). As mentioned earlier urine volume can vary from 
around 0.3 to 2.7 litres per day for adult males and females (Liappis, 1973). This is a 
variation of around 10-fold which would reflect a variation in concentration of 
salbutamol of around 10-fold. Even when accounting for this 10-fold variation, the 
inter-patient variation still remains large. Inter-patient variation in urinary dilution 
or time since last dose (within the preceding 24 hours) could not account for the 
large variations alone. 
Differences in dose related to the route of administration may be responsible for 
some of the variability observed since a typical nebulised dose is around 10 times 
higher than MDI (Newman, 1985). However, even when comparing the variability 
within community patients using MDI only and hospital patients using nebuliser 
only, there is still a large variation. The inter-patient variation in level divided by 
dose in community patients reportedly taking MDI only was 40-fold and variation 
in hospital patients using nebuliser only was 108-fold. Even more surprising is that 
fact that these variations do not take into account those patients with levels below 
the detection limit. It would be expected that the variation would be even greater 
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if the detection limit was lower as several community patients had levels below the 
detection limit. 
This large inter-patient variation is most likely due to a combination of differences 
in pharmacokinetics, administration technique and urinary dilution. It has been 
noted previously that there are large inter-patient variations in plasma 
concentrations of salbutamol required to produce similar responses (Morgan, 1990; 
Penna et al, 1993). Even in the same individual, responsiveness can decrease with 
time during continuous therapy (Morgan, 1990). Therapeutic response and onset 
of side effects is therefore often a better indicator of required dose than plasma 
levels (Morgan, 1990). 
The median percent of recovered dose excreted as metabolite in patients using 
nebuliser was 70% compared to 84% for those using MDI. This compares with 
Morgan et al, (1986) who found approximately 60% of recovered dose excreted as 
metabolite in patients taking oral salbutamol. The median levels in this study are 
generally higher and are likely to be due to limitations of the assay of hydrolysed 
samples including the reduced sample size due to unresolvable salbutamol peaks. 
Patients using nebuliser (with higher doses than MDI) had a lower median 
percentage of total recovered drug excreted as metabolite compared to patients 
using MDI, however, the difference was not significant (Table 9.9). It has been 
previously reported that the metabolite to unchanged drug ratio in plasma and 
urine following nebuliser use is less than with oral or MDI administration 
(Morgan, 1990). It has been suggested that this is due to a greater proportion of the 
dose being absorbed by the lungs and not swallowed via nebulised administration 
compared to MDI administration (Shenfield et al, 1974; Morgan, 1990). With less 
dose absorbed orally, the fraction of drug that undergoes first-pass metabolism is 
reduced, hence the metabolite to unchanged drug ratio is lower. There is some 
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evidence in this current study to suggest that the lower metabolite to unchanged 
drug ratio seen with nebulised therapy may also be caused by dose related 
metabolism effects. 
There were indications that the percent of dose recovered as metabolite decreased 
with increasing dosage, not just in comparison between MDI and nebulised drug 
users but also in community patients using MDI alone. In addition, there was 
almost a significant relationship in hospital patients using nebuliser only. A low 
fraction of the dose recovered as the metabolite in urine implies a low fraction as 
the metabolite in the body. This evidence would seem to indicate possible 
saturable metabolism of salbutamol. If saturation is in fact occurring, observed 
higher proportions of unchanged drug in plasma or urine following nebulised 
administration may not indicate more efficient pulmonary delivery via nebuliser 
but could be due to saturated sulphation of salbutamol. 
Extensive literature searches have shown that there has been little study into 
possible saturation of sulphation pathways with salbutamol. Saturation of 
sulphation pathways has been well documented in animals with drugs such as 
salicylamide and paracetamol, both in vivo and in vitro (Kane et al, 1991; Pang et 
al, 1994). It has also been shown that there are differences in saturation between 
the gut wall and liver (Goon and Klaassen, 1990). The possible saturation seen here 
with salbutamol is at a much lower concentration than would normally be 
associated with saturation of the sulphation pathway observed in the studies 
shown above. More work in this area is required to confirm that there is in fact 
saturation at low doses and if so, the therapeutic consequences. 
As discussed in Chapter 7, there are large variations in reported pulmonary 
deposition of MDI, DPI and nebulised salbutamol. It is well documented that 
variation is affected by factors such as technique, mode of delivery and disease 
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severity. It seems unlikely that these variations in pulmonary deposition of drug 
combined with variability in the assay, urine volumes and patient reporting of 
dosage could alone account for all of the total inter-patient variability in urinary 
levels of salbutamol seen in this study. 
This study suggests that inter-patient pharmacokinetic differences (for example 
saturable metabolism) and differences in administration technique may play a 
major part in the overall variability. Does this have any bearings on studies 
showing worsening of asthma symptoms with regular use of inhaled (3 2-agonists? 
As Morgan (1990) pointed out, plasma levels are not an important parameter with 
which to adjust dosage as there is very large inter-subject variation in levels 
required to produce the same response. This study has also clearly shown large 
inter-patient variations in urinary levels corrected for dosages. This suggests that a 
dose that may be satisfactory for one patient may be unsatisfactory for another 
(due to differences in administration technique and/or pharmacokinetics) and has 
more widespread implications. 
It has been shown that regular use of salbutamol can worsen asthma control (Sears 
et al, 1990; van Schayck et al, 1991). In the study by van Schayck et al (1991), a 
patient group taking continuous salbutamol with a strict regimen of salbutamol 
400 tg four times daily from DPI was compared with patients taking treatment on 
demand. A large number of patients taking continuous therapy withdrew from the 
study because of insufficient bronchodilator treatment. In addition, lung function 
was worse in the continuous treatment group compared to the treatment on 
demand group. Given the large inter-patient variation seen here (due to differences 
in administration technique and/or pharmacokinetics), it is possible that the 
1600 ig of salbutamol per day did not provide plasma levels adequate to control 
symptoms in some patients in the study by van Schayck et at (1991). Inadequate 
asthma control may have been caused, not by drug related increases in disease 
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severity as suggested by van Schayck et al (1991), but due to an inadequate amount 
of drug exerting a pharmacological effect. 
In the study by Sears et al (1990), patients were taking either continuous fenoterol 
400 lig four times daily from DPI or placebo with extra bronchodilator therapy if 
needed, then after 24 weeks treatment groups were crossed-over. It was found that 
asthma control was better in the period of taking placebo with extra 
bronchodilator therapy as required. As in the study by van Schayck et al (1991) 
inadequate asthma control with continuous therapy in some patients may have 
been caused, not by drug related increases in disease severity but due to an 
inadequate amount of drug exerting a pharmacological effect due to inter-patient 
differences in pharmacokinetics. 
Sears et al (1990) did find the average daily use of supplementary bronchodilators 
during the placebo period did not exceed the combined use of supplementary 
bronchodilator and fenoterol therapy during the continuous treatment phase for 
any patient. However, this result may have been confounded as patients taking 
placebo plus supplementary bronchodilators may have been reluctant to use 
supplementary bronchodilation for fear of 'over-using' their medication because 
they believed the placebo DPI to be active drug. 
Both of these studies mentioned above should be re-examined in light of the large 
inter-patient differences that have been observed here. Future studies examining 
regular versus as needed bronchodilator therapy should be designed to reduce any 
error brought about by differences in pharmacokinetics and/or administration 
technique and the variation in drug levels that these bring. Ideally, plasma levels of 
(32-agonists should be measured in these studies. 
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As stated earlier, there are severe limitations with the reliability of 'spot' urine 
testing. What this study has done is identify two areas, possible metabolism 
saturation and a large inter-patient variation, that have the potential to be 
clinicaly significant with regard to control of asthma symptoms and require 
further investigation. 
9.6 	 CONCLUSION 
Keeping in mind the vast limitations presented by 'spot' urine sampling, this study 
has shown that there is a large inter-patient variability in excretion of drug in 
proportion to dose, most likely accounted for by diferences in administration 
technique and/or pharmacokinetics. In addition it was shown that there was 
possible saturable metabolism of salbutamol at relatively low levels. It is suggested 
that some studies reporting worsening of asthma control with regular fixed dosages 
of [32-agonists are limited due to inter-patient differences in administration 
technique and/or pharmacokinetics. There are strong indications that more work 
is urgently required in this area to answer the specific issues raised in this study. 
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General Discussion 
Despite advances in drug treatment over the last twenty years asthma morbidity 
and mortality in the community remains high. The annual cost of asthma in 
Australia has been estimated at up to $720 million (NAC report, 1992). With other 
chronic diseases, in addition to drug treatment, quality of life and prognosis can 
often be improved by other variables such as life style changes (for example diet 
and exercise) or treatment such as surgical intervention. This is of course 
important from a public health aspect. By educating the community with regard to 
life style changes, morbidity, mortality and health care costs can be reduced. 
Unfortunately this is not really the case with asthma. 
The aetiology of asthma remains unclear and in the majority of cases drug 
treatment is the only mainstay for improving quality of life for patients with the 
disease. Therefore the pharmacotherapeutic aspects of asthma are relatively more 
important than for many other chronic diseases. This is especially so given 
suggestions that over-reliance on certain types of drug therapy may increase 
morbidity and mortality. This thesis has examined several current 
pharmacotherapeutic aspects of asthma and airways diseases in general. 
The utilisation of anti-asthmatic medication both nationally and within Tasmania 
was found to be changing in line with current prescribing guidelines. There was 
evidence to suggest that reliance on 132-agonists has diminished with greater 
emphasis now on inhaled corticosteroid utilisation. There were some regional 
differences between Northern and Southern Tasmania but drug consumption in 
both regions appeared to be changing in line with current management guidelines. 
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It was found that utilisation of sodium cromoglycate was lower than anticipated 
and it is suggested that this drug may be under-utilised at present. 
The practice of mixing nebuliser solutions in bulk has been noted to improve 
patient compliance but questions have been raised concerning the physicochemical 
stability of these solutions being mixed in bulk and stored for several days. The 
evidence presented in this thesis suggests that these solutions are stable for at least a 
period of up to 5 days if stored at or below 22°C. There is some doubt, however, 
over adequate preservative strength with the diluted admixture. Microbial 
contamination was not studied but a storage period of 5 days with refrigeration 
and protection from light was recommended. 
This thesis has also identified large inter-patient variation with respect to urinary 
salbutamol levels corrected for dose in patients receiving inhaled therapy. Even 
conceding the limitations of 'spot' urine analysis, this suggests large inter-patient 
variation in administration technique and/or pharmacokinetics between patients. 
Inter-patient differences in administration techniques affecting bioavailability are 
indirectly supported by the large variation seen in pulmonary deposition studies 
(Table 7.1). In addition, there was evidence to support a hypothesis of saturation of 
salbutamol metabolism at relatively low levels. Confirmation of both of these 
findings would have important implications. 
Firstly, the fact there are large inter patient variations in levels corrected for dose 
(with or without correction for dilution) suggests that there is also large inter-
patient variation in therapeutic effect corrected for dose. A dose satisfactory for 
relief of symptoms in one patient may not provide sufficient drug levels in another 
patient for adequate relief of symptoms. In other words, inter-patient differences in 
the bioavailability (due to variations in pharmacokinetics and/or administration 
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technique) may determine the dosage of salbutamol required for control of 
symptoms rather than disease severity. Studies that have shown worsening of 
asthma control with regular versus as needed therapy should take into account 
these large inter-patient differences. 
Secondly there is little literature available on salbutamol metabolism or possible 
low level sulphate metabolism saturation. The clinical importance of this 
saturation and whether it is linked to the inter-patient differences is not clear at 
present. More research is urgently required into both of these areas to gain a better 
understanding of p-agonist pharmacotherapy. 
Essentially aspects of the pharmacotherapy of asthma have been examined from a 
macro to a micro scale in this thesis. The research material presented here has (i) 
confirmed that anti-asthmatic drug utilisation in the community (both locally and 
nationally) is improving, (ii) shown bulk mixing of salbutamol and ipratropium 
nebuliser solutions is reasonable on the grounds of physicochemical stability and, 
(iii) found large inter-patient variability in P-agonist administration techniques 
and/or pharmacokinetics, including possible saturable metabolism, that could have 
significant clinical relevance. 
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APPENDIX 3: Informed consent form (Chapter 9) 
The University of Tasmania at Hobart 
Statement of Informed Consent for Research and Teaching Purpose. 
INVESTIGATION OF URINARY LEVELS OF SALBUTAMOL 
IN ASTHMATIC PATIENTS RECEIVING INHALED THERAPY 
The aim of this study is to investigate the range of levels in urine of the drug salbutamol (Ventolin or 
Respolin) in a large group of asthmatic patients using the drug. This information may prove useful in 
improving the treatment of asthma. 
As a subject, you wil be asked to provide a urine specimen and answer some questions relating to your 
use of salbutamol (Ventolin or Respolin). Also, we wil take some limited information (age and 
relevant medical history) from your medical record. Al this information wil be kept strictly 
confidential. If you agree to participate in this study, please sign this form, indicating your consent, on 
the understanding that:- 
1.1 have read the information above and any questions I have asked have been answered to my 
satisfaction. I agree to participate in the investigation and complete the relevant questionaries 
provided. 
2.1 understand that I can refuse to take part in this research, or withdraw from it at any time without 
affecting my medical care or relationship with the Community Health Centre and my doctors. 
3.1 agree that research data gathered in this investigation may be published, provided that I cannot be 
identified as a subject. 
After considering al of these points, I accept to participate in this investigation. 
Signature : 	 Date • 	  
Witness • 	 Date • 	  
Further information can be obtained from Dr.Greg Peterson or Mr.Glenn Jacobson at the University of 
Tasmania (ph 20 2190) 
Statement By the Investigator 
I have explained this study and the implications of participation to the subject and believe that the 
participant understands it, and that this consent is based on adequate information. 
Signature of Investigator : 	 Date • 	  
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APPENDIX 4: Questionnaire of salbutamol use (Chapter 9) 
INVESTIGATION OF URINARY LEVELS OF SALBUTAMOL 
IN ASTHMATIC PATIENTS RECEIVING INHALED THERAPY 
Name/I.D No 	 Age • 	 Sex: M/F 	 Date: 	  
1.Current drug therapy prescribed by a doctor for the 24 hours prior to visit 
(drugs and dosages- please indicate where applicable) 
Ventolin®  Inhaler 	 Ventolin®  Nebules 5.0mg 
Ventolin®  Rotacaps 	  Ventolin®  Tablets 4mg 
Ventolin®  Rotahaler 	  Ventolin®  Respirator Solution 	  
Ventolin®  Syrup  Ventolin®  Injection 5001Ag 
Ventolin®  Nebules 2.5mg 	  
2.Other drug therapy prescribed by a doctor for the 24 hours prior to visit 
(drugs and dosages) 
3.Severity of asthma (according to the 1989 Asthma management plan guidelines below) 
Severe 	 1 Moderate 	 [ ] Mild 
4.Number of hospital admissions due to acute asthma in the past 12 months? 
5.On a typical day, how many times does this patient Actualy use a Ventolin metered 
dose inhaler? 	 (i) Number of times? 	 (i) Number of puffs each time? 	  
6.How many times has this patient ActuAly_And a Ventolin metered dose inhaler in the 
last 24 hours? 
(i) Number of times? 	 (i) Number of puffs each time? 	  
(ii) How many hours since the patient last used their Ventolin? 
7.Has this patient used a Volumatic Spacer in conjunction with a metered dose inhaler 
in the last 24 hours? Y/N 
8.In a typical week, does this patient use Ventolin by nebuliser as wel? 	  
(i) - If yes, number of times usualy per day9 	 (i) Number of ml. each time? 	  
9.In the last 24 hours, has this patient used Ventolin by nebuliser? 	  
(i)- If yes, number of times? 	 (i) Number of ml. each time? 	  
10.Would you expect this patient to have normal renal function? YIN 
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APPENDIX 5: Newspaper advertisement used for patient recruitment (Chapter 9) 
ASTHMA 
SUFFERERS 
Subjects are required for a study into 
asthma medication usage. The 
research project is being conducted by 
the School of Pharmacy, at the 
University of Tasmania, and is 
approved by the University Ethics 
Committee. Participation requires 
little time or effort. If you are 
currently using Salbutamol (brand 
name Vent°lin, Respolin, Asmol or 
Respax) and would like to participate, 
phone (002) 20 2202 or 20 2190 
during business hours for further 
details. Subjects will be reimbursed 
$5 for their time. 
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APPENDIX 6: Poster used for patient recruitment (Chapter 9) 
ASTHMA RESEARCH PROJECT 
The School of Pharmacy at the University of Tasmania is conducting a 
research project, approved by the University Ethics Committee, into 
asthma medication usage and requires volunteers. 
We need asthmatic patients who.... 
are currently using Vent°lin® medication, 
• are willing to provide one urine sample (containers provided), 
• are willing to answer a short questionnaire about medication 
usage. 
All patient identifying information is confidential and names are not 
recorded. 
If you are interested in volunteering, please call either Mr. G. Jacobson 
(ph. 20 2202) or Dr. G. Peterson (ph. 20 2197) at the University of Tasmania. 
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APPENDIX 7: Information for nurses on the salbutamol urine project (Chapter 9) 
The University of Tasmania at Hobart 
INVESTIGATION OF URINARY LEVELS OF SALBUTAMOL 
IN ASTHMATIC PATIENTS RECEIVING INHALED THERAPY 
The aim of this study is to investigate the range of levels in urine of the drug salbutamol 
(Ventolin or Respolin) in a large group of asthmatic patients using the drug. This information 
may prove useful in improving the treatment of asthma. 
Patients using salbutamol that give informed consent are asked to provide a single spot urine 
specimen  and answer some questions relating to their use of salbutamol (Ventolin or Respolin). 
Also, we will take some limited information (age and relevant medical history) from their medical 
record. All this information will be kept strictly confidential. 
Sample bottles are delivered to the ward and nursing staff are asked to collect a single 
spot urine specimen (approximately 10 to 50m1) from the patients that give consent. It is 
important that the time is noted on the sample bottle. The sample bottle can be labelled 
with the patients UR label. The sample should be refrigerated. 
Further information can be obtained from Mr.George Taylor (RHH Pharmacy) or Dr.Greg 
Peterson or Mr.Glenn Jacobson at the University of Tasmania (ph 20 2190) 
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APPENDIX 8: Patient profiles of salbutamol users (Chapter 9) 
•metabolite level expressed in terms of equivalent salbutamol 	 C= community patient 
** total level expressed in terms of equivalent salbutamol 	 H= hospital patient 
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MDI 	 1262 
MDI 	 163 
MDI 	 247 
MDI 	 150 
MDI 	 0 
MDI 	 759 
MDI 	 92 
MDI 	 255 
MDI 	 0 
MDI 	 261 
MDI 	 166 
MDI 	 548 
MDI 	 119 
MDI 	 248 
MDI 	 238 
MDI 	 185 
MDI 	 148 
MDI 	 478 
MDI 	 221 
MDI 	 390 
MDI 	 127 
MDI 	 0 
MDI 	 • 
MDI 	 0 
MDI 	 0 
MDI+neb 500 
MDI 	 523 
MDI 	 0 
MDI 	 143 
MDI 	 4714 
MDI 	 0 
MDI 	 53 
MDI 	 281 
• 1.34 
0 163 0 1.58 
305 551 55 1.25 
209 359 58 1.15 
60 60 0.49 
• 1.15 
0 92 0 1.17 
117 372 32 0.90 
501 501 1.58 
471 732 64 2.24 
487 653 _ 75 0.55 
• • 3.29 
349 468 75 0.43 
• • 1.77 
• 0.43 
• 1.48 
1006 1154 87 1.28 
3359 3838 88 1.07 
• 1.69 
5035 5425 93 3.75 
• • 1.46 
• 2.00 
• • 1.25 
• • 2.39 
• 3.87 
• 0.92 
• • 1.96 
• 3.13 
806 949 85 2.16 
• 3.52 
1190 1190 107 5.23 
1338 1391 96 1.50 
• 1.42 
1 57 M C Severe Y 0 400 
2 23 F C Moderate Y 0 400 
3 21 M C Mild N 0 200 
4 32 M C Moderate Y 0 1000 
5 20 M C Mild N 0 100 
6 11 M C Moderate Y 0 1000 
7 38 M C Mild N 0 300 
8 20 F C Mild N 0 400 
9 33 M C Severe Y 0 1000 
10 19 M C Moderate Y 0 1600 
11 29 M C Mild Y 0 1000 
12 26 F C Moderate N 0 200 
13 20 F C Mild N 0 200 
14 21 F C Moderate Y 0 200 
15 18 M C Severe Y 0 2000 
16 20 F C Mild N 0 200 
17 19 F C Moderate Y 0 400 
18 18 F C Mild N 0 200 
19 69 F C Moderate Y 0 800 
20 66 F C Mild Y 0 100 
21 25 M C Mild N 0 200 
22 32 F C Mild Y 0 400 
23 54 M C Moderate Y 0 800 
24 20 M C Mild N 0 800 
25 17 F C Moderate Y 0 400. 
26 48 F C Severe Y 2 10400 
27 26 M C Moderate N 0 600 
28 19 F C Moderate Y 0 400 
29 18 M C Mild N 0 300 
30 18 F C Severe Y 2 1400 
31 24 M C Mild Y 0 200 
32 40 M C Mild N 0 400 
33 19 F C Mild N 0 200 
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34 20 M C Mild Y 0 200 MDI 54 374 428 87 1.69 
35 25 M C Mild N 0 300 MDI 0 2552 2552 • 2.16 
36 19 M C Moderate N 0 1200 MDI 816 3393 4209 81 2.00 
37 21 F C Mild N 0 100 MDI 71 1621 1692 96 1.40 
38 29 F C Mild N 0 200 MDI 0 • • 0.76 
39 18 F C Mild N 0 400 MDI 122 • • 1.23 
40 50 M C Moderate N 0 800 MDI 0 • • 0.24 
41 61 F C Severe Y 0 800 MDI 3771 • • 0.37 
42 20 M C Moderate N 0 200 MDI 498 • • 1.65 
43 19 F C Moderate N 0 800 MDI 378 • • 1.09 
44 77 M C Moderate Y 0 5400 MDI+neb 980 565 1544 37 0.80 
45 26 F C Severe N 0 800 MDI 249 • • 0.22 
46 43 F C Moderate Y 0 400 MDI 256 767 1023 75 1.26 
47 20 M C Moderate N 0 800 MDI 412 1731 2142 81 2.62 
48 39 F C Moderate Y 0 800 MDI 643 • • • 1.50 
49 21 F C Mild N 0 200 MDI 118 818 936 87 1.40 
50 18 F C Moderate Y 0 400 MDI 160 • • • 2.39 
51 72 M C Severe Y 1 800 MDI • • • 0.55 
52 62 F C Mild Y 0 800 MDI 1268 • • • 2.51 
53 33 M C Moderate Y 0 1200 MDI 841 1602 2442 66 0.66 
54 28 M C Moderate Y 0 200 MDI 371 1941 2312 84 1.54 
55 60 M C Moderate Y 0 2000 MDI 1547 • • • 2.66 
56 63 F C Moderate Y 0 15000 neb 270 735 1005 73 1.38 
57 63 F C Mild Y 0 100 MDI 204 • • • 1.85 
58 61 M C Severe Y 0 1200 MDI • • • • 1.46 
59 38 F C Severe N 0 5800 MDI+neb 308 • • • 0.62 
60 66 F C Moderate Y 0 800 MDI 333 • • • 0.24 
61 66 F C Moderate Y 0 400 MDI 51 2556 2607 98 0.33 
62 69 F C Severe Y 1 10000 neb 3866 • • • 0.39 
63 11 M C Moderate Y 0 400 MDI 141 • • • 2.00 
64 13 M C Moderate Y 0 400 MDI 367 874 1241 70 4.45 
65 74 M H Severe Y 0 25000 neb • • • • 0.49 
66 72 F H Severe Y 0 30000 neb • • • • 0.25 
67 73 F H Severe N 1 20000 neb • • • • 0.43 
68 41 M H Moderate Y 0 800 MDI 1044 8428 9473 89 1.54 
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ABBREVIATIONS 
°C 	 degrees Celsius 
cAMP 	 cyclic 3',5'-guanosine monophophate 
COPD 	 chronic obstructive pulmonary disease 
dB 	 decibel 
df 	 degrees of freedom 
DDD 	 defined daily dose 
DPI 	 dry powder inhaler 
DUSC 	 Drug Utilisation Subcommitee 
EDTA 	 ethylenediamine tetra-acetic acid 
i.d. 	 internal diameter 
i.s. 	 internal standard 
molar 
MDI 	 metered dose inhaler 
1-tg 	 microgram 
11 	 microlitre mg 	 miligram 
ml 	 mililitre 
mM 	 milimolar 
normal 
NAG 	 National Asthma Campaign 
ng 	 nanogram 
NSAID 	 non-steroidal anti-inflammatory drug 
probability 
PBS 	 Pharmaceutical Benefits Scheme 
PMS 	 post marketing surveilance 
RPBS 	 Repatriation Pharmaceutical Benefits Scheme 
S3R 	 recordable S3 drugs (poisons scheduling) 
SN 	 signal-noise 
SPE 	 solid-phase extraction 
UV 	 ultraviolet 
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